Synthesis of Complex Sugar Mycolates of Mycobacterium Tuberculosis by Ali, Omar Thanoon
  
 
Synthesis of Complex Sugar Mycolates of 
Mycobacterium Tuberculosis 
 
A thesis submitted to Bangor University 
for the degree of Doctor of Philosophy 
 
By 
 
Omar Thanoon Ali 
 
 
 
 
 
2017 
                                                     
 I 
 
Declaration and Consent 
Details of the Work: 
I hereby agree to deposit the following item in the digital repository maintained by Bangor 
University and/or in any other repository authorized for use by Bangor University. 
Author Name: Omar Thanoon Ali  
Title: Mr. 
Supervisors/Department: Professor Mark S. Baird & Dr. Juma’a R. Al-Dulayymi /Chemistry. 
Funding body (if any):  
Qualification/Degree obtained: PhD in Chemistry. 
This item is a product of my own research endeavours and is covered by the agreement below 
in which the item is referred to as “the Work”.  It is identical in content to that deposited in 
the Library, subject to point 4 below. 
 
Non-exclusive Rights: 
Rights granted to the digital repository through this agreement are entirely non-exclusive. I 
am free to publish the Work in its present version or future versions elsewhere. I agree that 
Bangor University may electronically store, copy or translate the Work to any approved 
medium or format for the purpose of future preservation and accessibility.  Bangor University 
is not under any obligation to reproduce or display the Work in the same formats or 
resolutions in which it was originally deposited. 
 
Bangor University Digital Repository: 
I understand that work deposited in the digital repository will be accessible to a wide variety 
of people and institutions, including automated agents and search engines via the World Wide 
Web.  
I understand that once the Work is deposited, the item and its metadata may be incorporated 
into public access catalogues or services, national databases of electronic theses and 
dissertations such as the British Library’s EThOS or any service provided by the National 
Library of Wales. 
I understand that the Work may be made available via the National Library of Wales Online 
Electronic Theses Service under the declared terms and conditions of use 
(http://www.llgc.org.uk/index.php?id=4676). I agree that as part of this service the National 
Library of Wales may electronically store, copy or convert the Work to any approved 
medium or format for the purpose of future preservation and accessibility. The National 
 II 
 
Library of Wales is not under any obligation to reproduce or display the Work in the same 
formats or resolutions in which it was originally deposited. 
 
Statement 1: 
This work has not previously been accepted in substance for any degree and is not being 
concurrently submitted in candidature for any degree unless as agreed by the University for 
approved dual awards. 
 
Signed ……………………….…. (candidate)     Date …………………….. 
Statement 2: 
This thesis is the result of my own investigations, except where otherwise stated.  Where 
correction services have been used, the extent and nature of the correction is clearly marked 
in a footnote(s). 
All other sources are acknowledged by footnotes and/or a bibliography. 
 
Signed …………………………… (candidate)     Date …………………………… 
Statement 3 (bar): 
I hereby give consent for my thesis, if accepted, to be available for photocopying, for inter-
library loans and for electronic repositories after expiry of a bar on access. 
 
 
Signed……………………………  (candidate)    Date ……………………… 
 
Statement 4: 
Choose one of the following options:  
a) I agree to deposit an electronic copy of my thesis (the Work) in the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor University 
and where necessary have gained the required permissions for the use of third 
party material. 
 
b) I agree to deposit an electronic copy of my thesis (the Work) in the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor University 
when the approved bar on access has been lifted. 
 
 III 
 
c) I agree to submit my thesis (the Work) electronically via Bangor University’s       
e-submission system, however I opt-out of the electronic deposit to the Bangor 
University (BU) Institutional Digital Repository, the British Library ETHOS 
system, and/or in any other repository authorized for use by Bangor University, 
due to lack of permissions for use of third party material. 
 
Options B should only be used if a bar on access has been approved by the University. 
 
In addition to the above I also agree to the following: 
1. That I am the author or have the authority of the author(s) to make this agreement and 
do hereby give Bangor University the right to make available the Work in the way 
described above. 
2. That the electronic copy of the Work deposited in the digital repository and covered 
by this agreement, is identical in content to the paper copy of the Work deposited in 
the Bangor University Library, subject to point 4 below. 
3. That I have exercised reasonable care to ensure that the Work is original and, to the 
best of my knowledge, does not breach any laws – including those relating to 
defamation, libel and copyright. 
4. That I have, in instances where the intellectual property of other authors or copyright 
holders is included in the Work, and where appropriate, gained explicit permission for 
the inclusion of that material in the Work, and in the electronic form of the Work as 
accessed through the open access digital repository, or that I have identified and 
removed that material for which adequate and appropriate permission has not been 
obtained and which will be inaccessible via the digital repository. 
5. That Bangor University does not hold any obligation to take legal action on behalf of 
the Depositor, or other rights holders, in the event of a breach of intellectual property 
rights, or any other right, in the material deposited. 
6. That I will indemnify and keep indemnified Bangor University and the National 
Library of Wales from and against any loss, liability, claim or damage, including 
without limitation any related legal fees and court costs (on a full indemnity bases), 
related to any breach by myself of any term of this agreement.  
 
Signature: …………………        Date: …………… 
 
 
 IV 
 
Table of Contents 
Declaration and Consent ......................................................................................................... I 
Table of Contents .................................................................................................................. IV 
Acknowledgments ................................................................................................................ VII 
Abbreviations and acronyms ............................................................................................ VIII 
Abstract ............................................................................................................................... XIII 
Chapter 1 .................................................................................................................................. 1 
Introduction .............................................................................................................................. 1 
1.1 TUBERCULOSIS ........................................................................................................................................... 1 
1.2 MYCOBACTERIA ......................................................................................................................................... 5 
1.2.1 Non-Tuberculosis Mycobacteria .............................................................................................. 5 
1.2.2 Tuberculosis Mycobacteria ....................................................................................................... 6 
1.3 THE MYCOBACTERIAL CELL WALL ......................................................................................................... 7 
1.3.1 MYCOLYL-ARABINOGALACTAN COMPLEX .......................................................................................... 8 
1.4 MYCOLIC ACIDS ....................................................................................................................................... 10 
1.5.1 CARBOHYDRATES ................................................................................................................................. 13 
1.5.2 Carbohydrate Conformations ................................................................................................. 13 
1.6 Preparation of Glycosidic Linkages in furanose system ......................................................... 16 
1.6.1 Type 1,2-trans-Glycosidic Linkages ................................................................... 17 
1.6.2 Type 1,2-cis-Glycosidic Linkages ....................................................................... 19 
1.7 TREHALOSE MYCOLATES (CORD FACTOR): .......................................................................................... 23 
1.8 GLUCOSE MONO-MYCOLATE (GMM) .................................................................................................. 24 
1.9 NATURAL DI-MYCOLYL DI-ARABINO GLYCEROL (DMAG) .............................................................. 25 
1.10 DI-MYCOLYL TRI-ARABINO GLYCEROL (DMTAG) ......................................................................... 27 
1.11 GLYCEROL MONO-MYCOLATE (GROMM) ........................................................................................ 27 
1.12 TB DETECTION ....................................................................................................................................... 30 
1.13 ELISA IN THE SERODIAGNOSIS OF TB ................................................................................................. 31 
1.15 OVERALL AIM OF THIS RESEARCH: ...................................................................................................... 32 
Chapter 2 ................................................................................................................................ 33 
Results and Discussion ........................................................................................................... 33 
Section 1 .................................................................................................................................. 33 
2.1 SYNTHESIS OF A SINGLE ENANTIOMER OF DI-MYCOLYL DI-ARABINOFURANOSYL GLYCEROL 
(DMAG)......................................................................................................................................................... 33 
2.1.1 THE AIMS OF THIS PART......................................................................................................................... 33 
2.1.2 Synthesis of 2',3'-di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-α-D-arabinofuranoside (DAG) ....................................................................... 33 
2.1.3 COUPLING THE DONOR AND THE ACCEPTOR ....................................................................................... 40 
2.1.4 Esterification of the glycan (68) with simple fatty acids using the CsHCO3 method 49 
2.1.5 Comparison of the NMR data for the glycan part of the synthetic and natural DMAG  . 53 
2.1.6 Esterification of the glycan (68) with synthetic methoxy-MA (73) using the CsHCO3 method 56 
 V 
 
2.1.7 Esterification of the glycan (67) with different synthetic MAs using the EDCI method . 59 
2.1.7.1 Deprotection of TBDMS groups from the MAs core: ..................................................... 62 
2.1.7.2 Esterification of the glycan (67) with -MA (76g) using the EDCI method ................. 66 
2.1.7.3 Esterification of the glycan (67) with keto-MA (76h) using the EDCI method ............ 69 
Section 2 .................................................................................................................................. 73 
2.2 SELECTIVE ESTERIFICATION AT EACH PRIMARY ALCOHOL POSITION .......................................... 73 
2.2.1 Selective esterification of the glycan (66) with behenic acid .............................................. 74 
2.2.2 Selective esterification of the glycan (66) with a protected keto-MA (76f) ...................... 77 
2.2.3 Summary................................................................................................................................... 80 
Section 3 .................................................................................................................................. 83 
2.3.1 SYNTHESIS OF DI-MYCOLYL TRI-ARABINOFURANOSYL GLYCEROL (DMTAG) ....................... 83 
2.3.2 The aims of this part ................................................................................................................ 83 
2.3.3 Synthesis of fully protected tri-arabino-furanosyl glycerol (TAG) .................................... 83 
2.3.3.1 Synthesis of the donor (84) ............................................................................... 84 
2.3.3.2 Synthesis of the acceptor (85) ............................................................................................. 84 
2.3.3.3 Coupling the donor and the acceptor ................................................................ 86 
2.3.4 Esterification of lipids with the glycan tri-arabino-glycerol (90) ........................................ 91 
2.3.4.1 Esterification with a simple fatty acid .............................................................. 91 
2.3.5 Esterification of the glycan (89) with mycolic acids (76f-h) using the EDCI method . 95 
2.3.5.1 Esterification of the glycan (89) with keto-MA (76f) ....................................... 95 
2.3.5.2 Esterification of the glycan (89) with -mycolic acid (76g) ............................ 97 
2.3.5.3 Esterification of (89) with trans-cyclopropane keto-MA (76h) ..................... 101 
2.3.6 Summary: ............................................................................................................................... 103 
Section 4 ................................................................................................................................ 105 
2.4 Synthesis of Glycerol Mono-Mycolate (GroMM) ....................................................... 105 
2.4.1 The aims of this part .............................................................................................................. 105 
2.4.2 Synthesis of 1-O-p-toluenesulfonyl-2,3-di-O-benzyl-S-glycerol (102) ........................... 105 
2.4.3 Esterification of the tosylate (102) with a simple fatty acid .............................................. 106 
2.4.4 Esterification of the tosylate (102) with synthetic mycolic acids (103b-f) ...................... 108 
2.4.4.1 Esterification of the tosylate (102) with the keto-mycolic acid (103b) .......... 108 
2.4.4.2 Esterification of the tosylate (102) with α-MAs (103c,d) .............................. 110 
2.4.4.3 Esterification of the tosylate (102) with the methoxy-MAs (103e,f).............. 113 
2.4.5 Summary................................................................................................................................. 116 
2.5 DMAGs as antigens in the serodignosis of bovine tuberculosis........................... 117 
2.5.1 ELISA assay ........................................................................................................................... 117 
2.5.2 TNF-α cytokine stimulation ................................................................................................. 120 
Chapter 3 .............................................................................................................................. 123 
Conclusion and further work .............................................................................................. 123 
3.1 CONCLUSIONS: ...................................................................................................................................... 123 
3.2 FURTHER WORK: ................................................................................................................................... 130 
 
 VI 
 
Chapter 4 .............................................................................................................................. 131 
EXPERIMENTAL ......................................................................................................................................... 131 
4.1 GENERAL CONSIDERATIONS: ................................................................................................................ 131 
4.2 EXPERIMENTS: ....................................................................................................................................... 132 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VII 
 
Acknowledgments 
I would like to thank my supervisors Professor Mark S. Baird and Dr. Juma’a R. Al-Dulayymi 
for giving me the opportunity to carry out a PhD under their supervision and for all their 
excellent advice and support throughout my study. I am extremely grateful to them for their 
guidance, teaching, valuable discussions and assistance. 
I am also grateful to all the staff at the school of chemistry especially my research committee, 
Dr. Martina Lahmann and Dr. Paddy J. Murphy, for their editing and corrections that continue 
to benefit me. Also, special thanks to all the technicians David, Gwynfor, Denis, Glyn and Nick 
and the secretaries Caroline, Tracey, Siobhan and Bryony for always being very helpful.  
I would like to thank Prof. Martin Vordermeier, Animal Health and Veterinary Laboratories 
Agency (AHVLA), Surrey, UK, for making the samples that were known to be infected with 
bovine TB available.   
I am also thankful to Mr. Paul Mason (school of chemistry, Bangor University, UK) for 
running ELISA assays. 
I would like to thank Dr. Andy Chancellor (University of Southampton, UK) for running 
THP-1 cell assays.  
I am also thankful to Dr. Alison Jones for her assistance with the mass spectrometry, and all her 
help throughout the project. 
Many thanks to all my friends on the 10th floor who have helped me throughout this project, 
especially Dr. Mohsin O. Mohammed. 
I would like to thank my country (IRAQ) and the Iraqi Ministry of Higher Education and 
scientific research (MOHESR)-University of Mosul for sponsoring me. 
Finally, I would also like to thank every member of my family in Iraq and Bangor. Special 
thanks go to my wife Intisar, my daughter Maryam and my son Mustafa, for their support, 
encouragement and patience. 
 
 
 
 VIII 
 
Abbreviations and acronyms  
 [α] D  Specific rotation 
Ac Acetyl 
Å Angstrom  
AIDS Acquired immunodeficiency syndrome 
AG Arabinogalactan 
Aq Aqueous 
All Allyl 
br Broad 
Bn Benzyl 
Bu Butyl 
Bz Benzoyl 
CAN Ceric ammonium nitrate 
ºC Degrees Celsius 
cm-1 Wavenumbers(s) 
COSY Correlation spectroscopy 
 Chemical shift 
d Doublet 
dt Doublet of triplet 
dd Double doublet 
DCC N,N′-Dicyclohexylcarbodiimide 
DEPT Distortionless enhancement by polarization transfer 
DCs Dendritic cells 
DMAP 4-(N,N-Dimethylamino)pyridine 
 IX 
 
DMAG Di-mycolyl-di-araf-glycerol 
DMF  Dimethylformamide 
DMSO Dimethylsulfoxide 
DMTAG Di-mycolyl-tri-araf-glycerol 
ELISA Enzyme-linked immunosorbent assay 
Ether Diethyl ether 
EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
Et Ethyl 
equiv Equivalents 
GAM Glycerol-arabino-mycolates  
GMM Glucose mono-mycolate  
GroMM Glycerol mono-mycolate 
h Hours 
HIV  Human immunodeficiency virus 
HSQC Heteronuclear single quantum coherence  
Hz Hertz 
IMS Industrial methylated spirit 
I.R. Infra-red 
i-Pr Isopropyl 
ISO Isopropyl alcohol 
J Coupling constant 
LAM Lipoarabinomannan 
LiAlH4 Lithium aluminium hydride 
lit. literature value 
 X 
 
LM Lipomannan 
LPS Lipopolysaccharide 
m Multiplet 
M Molar (moles per liter) 
M+ Parent molecular ion (in MS) 
MA Mycolic acid 
MAC Mycobacterium avium complex 
mAG                            Mycolyl arabino galactan 
 
MALDI Matrix-assisted laser desorption/ionization 
MALDI-TOF Matrix-assisted laser desorption/ionization-time of flight 
MAM Methyl arabino-mycolates 
MDR-TB Multiple drug resistant tuberculosis 
Me Methyl 
MHz Megahertz 
min Minute(s) 
mL Milliters   
mmol Millimol 
m/z Mass to charge ratio 
Mincle Macrophage-inducible C-type lectin 
mol eq. Molar equivalents 
m.p. Melting Point 
MS Mass spectrometry 
MTADM Methyl tri-araf-di-mycolates 
 XI 
 
M.tb Mycobacterium tuberculosis 
NIS N-Iodosuccinimide 
NMR Nuclear magnetic resonance 
NSI Nano-electrospray Ionization 
Petrol Petroleum spirit (boiling point 40 to 60 oC) 
PG                                Peptidoglycan         
Ph Phenyl 
PIMs Phosphatidylinositol mannosides 
PMB p-Methoxybenzyl 
ppm Parts per million 
Pyr Pyridine 
q Quartet 
Rf Retention factor 
r.t Room temperature 
sat. Saturated 
s Singlet 
SN2 Nucleophilic substitution, bimolecular 
Sensitivity Probability (%) of being test positive when disease present 
Specificity Probability (%) of being test negative when disease absent 
STol 4-Methylbenzenethiol 
t Triplet 
T-cells T Lymphocytes 
TB Tuberculosis 
TBAF Tetrabutylammonium fluoride 
 XII 
 
TBAI Tetrabutylammonium iodide 
TBDMSCl Tetrabutyldimethylsilyl chloride 
TBDPSCl Tetrabutyldiphenylsilyl chloridc 
TDM Trehalose dimycolate 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
THP Tetrahydropyranyl 
TIPDS 1,3-(1,1,3,3)-Tetraisopropyldisiloxanylidene 
TLC Thin layer chromatography 
TMM Trehalose monomycolate 
TMS Tetramethylsilane 
TMSOTf Trimethylsilyl trifluoromethanesulfonate 
TNF-α                          Tumor necrosis factor-α 
Ts p-Toluene sulfonyl 
Trityl Triphenylmethyl 
p-TsCl  p-Toluene sulfonyl chloride 
p-TsOH p-Toluene sulfonic acid 
VLA Veterinary laboratories agency 
WHO World health organisation 
XDR-TB Extensively drug resistant tuberculosis 
 
 
 
 
 XIII 
 
Abstract 
Mycobacteria are present in many environments and complex mixtures of sugar esters and 
mycolic acids are present in their cell wall structure. This complicated mixture is thought to 
be responsible for their high resistance to known antibiotics and chemotherapeutic treatments. 
Mycolic acids are high molecular weight α-alkyl-branched β-hydroxy long-chain fatty acids, 
have 60-90 carbon atoms, and various classes of mycolic acids are made by different species 
of mycobacteria. Sugar esters of mycolic acids associated with the cell wall of mycobacteria 
have very interesting toxic and immunological properties, and thus could be useful for the 
control and treatment of mycobacterial infections. The main objectives of this thesis will be 
discussed in three parts.  
The main target of the first part involved the first synthesis of a single enantiomer of the 
glycolipid di-mycolyl di-arabino glycerol (DMAG) (I), which has interesting toxicological and 
immunological properties. This was achieved by a successful synthesis of the glycan moiety of 
DMAG with the L-stereochemistry of the glycerol component, followed by the successful 
esterification of the glycan di-arabino glycerol with three normal fatty acids, a model mycolic 
acid, and five different mycolic acids. The NMR spectra of the synthetic isomer of the DMAG 
penta-acetate analogue, in the sugar region, matched very well those reported for the peracetate 
formed from the natural mixtures, confirming the stereochemistry of the arabinose units and 
establishing the absolute stereochemistry of the glycerol unit. An efficient route to prepare the 
DMAG glycan with excellent β-selectivity and in excellent yield was achieved. 
 
(I) 
 
 XIV 
 
The second part entailed the first preparation of di-mycolyl tri-arabino glycerol (DMTAG) (II), 
which involved the synthesis of the donor moiety part according to literature methods with 
slight modifications, and the new arabino glycerol acceptor. The coupling of the donor and the 
acceptor to prepare the desired glycan was carried out using known coupling conditions. After 
the success in synthesising this tetra-saccharide, a model glycolipid was prepared through 
esterification with a normal fatty acid. Furthermore, a series of three DMTAG compounds were 
prepared, based on two common classes of mycolic acids. 
 
(II) 
The final part of this project was the synthesis of glycerol mycolates (GroMM) (III), which 
have interesting adjuvant properties in vaccines, by coupling five common classes of 
synthetic mycolic acids with the S-glycerol stereoisomer. One model GroMM was prepared 
from a simple fatty acid. These compounds were prepared to study whether the 
stereochemistry of the glycerol component (R & S) has any effect on their biological 
activities.  
 
(III) 
Initial studies of the biological activity of the synthetic DMAGs showed that some could be 
used to distinguish serum from cattle infected with bovine TB from uninfected cattle, and that 
they selectively activate THP-1 cells. In contrast, initial ELISA results with the synthetic 
GroMM showed little response to serum from patients with active TB. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Chapter 1 
Chapter 1                                                                                                                 Introduction 
1 
 
Chapter 1 
Introduction 
Mycolyl-arabinogalactan complex (mAG) is the major component in the cell wall of 
mycobacteria, and acts as a permeability barrier that prevents the passage of known 
antibiotics. Therefore, blocking the biosynthesis of this component is an important strategy 
for developing new anti-tuberculosis (anti-TB) medications. This thesis reports the synthesis 
of three different complex sugar mycolates of the Mycobacterium tuberculosis (M.tb) cell 
wall, which allows their biological activity to be investigated. The following introduction will 
provide some background information on tuberculosis and some related topics. 
1.1 Tuberculosis 
Tuberculosis (TB) is a contagious bacterial disease caused by an infection with a type of 
bacterium and several closely related mycobacterial species belonging to the so-called M.tb 
complex. The origin of this infection is not clearly known but it is believed to have originated 
in cattle and then transferred to human beings. Overcoming the immune system defences by 
the TB bacilli and the start of reproduction changes TB from infection to disease.1,2 The lung is 
the most common place of infection in the body, however, any other organ can be infected, 
such as the lymph nodes, kidneys and central nervous system. The bacteria of TB are spread 
easily in the air by talking, coughing, breathing or exchange of blood fluids, and the 
symptoms, which may not appear immediately, are fever, loss of appetite, weight loss, chest 
pain and prolonged coughing, night sweats, swollen glands and no response to antibiotics.3,4 ,5  
TB has been found in humans from the early dawn of history, and is believed to date back 
more than one hundred and fifty million years.6,7 It is known by several names, for instance: 
‘The king of diseases’ in India, ‘The captain of all these men of death’,8 and ‘phthisis’ by the 
Greek physician Hippocrates.9 The earliest specific discoveries of TB were in the remains of 
a bison from 18000 years ago.10 Studies have demonstrated the presence of TB in Egyptian 
mummies over 5000 years old, and have also shown signs of death as a result of TB.11 There 
is evidence which shows the presence of TB in China 2300 years ago and in India 3300 years 
ago.12,13 It is believed that TB in the North and South America was present before the arrival 
of European explorers, with a similarity to that found in Egypt.14,15 TB was well documented 
in ancient Greece and its treatment was devised by the physician Clarissimus Galen as sea 
voyages, fresh air and milk.16  
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In 1720, Marten first suggested that TB was caused by a microscopic air-bound organism.17 
Regrettably, his findings were ignored until 1865 when surgeon Jean-Antoine Villemin, 
demonstrated the nature of TB transmission from humans to rabbits by injecting a rabbit with 
liquid from the lung of a patient who had died from infection with TB, and so confirmed the 
theory proposed by Marten that TB was a contagious disease.18 In 1882 Robert Koch, who 
was awarded the Nobel Prize in Medicine and Physiology in 1905 for his work on 
tuberculosis, first described the causative agent of TB when he discovered a stain which 
enabled the bacilli of M.tb to be seen.19,20,21 Since Koch’s discovery, and due to the 
complexity of TB disease, a reliable vaccine was not developed until 1921, when Albert 
Calmette and Camelle Guérin developed a vaccine from Mycobacterium Bovis (M.bovis) 
called Bacillus Calmette-Guérin (BCG).22 The BCG vaccine became more widespread in the 
1940’s, being used in Scandinavia, France, Spain, Russia, Germany, Latin America and some Eastern 
European countries.23,24 Currently, more than 115 million units of BCG as a freeze-dried form 
are dispersed annually in 172 countries on average.25 
 In the 18th and 19th centuries, TB spread over Asia, Africa, South America and Europe, and 
approximately one fourth of all deaths in the world was caused by TB.26 In Europe it was 
responsible for 25% of adult deaths in major cities.27 Population intensity, poor living 
standards and a shortage in health services led to an increase in TB infection and led to it 
being considered a public health problem.28 In the 20th century, the disease was slowly 
controlled as living conditions and health care improved, and several medicines were 
discovered, such as streptomycin in 1944, and isoniazid in 1952, which are now used to treat TB.27  
In 1990, a significant rise in the number of deaths of TB patients was reported, in contrast to 
the number of deaths due to other illnesses. In 1993, the World Health Organization (WHO) 
announced TB as a major health problem and declared a global health emergency.29  
According to WHO, TB is among the top ten causes of death and disability globally. Between 
2013-2015, new incidents of TB increased, with around 10.4 million new cases of TB being 
recorded worldwide in 2015 leading to 1.8 million deaths, with most being concentrated in 
six countries, South Africa, China, India, Nigeria, Indonesia and Pakistan.30,31 Figure 1 
shows the estimated number of new cases of TB per 100,000 population in 2016.31 
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Figure 1: Map showing the estimated number of new TB cases in 2016.31 
Infection with TB can be active or latent, depending on the immune system response of the host. 
In the case of a strong immune response, the bacilli are killed after being inhaled into the lung, 
and no symptoms of TB infection will appear. However, when the immune system becomes 
weak for any reason, the bacteria will start to spread through the blood, and then the infection will 
become serious. An individual infected with active TB will produce small droplets containing 
M.tb, which are spread as aerosolised drops when an infected patient sneezes.32,33 
The continuing occurrence of TB remains globally uncontrolled, due to the evolution of strains 
highly resistant to drug treatment and a higher incidence of human immunodeficiency virus (HIV) 
co-infection. TB/HIV together produce a fatal combination, each increasing the progression rate of 
the other disease, with HIV infection being one of the major conditions that make people more 
vulnerable to developing active TB. HIV has contributed to a significant rise in the global rate of 
TB by weakening the individual’s immune system. The risk of developing active TB for 
individuals infected with HIV is up to 30 times greater than for uninfected persons.31 Although HIV 
and TB are both preventable and treatable, they continue to increase in developing countries in 
which TB infection and HIV are prevalent and resources are limited.31,34,35 Similarly, TB may also 
destructively affect the natural progress of HIV infection.36,37 The effect of TB on HIV illness 
development is assumed to be assignable to increased immune system activation.38 The WHO 
estimates that nearly one third of the world’s population is currently infected with M.tb and about 
22% of these are believed to be co-infected with HIV Figure 2.31,39  
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Figure 2: Map showing the estimated number of TB patients co-infected with HIV in 2016.31 
The treatment of TB is difficult and involves long courses of multiple antibiotics.40,41 In 
addition to an increase in the number of people infected with TB since 1980, there has also 
been a large increase in the number of drug-resistant tuberculosis cases. The emergence of 
multi drug resistant tuberculosis (MDR-TB) is another factor which contributes to the failure 
of controlling TB. Strains of M.tb showing resistance to the anti-TB drug streptomycin 
developed during early attempts to treat TB.42 Nowadays, strains of M.tb showing resistance 
to other anti-TB drugs have developed. When a strain of TB is found to be resistant to two or 
more front line drugs like Isoniazid, Rifampicin, Pyrazinamide, Ethambutol and 
Streptomycin, it is considered to be multiply drug resistant MDR.43 The WHO estimated that 
there were about 480,000 new cases of MDR-TB in 2015 and their last report estimated that 
3.5% of new cases and 20% of previously treated cases are multidrug-resistant.31,44,45 More 
recently, extensively drug-resistant tuberculosis (XDR-TB) cases have emerged where the 
M.tb is resistant to Rifampicin, Isoniazid, a Fluoroquinolone and a seconD-line injectable 
drug (Capreomycin, Amikacin). This type of resistance was reported for the first time in 
KwaZulu-Natal in South Africa.46 In 2008, 963 infections of XDR-TB were reported,45 while 
in 2015 around 45600 people with MDR-TB had XDR-TB globally.30 Resistance of M.tb to 
the treatment makes this disease more problematic and an estimated budget of approximately 
$2 billion was promised in 2016 in order to address and control, by diagnosis and 
treatment, the serious problem of TB.30  
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1.2 Mycobacteria 
Mycobacteria are a genus of bacteria which can cause fatal diseases in both humans and 
animals. There are over 150 known species, which can be divided into two classes, 
tuberculosis mycobacteria and non-tuberculosis mycobacteria.47,48 They include both 
pathogenic and non-pathogenic species.49,50 Species of pathogenic mycobacteria causing TB 
in mammals are M.tb, Mycobacterium bovis (which is responsible for causing bovine TB), 
Mycobacterium africanum (a heterogenous group of strains isolated from equatorial African 
inhabitants) and Mycobacterium microti (a rodent pathogen).51 Other mycobacterial species 
causing disease in man are Mycobacterium leprae (which causes leprosy), Mycobacterium 
ulcerans (which is responsible for the dangerous and potentially fatal Buruli ulcer, a skin and 
sometimes bone infection).52,53 Other pathogens include Mycobacterium marinum (which 
causes disease in fish and skin infections in humans) and Mycobacterium avium (an illness of 
poultry first discovered in 1890, also known as Battery bacillus).54,55 M. bovis has the most 
diverse range of hosts, as it is found not just in bovine animals but also in man, dogs, cats, 
pigs, goats and wild animals such as deer.51 Nevertheless, unlike M. tb, M. bovis, M. microti, 
Mycobacterium kansasii and Mycobacterium smegmatis, a large number of other 
mycobacterial strains only affect individuals whose immune system is suppressed, for 
example HIV/AIDS sufferers or transplant patients.54,55 
1.2.1 Non-Tuberculosis Mycobacteria 
Non-tuberculosis mycobacteria, also known as environmental mycobacteria, are small, rod 
shaped bacilli which enter the human body through environmental sources such as natural 
water, soils, foods, and water pipes. The reason for the survival of these bacteria in water 
pipes is due to their resistance to chlorine in water.56 These species do not cause tuberculosis, 
but have the ability to cause other diseases in both humans and animals such as skin diseases, 
disseminated disease (a diffuse disease-process, either infectious or neoplastic, throughout the 
body over a considerable area), and pulmonary disease in HIV negative patients.48 Unlike 
tuberculosis, non-tuberculosis mycobacteria are not transmitted from one person to another, 
the organism being acquired exclusively from environmental sources.57  
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1.2.2 Tuberculosis Mycobacteria 
The tuberculosis mycobacteria constitute a collection that contains more than 70 different 
species, together known as Mycobacterium tuberculosis (M.tb) complex, which can all cause 
tuberculosis disease in both humans and animals.58 Some species cause TB in humans only, 
such as M.tb, while some, such as M. bovis, can cause TB in both humans and animals. 51,59,60 
The most common in the family of tuberculosis mycobacteria is M.tb, which was isolated and 
identified for the first time by the German physician, Robert Koch, in 1882. It is highly 
aerobic (grows most successfully in tissues with oxygen content, such as the lungs), appears 
under the microscope as straight or slightly curved rods approximately 1-4 x 0.3-0.6 µm in 
size (Figure 3), non-encapsulated, non-spore forming, aciD-fast (do not retain the methyl 
violet stain well), weak Gram-positive bacilli.61 However, it was reported recently that they 
have features of both Gram-positive and Gram-negative bacteria (Gram-positive bacteria 
have a greater amount of peptidoglycan, lower lipid content and they retain the gram’s stain, 
while, Gram-negative bacteria have a thin peptidoglycan cell wall and they do not retain the 
gram’s stain), divides aerobically every 16 to 20 hours,8,62,63,64 an extremely slow rate 
compared with other bacteria, such as Escherichia coli that can divide roughly every 20 
minutes.65 M. tuberculosis is very resistant to environmental conditions, and can survive in 
dry conditions for a long time; this is due to its unique cell wall structure compared with the 
cell walls of other bacteria. The cell wall is rich in mycolic acids (MAs) and glycolipids, 
which are crucial for the survival and growth of M. tuberculosis inside the infected 
organism.66  
 
Figure 3: Scanning electron micrograph of M. tuberculosis.67 
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1.3 The Mycobacterial Cell Wall 
It is important to have an understanding about the nature, the organisation and the structure of 
the cell envelope in the fight against TB and other related diseases. The cell wall of M.tb has 
an unusual structure. The thick, multi-layered and extremely hydrophobic structure of the cell 
wall, is important for the organism, because it prevents the passage of antibiotics into the cell 
and protects it from the immune system of the host, by allowing it to survive in macrophages, 
acting as a permeability barrier. A high resistance to the majority of antibiotics, therapeutic 
agents and disinfectants is a big problem in the eradication of mycobacterial organisms, and 
this resistance is thought to be related to the unique structure of the mycobacterial cell wall. 
The general structure of the mycobacterial cell wall is now well understood, and it was 
basically proposed by Minnikin with its complex architecture of lipids, glycolipids, 
polysaccharides and proteins.68,69,70 Generally, the M.tb cell wall consists of the significant 
components shown in Figure 4, namely, the plasma membrane (PM) (inner membrane), 
peptidoglycan (PG), mycolyl-arabinogalactan (mAG), and an outer capsule-like layer.71,72,73  
 
Figure 4: General structure of M. tuberculosis cell wall.74,75 
The main components of the capsule outer layer are polysaccharides and proteins with low 
amounts of lipids.76 The plasma membrane is about 5 nm thick, and its composition is similar 
to that in other organisms. The PG is a polymer that forms the backbone of the cell wall 
skeleton, consisting of N-acetylglucosamine (NAG), and N-acetylated muramic acid (NAM) 
Chapter 1                                                                                                                 Introduction 
8 
 
saccharides.77,78 The mAG, is a heteropolysaccharide consisting of D-arabinose in the 
furanose form joined to linear D-galactose units.79,80 Mycolic acids (MAs),  are α-alkyl 
branched -hydroxy long chain fatty acids (60-90 carbon atoms, see section 1.4). Together, 
mycolic acids, arabinogalactan and peptidoglycan produce the tightly packed bilayer of the 
M. tb cell wall and are known as the mycoyl-arabino-galactan-peptido-glycan complex 
(mAPG).79 Moreover, though the main component of the cell wall is mycolic acids, there are 
also large amounts of very complicated lipids amounting to around 40% dry weight of the 
cell wall. These lipids are highly complex and are thought to be responsible for the high 
resistance and low permeability of the cell wall to hydrophilic compounds. In addition, there 
are many glycolipids present in the cell wall of mycobacteria, for example di-mycolyl di-
arabino-glycerol ester (DMAG ester), which is di-arabino-glycerol esterified with mycolic 
acids, has been reported to have interesting toxicological and immunological properties.81,82     
1.3.1 Mycolyl-arabinogalactan complex  
The mycolyl-arabino-galactan complex (mAG) (Figure 5), is the largest component in the 
cell wall of mycobacteria and is located directly outside the PG layer. It is believed that the 
mAG complex acts as a permeability barrier that prevents the passage of antibiotics. It 
forms from cross bonding between both α-D-arabinofuranose (α-D-Araf) and β-D-
galactofuranose (β-D-Galf) esterified with mycolic acid (long chain α-alkyl branched β-
hydroxylated fatty acid). Carbohydrates (Araf) and (Galf), creating about 35% of the cell 
wall mass, are bound to NAG residues of PG through a covalent bond at the non-reducing 
end of the wall by a unique linker disaccharide, α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-
deoxy-α-D-glucopyranosylphosphate. The galactan part is a linear chain of around 30 - 40 
units of (β-D-Galf) with alternating β-(1→5) and β-(1→6) galactofuranose residues. The 
arabinan unit is composed of 60 - 70 units of linear (1→5) (α-D-Araf) residues and 
branches to form a (3,5-α-D-Araf) linked fork.83,84,85,86 Galactan and arabinan are bonded 
from the C-5 position in the galactan core.79,74,87,88,89 The arabinose motif of the cell wall 
contains 1,3-branched Araf-based mycolated hexasaccharides, via ester linkages at each of 
the four primary hydroxyl groups to form the mycolyl-arabinan moiety.72,90  
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Figure 5: Structure of the mAG complex. 
Both galactosyl and arabinosyl units in the mAG complex are in the furanose form which is less 
thermodynamically stable than the pyranose form (the six-membered pyranose ring is 
thermodynamically more stable than the five-membered furanose ring, because the six membered 
ring can be in the chair form in which there is no angle or eclipse strain).91 It is believed that this 
plays an important role in raising the flexibility of the polysaccharide and making the MAs pack 
strongly by van der Waals interactions. Thus, the structure of the cell wall has extremely low 
permeability, which provides the organism with high protection from drugs and from its 
environment. On the other hand, given its importance to the life cycle of the organisms, 
mycobacteria must produce a complete mAG complex.92 As mentioned previously, targeting 
mAG biosynthesis is therefore an important strategy for developing new anti-TB drugs. Indeed, 
isoniazid and ethambutol, two of the standard antibiotics, target the mAG complex biosynthesis; 
ethambutol inhibits arabinosyltransferases which contribute to the biosynthesis of the arabinan 
part of the polysaccharides, while isoniazid inhibits MA biosynthesis.93 
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1.4 Mycolic Acids  
Mycolic acids (MAs) are high molecular weight (60-90 carbon atoms) hydrophobic fatty 
acids alkylated at the α-position and hydroxylated at the β-position and can be isolated from 
the waxy extract of M.tb.94 Mycolic acids are unique to mycobacteria, and are considered as 
one of the main and characteristic components of the cell wall of all the mycobacterial 
species. In 1938, Anderson et al. first reported and isolated mycolic acids as unsaponifable 
ether-soluble hydroxy acids from the human tubercle bacillus. Mycolic acid is very difficult 
to purify and not possible to crystallize.95,96 The first mycolic acid structures were published 
by Minnikin et al in 1967.97,98,99,100 Mycolic acids exist in the mycobacterial cell wall in the 
free form or esterified with other lipids, such as trehalose mono-mycolates (TMM) and 
trehalose di-mycolates (TDM), glucose mono-mycolate (GMM), glycerol mono-mycolate 
(GroMM), and di-mycolyl di-arabino glycerol (DMAG).  
The structure of mycolic acids can be divided in to two parts. The main part is called the 
meromycolate moiety and the second part is called the mycolic motif. The mycolic motif part 
contains the α-alkyl β-hydroxy fatty acid, which is similar in all mycolic acids except for a 
slight variation in the chain length at the -alkyl position. The main part is the meromycolate 
moiety, which normally has two intra-chain functional groups at the distal and proximal 
positions labelled as [X] and [Y] (Figure 6). The proximal position can be a cis or trans 
cyclopropane, or double bonds, while the distal position can be a cis or trans cyclopropane, 
cis or trans double bond, epoxy group, methoxy group, carbonyl group, hydroxyl group or 
ester group. Due to the possible variations in the functional groups that could be present in a 
certain mycolic acid, Watanabe et al. proposed a broad classification method to divide the 
mycolic acids into three types: Types 1, 2 and 3 as shown in (Figure 6). Type 1 MAs have a 
cyclopropane ring at the proximal position (which can be either cis or trans), type 2 MAs 
have a trans double bond at the proximal position, while type 3 MAs contain a cis double 
bond at the proximal position.101,102 
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Figure 6: General structure of mycolic acids and various functional groups.101,102 
 
Asselineau et al. reported the pyrolysis of mycolic acid (MA) (1), and confirmed the 
positions of the hydroxyl group (β) and a long alkyl chain (α) in relation to the carboxylic 
acid (Scheme1).103 
 
Scheme 1: Thermal cleavage of the β-hydroxy group of MA.94 
Mycolic acids (MAs) have a role in the permeability of the outer cell envelope of the 
bacteria, but the stacking and arrangement of the long hydrocarbon chains of the acids within 
the cell wall is complicated.94,101 The cell wall of M.tb is believed to contain a mixture of 
over 500 different mycolic acids with a varying combination of functional group type and 
chain length. These most important components in the cell wall with this large number of 
different structures have significant biological properties.94 The isolation of mycolic acids 
and separation from the mixture of various similar structures in the cell wall was the main 
problem in identifying their individual structures. For this reason, highly developed analytical 
techniques were required in order to determine the correct structures of these series of 
mycolic acids. Over the last fifty years, by using new analytical techniques such as TLC, 
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HPLC, GC, MS, and NMR, it has been less difficult to separate and identify several mycolic 
acids.104,105,106,107,108  
Based on the nature of the functional groups present in the meromycolate chains, mycolic acids 
from M.tb can be divided into three main categories: 
1. Alpha-mycolic acids with no oxygen-containing intra-chain groups.  
2. Methoxy-mycolic acids in which the distal group has a methoxy group. 
3. Keto-mycolic acids in which the distal group has a carbonyl group (with a cis or trans 
cyclopropane).  
Figure 7: Major types of mycolic acids from M. tuberculosis. 
In 2003, Al-Dulayymi et al. reported the synthesis of a single enantiomer of an alpha mycolic 
acid from M. tuberculosis.109 Various types of single enantiomers of mycolic acids have also 
been prepared by the same group such as methoxy,110 keto111,112 and alpha-mycolic acids113 
which are major mycolic acids present in M. tuberculosis.114 
As discussed before MAs are often present in the cell wall esterified to sugars. The different 
types of sugar esters with different glycolipid linkages are described in the following 
sections.  
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1.5 Synthesis and control the stereochemistry of different sugars 
1.5.1 Carbohydrates  
Carbohydrates are the most abundant and diverse bio-molecules in nature. They were named 
as glycans or saccharides (Greek, meaning sugar). Virtually all important biomolecules have 
a glycan in their structures, e.g. secondary metabolites, t-RNA, lipids and proteins.115 
Initially, the function of carbohydrates was known as a source of energy; however, it has 
since been proven that they play an essential role in many biological progressions, for 
instance growth, development and the survival of living organisms.116 Although 
carbohydrates have significant characteristics in biological systems, due to their complex 
forms, their functions and structures are still less understood in comparison with other 
biological molecules like proteins and nucleotides.117 Carbohydrates often contain a 
glycosidic bond in their structures, which is in either an α- or β-configuration, and this bond 
is created when two glycan units are bound to form a disaccharide. In nature, this 
stereochemistry plays a significant role in biological activity. Furthermore, each glycan unit 
contains many hydroxyl groups which can also react with another molecule to produce 
oligosaccharides, which can be linear or branched macromolecules. In addition to that, the 
hydroxyl groups in glycans can be modified through different reactions such as esterification, 
oxidation and methylation.118 Monosaccharides can adopt various forms due to free rotation 
around the glycosidic bond, therefore monosaccharides have a heterogeneous conformation. 
In addition, in oligosaccharides there is an internal rotation around exocyclic bonds, such as 
the primary hydroxyl groups in most glycan forms. The saccharide molecule itself can adopt 
different ring forms such as furanose rings. In conclusion carbohydrates can possess complex 
branched and modified forms, and they are more complicated compared with the two other 
main classes of molecules, nucleotides and proteins.119,120 
1.5.2 Carbohydrate Conformations 
The overall structure of an oligosaccharide is determined by many factors such as, the 
stereochemistry of the glycosidic bond (α or β-anomer); pseudo-rotation of the furanose rings; 
stereoelectronic effects and the conformation of the attached groups in the glycan ring. The 
stereochemistry of the glycosidic bond is important for the biological functionality of the 
oligosaccharide.118 The main conformations of the furanose ring are: envelope (E) (8), in this form, 
four adjacent atoms are all in one plane and only one atom is out of the plane (above or below) and 
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twist (T) (9), in this form, two atoms are outside the plane and the other three atoms are in the 
plane (Figure 8). 
 
Figure 8: Envelope and twist conformations in furanose rings. 
The energy difference between the E and T conformations in the case of the mono-saccharide 
is small, therefore the furanose is present in a dynamic equilibrium through a pseudorotation. 
Consequently, due to the flexibility of the furanose ring, the exocyclic methyl hydroxy link 
and the flexibility of the glycosidic bond, there are twenty different conformations, ten 
different twist conformations and ten different envelope conformations. These conformations 
are represented on the pseudorotational wheel for the D-aldofuranose ring (Figure 9).121 
 
Figure 9: Pseudorotational wheel for a-D-aldofuranose ring.121 
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In solution, furanose rings are present as a mixture of conformers, therefore, analysis of NMR 
data such as measuring the 3JH-H coupling constant or the chemical shifts is more complicated 
because all the data is an average from more than one conformation.122  
Stereoelectronic effects (defined as the kinetic and chemical consequences of molecular 
orbital overlapping in space) are other factors which have an effect on the conformation of 
the oligosaccharide. According to molecular orbital theory, the total energy of any molecule 
is equal to the summation of the occupied molecular orbitals. Different reactivities and 
conformations are obtained due to the overlap between occupied and unoccupied orbitals 
because this overlap causes a change in energy (lower energy). In carbohydrate chemistry, 
this effect is known as the anomeric effect, which was first proved by Jungins in 1905 and 
revived by Edward in 1955 and by Lemieux and Chiu in 1958. They showed the 
predominance of alkyl α-D-glucopyranosides (11) compared to the corresponding β-anomers 
of this compound (Figure 10).123,124 
 
Figure 10: Glycosylation of D-glucose. 
Further studies on the anomeric effect showed that highly electronegative substituents, for 
example aryl derivatives, S- or O-alkyl and halides, at the anomeric carbon (C-1) on the ring 
typically favour the axial α-anomer, which lead to stabilization of the axial substituent 
compared to the equatorial substituent.125,126 
The Gauche effect is another example of a stereoelectronic effect which shows that the two 
vicinal heteroatom groups prefer the synclinal orientation which allows a good interaction 
between the anti-bonding orbital of C-X and the bonding orbital of C-H leading to 
minimizing the energy of the molecule (Figure 11).127 
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Figure 11: Stereoelectronic effects: A. Gauche effect; B. Anomeric effect. 
1.6 Preparation of Glycosidic Linkages in furanose system 
Disaccharides or higher molecules can be formed through glycosidic bonds between two 
mono-saccharides. Chemical or enzymatic methods are the main approaches for their 
synthesis. In nature, the glycosidic linkages originate through a reaction involving an enzyme 
(glycosyltransferase). Enzymatic preparation is a highly stereospeciﬁc and regiospeciﬁc 
method to synthesise significant carbohydrates.128 However, it is high in cost and requires a 
specific enzyme (sometimes not available) which limits its application, therefore, chemical 
methods are usually applied. Glycosylation is the reaction between the glycosyl acceptor, 
which has a free hydroxyl group (nucleophile), with a glycosyl donor, which has a leaving 
group (electrophile). The coupling between these two glycans is done in the presence of an 
activator to give a disaccharide with a new anomeric centre. The product could be either the 
α- or the β- anomer, depending on many factors. Controlling this is a challenge which has 
been broadly studied (Figure 12).129,130,131,132,133,134,135,136,137 
 
Figure 12: Glycosidic linkage formation. 
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Mostly, glycosidic linkages exist as two types, 1,2-cis and 1,2-trans glycosides (Figure 13). 
Cis and trans refers to the stereochemistry of the substituents at the C-1 and C-2 positions. 
 
Figure 13: Types of the glycosidic linkages (15&16). 
1.6.1 Type 1,2-trans-Glycosidic Linkages 
Type 1,2-trans glycosidic bonds, can be straightforwardly achieved by using a donor 
protected at the C-2 position with an O-acyl which allows for neighbouring group 
participation. As illustrated (Figure 14), losing the leaving group from the anomeric centre 
through Lewis acid activation, leads to the formation of an oxocarbenium ion which is 
attacked directly by the O-acyl protecting group to produce a dioxolenium ion intermediate. 
The desired 1,2-trans glycoside is thus the major product because the dioxolenium ion blocks 
one face of the molecule and hence the acceptor is forced to attack the anomeric centre from 
the less hindered face, through a process that is kinetically favoured. The dioxolenium ion 
intermediate could, however, form several by-products through a series of rearrangements. 
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Figure 14: Proposed formation of stabilized cation.138 
When the O-acyl group bears an electron-withdrawing substituent, the stereoselectivity of the 
glycosylation is reduced because of the reduction of the electron density on the carbonyl 
oxygen atom, and thus its nucleophilicity; therefore, formation of the dioxolenium ion cannot 
proceed effectively. In this case, this compound shows more oxocarbenium ion character, and 
a mixture of both α and β anomers is produced.139 
In some cases, the participating group can be an electronegative atom, for example nitrogen, 
or a chiral auxiliary (Figure 15). However, the application of chiral auxiliaries is limited, due 
to the difficulty of fixing and removal of these groups. In addition there is the possibility of 
forming both glycosidic anomers because the intermediate species can be formed in diverse 
orientations.140,141,142 
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Figure 15: Neighbouring group participating approaches. 
1.6.2 Type 1,2-cis-Glycosidic Linkages 
A general route for the synthesis of β-arabinofuranoside (1,2-cis glycosidic linkage) has not 
been established, thus an understanding of the factors that control this reaction is still limited; 
however, most of these reactions are believed to occur through an SN1-type reaction via an 
oxocarbenium ion intermediate, therefore, the acceptor can attack the donor from both faces 
and the selectivity is difficult to predict.143 Numerous strategies for the preparation of β-
glycosidic linkages have been reported, however most of these focus on pyranose glycan 
classes. Lowary and co-workers,144 reported a study to find the best conditions to use in the 
glycosylation between the donor and the acceptor to improve β-selectivity. They reacted the 
acceptor 17 and the donor 18 in CH2Cl2 (Scheme 2), using the promoter silver 
trifluoromethanesulfonate and N-iodosuccinimide (AgOTf-NIS) as a coupling reagent. 
Firstly, they studied the effect of the temperature of the reaction on the ratio of α/β and the 
yield of the product (entries 1–5) (Table 1). They developed an approach where the reaction was 
initiated at a temperature of -60 ºC and then gradually warmed to -40 ºC over 2 h. The 
reaction gave improved yield and stereoselectivity.144 Studying the effect of the reactant 
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concentration (entries 6-8) was also carried out, and it was established that by using a low 
concentration, a slight increase in the β-selectivity was observed; variation of the 
concentration did not affect the yield. Finally, the effect of the activator (entries 9 and 10) 
was tested, and they proved that the utilisation of different promoters, such as NIS-
trimethylsilyl trifluoromethane sulfonate (TMSOTf) and diphenylsulfoxide, 2,4,6-tri-tert-
butylpyrimidine, and trifluoromethane sulfonic anhydride (Ph2SO-TTBP-Tf2O) (Table 1), 
gave a low yield and β-selectivity.  
 
Scheme 2: Synthesis of di-saccharides.144 
Table 1: Optimization of β-Arabinofuranosylation.144 
Entry Temperature 
ºC 
Time 
(h) 
Acceptor 
c (M) 
Activator Yield % 
(α/β) 
1 - 78 → R.T. 4 0.08 NIS-AgOTf a 81% (3.1:1) 
2 - 78 6 0.08 NIS-AgOTf a 85% (3:1) 
3 - 60 4 0.08 NIS-AgOTf a 91% (3.4:1) 
4 - 40 0.5 0.08 NIS-AgOTf a 74% (4.6:1) 
5 - 60 → - 40 1 0.08 NIS-AgOTf a 89% (4.2:1) 
6 - 60 → - 40 1 1.00 NIS-AgOTf a 84% (4.3:1) 
7 - 60 → - 40 1.5 0.05 NIS-AgOTf a 85% (4:1) 
8 - 60 → - 40 2 0.01 NIS-AgOTf a 93% (3:1) 
9 - 60 → - 40 0.5 0.01 NIS-AgOTf b 78% (5:1) 
10 - 60 → - 40 6 0.01 Ph2SO-TTBP-Tf2O c 63% (4:1) 
 
All reactions were carried out in CH2Cl2: aAcceptor 17 (1 equiv), donor 20 (1.2 equiv), NIS (1.2 equiv), AgOTf 
(0.1 equiv). bAcceptor 17 (1 equiv), donor 20 (1.2 equiv), NIS (1.2 equiv), TMSOTf (0.1 equiv). cAcceptor 17 
(1 equiv), donor 20 (1.2 equiv), Ph2SO (3 equiv), TTBP (6 equiv), Tf2O (1.1 equiv).  
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In the same study, an investigation of the effect of the protecting groups on both the donor 
and the acceptor was undertaken, as illustrated in Scheme 3. The best α/β ratio achieved was 
1:7.7 (entry 4), and the two anomers were inseparable. This ratio was obtained by utilising 
PMB as a protecting group at the C-1 position on both the donor and the acceptor.  
 
Scheme 3: Reaction of different donors and acceptors.187 
Ishiwata and co-workers,145 reported a new strategy for conducting β-selective glycosylation 
using donors protected with 3,5-TIPDS. An enhancement of β-selectivity was achieved by 
utilising a donor with an eight-membered ring (33, 34), which gave the best α/β ratio of 1:20 
(entry 3, Scheme 4).  
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Scheme 4: Effect of protection of the glycosyl donor in Arabinofuranosylation.145 
Using a donor containing an eight-membered ring 3,5-O-protection (34), in comparison to a 
six-membered ring 3,5-O-protection (35), with the same acceptor (37) showed a marked 
difference in β-selectivity (entries 3 and 4). In the case of α-attack of the anomeric carbon 
(Figure 16), there seems to be a large steric repulsion from the α-hydrogen atom at C-2.145 
Figure 16: A reasonable explanation for the β-selective addition to the activated donor.145 
Since this work involved the preparation of different sugar esters, the following section 
describes various sugar mycolates in the mycobacterial cell wall. 
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1.7 Trehalose Mycolates (Cord Factor): 
Cord Factor is a non-reducing disaccharide, in which two glucose units (linked by an α,α-1,1-
glycosidic linkage) has been esterified at both primary alcohol positions with mycolic acids 
(MAs) creating trehalose di-mycolate (TDM) or esterified at one primary alcohol position to 
form trehalose mono-mycolate (TMM).146 It is one of the most interesting and potentially 
valuable glycolipids found in the cell wall of M.tb. The mycobacterial cell wall contains high 
levels of the free trehalose and esterified trehalose TDM (43) and TMM (44) (Figure 17). 
Figure 17: Structures of TDM and TMM. 
 
The name cord factor has been used in the early papers, as far back as 1947.147 The toxicity of 
cord factors in mycobacteria was reported in 1953 by Bloch et al. when they extracted four 
different strains of cord factors and they tested them on mice. It was proven that cord factors 
caused inhibition of respiratory disease and inflammation.148,149  It has also been confirmed 
that cord factors have anti-bacterial, anti-tumour and anti-parasitic characteristics.150 In 1956, 
the structure of M.tb cord factor was identified by Noll et al.151 Mycobacterial cord factors 
are known as very interesting compounds due to their biological activity, which has been the 
subject of many investigations. Studies showed that these components of mycobacteria have 
immunogenic activity. TDM is necessary for the survival of the mycobacteria inside 
macrophages.152 It can also induce a wide range of cytokine and chemokine production in the 
host’s immune system such as (IL-1β, IL-6, and TNF).153 Early studies showed that cord 
factors can be used as an adjuvant (an agent that can enhance the immune response to an 
antigen) against immunological problems. Meyer and Azuma in 1975 discovered that the cell 
wall components of mycobacteria show adjuvant activity.154 A study by Saito confirmed that 
mycobacterial cord factor was a good adjuvant and could enhance the immune system in 
mice and rats through antibody production. Also, it can cause delayed hypersensivity.155 
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Finally, TMM, TDM and mAG complex are responsible for an extremely hydrophobic surface 
in the cell wall of mycobacteria, which plays a significant role in providing the bacterium with 
high protection from antibodies and from their environment. The enantioselective synthesis of 
these compounds is important to understand their biological properties such as their effects on 
the immune system, in diagnosis and controlling several diseases. 
1.8 Glucose Mono-Mycolate (GMM) 
Glucose mono-mycolate (GMM) is a glycolipid consisting of a mycolic acid attached to a 
glucose molecule at the C-6 position. GMM is present in several bacterial species including 
Mycobacterium Nocardia, Mycobacterium Rhodococcus and M. tuberculosis (Figure 18).156,157 
Figure 18: Glucose mono-mycolate (GMM, 6-O-mycoloyl-D-glucose) from M. tb.158  
GMM can induce a memory T cell response by acting as a protein antigen.157 GMM and 
other antigenic mycobacterial glycolipids are presented to T cells by the CD1 family of 
proteins and the antigen–protein complexes mediate the T cells response in the human 
host.159 However, depending on the species, the meromycolate chain carries variable 
functionalities in the proximal and distal positions, which are characteristic of the species.158 
The structure of GMM from M. tuberculosis is shown in Figure 18. 
The structure of human CD1b and CD1a in a complex with specific GMM glycolipids 
illustrates the binding of a natural bacterial lipid to CD1b and shows how its novel structural 
features fit this molecule for its role in the immune response to intracellular bacteria.160 Many 
health problems globally are caused by mycobacterial infections and it has been suggested 
that anti lipid antibodies may contribute to protection against mycobacterial infection.161 
GMMs have the ability to produce T cell reproductive responses in a number of species 
including cattle,162 humans,163 mice 164 and guinea pigs.165 Nguyen et al. have described cell-
mediated and humoral immune responses in cattle upon vaccination with GMM as the only 
antigen; as a result a T cell response was produced but no antibody responses, while the 
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vaccine comprising a pure protein as the only antigen generated both T cell and antibody 
responses. However, in humans and cattle,166,167 Nguyen et al assumed that a conjugate of 
GMM with a protein may provide T cell help for B cells to produce antibodies against surface 
exposed glycolipids on mycobacteria.162 
The synthesis of GMM from Mycobacterium phlei has been described by Branch et al,168,169 
and the synthesis of 6-O-mycolylglucoses (GMMs) from single synthetic mycolic acids 
matching the overall structure of some of the major natural glucose monomycolates of 
Mycobacterium tuberculosis and other mycobacteria, has been reported by Sahb et al.170 
1.9 Di-Mycolyl di-Arabino Glycerol (DMAG) 
The mAG complex is the largest component structure in the mycobacterial cell wall and acts as a 
permeability barrier that prevents the passage of antibiotics. It’s formed from both galactan and 
arabinan in the furanose form.88,89,171 It is believed that this plays an important role in raising the 
flexibility of the polysaccharide, causing the cell wall to have extremely low permeability, which 
provides the organism with high protection from drugs and from its environment.172 Mycolylated 
glycolipids like GMM, TDM, or GroMM (see Section 1.11), play a significant role in the 
variation of the immune system of the host and among them the mAGP serves as an anchoring 
matrix. Therefore, mAGP is seen as a target for several anti-tuberculosis drugs.82,173 Components 
such as triacylglycerols (TAGs), C70–90 mono-mycolyl glycerol (C70–90 GroMM) and 
phenolic glycolipids (PGLs), separated from the subcutaneous immunisation of mice, induced 
extremely high levels of all three cytokines IL-12, TNF-α and IL-6.174 An antigenic glycolipid, 5-
mycoloyl-β-arabinofuranosyl-(1→2)-5-mycoloyl-α-arabinofuranosyl-(1→1`)-glycerol (DMAG) 
(Figure 19), was isolated for the first time by Watanabe and co-workers in all 12 strains of the M. 
avium-M. intracellulare complex (MAI) and reacted immunologically with antisera from 
rabbits.81,82,173 
 
Figure 19: General structure of DMAG.81 
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DMAG also showed applicability for serodiagnosis of MAI infection by ELISA.175,176,177 In 
1997 DMAG was obtained from M. kansasii among glycolipid fractions of the cell wall.178 
Recently, Rombouts and co-workers identified DMAG in large quantities, in slow growing 
pathogenic species, including M.tb, M. bovis, BCG and M. Scrofulaceum, making this 
glycolipid more biologically potent and possibly important in mycobacterial pathogenesis. 
Studies showed that DMAG isolated from M. marinum and M. bovis BCG are very similar to 
each other except for the terminal lipid moiety MA, which consists of a mixture of alpha, 
keto and methoxy-mycolates in M. marinum while only alpha and keto-mycolates are found 
in M. bovis BCG. Furthermore, the cyclopropane ring in M. marinum seems more likely to be 
in the trans stereochemistry.82 Construction of DMAG in the growing mycobacterium requires 
the presence of glycerol. In addition, drugs used for the inhibition of mAG also inhibit DMAG, 
which again indicates the similarity between these two components and raises a possibility of 
metabolic interconnectivity between them. DMAG is formed during infection with M.tb and is 
not synthesized along with other lipids/glycolipids. It is considered a surface-exposed 
immunogenic molecule, suggesting that it is synthesized through TB infection. In addition, the 
existence of the anti-DMAG antibodies in the sera of patients infected with M. avium further 
suggested that DMAG is an immunogenic compound produced during infection.173,175 TNF-α 
has been proven as a significant inflammatory mediator, that can affect different kinds of 
cells.179,180,181 TNF-α, IL-1β, and IL-8 secretions have been widely used to investigate the 
biological activity of mycobacterial glycolipids; for instance DMAG isolated from M. marinum 
induced TNF-α, IL-1β, and IL-8 on separated cells.82,182,183 Depending on the high similarity 
between TDM and DMAG in their location in the mycobacterial cell wall and their analogous 
structures, it is expected that both glycolipids will show the same characteristics which are 
relevant to mycobacterial pathogenesis, for example, formation of granuloma and tissue-
destructive lesions and proinflammatory cytokine production.184  
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1.10 Di-Mycolyl tri-Arabino Glycerol (DMTAG) 
A new glycolipid, di-mycolyl tri-arabinofuranosyl glycerol (DMTAG) (Figure 20), was 
obtained by McNeil and co-workers after studying the effects of Smith degradation on the 
terminal tetra-mycolyl-penta-arabinofuranosyl unit of mAGP of M. tuberculosis.80 
 
 
Figure 20: General structure of DMTAG.80 
Methyl tri-arabinofuranosyl di-mycolate (MTADM) compounds derived from a natural 
mixture of MAs have been reported in the literature and showed a very high response in the 
stimulation of TNF-α cytokines.80,185 The synthesis, biological activity, particularly the 
antigenicity, of DMTAG glycolipids was not investigated. Furthermore, the stereochemistry 
of the glycerol, i.e. whether it is in the D- or L- configuration, has not been proven. 
1.11 Glycerol Mono-Mycolate (GroMM) 
Complex mixtures of mycolic acids are characteristic components of  mycobacterial cells, either 
bound to the wall as arabinose esters or  not bound to the wall, as free acids or esterified to sugars 
such as glucose (GMM), or trehalose (dimycolate, TDM; monomycolate,  TMM).185 As early as 
1956, it was shown that M. tuberculosis contains C-90 mycolylglycerols.146,186,187,188 Later, 
shorter chain glycerols esters were isolated from Nocardia rhodochrous, which contains 40  44 
carbon atoms (nocardomycoloylglycerols),189 from Corynebacterium pseudoytuberculosis,190 
from Nocardia asteroids,191 and from Rhodococcus lentifragmentus.192 Glycerol monomycolate 
(GroMM, also known as MMG) (Figure 21), is also present in the wax C fraction of BCG.193 
GroMM has been extracted from M. bovis by Layre et al. and the identification of this novel 
antigen is supported by 1H-NMR analysis for the structure of M. bovis BCG GroMM and by the 
mass spectrum.194  
Andersen et al. identified GroMM  in vitro as the most immunopotentiating compound among 
several different lipids isolated from the mycobacterial cell wall.195 Hattori et al. identified 
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GroMM as a specific immune target in human individuals with latent, but not active tuberculosis. 
The in vivo response to GroMM and the relevance of it to latent infection remain poorly 
understood.   
 
Figure 21: General structure of GroMM. 
Hattori et al. immunized guinea pigs with bacillus Calmette–Guerin (BCG) expressing high levels 
of GroMM and then monitored skin reactions at the site of inoculation with GroMM-containing 
liposome. The host responses to GroMM produced by inactive mycobacteria contribute to their 
long-term survival in the host.196 Glycerol esters of complex mixtures of natural mycolic acids have 
strong effects in the immune system.197 The identification of GroMM lipid species formed by 
mycobacteria infected hosts, as well as the analysis of the host response directed toward them, will 
provide important new insights into host-microbe interactions in tuberculosis. These latent 
mycobacteria are unlikely to produce cell wall lipids at a level comparable with that for actively 
replicating microbes, as in the case of the former the bacteria can be eradicated by the host’s 
immune system.198 but a recent study has identified GroMM as a mycobacterial lipid species 
potentially associated with latent infection.199 Mycobacteria have been known as modulators of the 
immune system and as a source of adjuvant preparations. The role of the adjuvants is to potentiate 
or prolong the specific action of a vaccine.174 GroMM has been observed to have adjuvant activity 
in murine models,200,201 with the fine structure of the mycolate components being of importance for 
its proinflammatory activity.202 The GroMM lipid, isolated from M. bovis bacillus Calmette- Guérin 
(BCG), has potent immunostimulatory activity on human dendritic cells, which play an essential 
role in directing the immune response upon infection with pathogens, such as M. tuberculosis. This 
activity was shown by a synthetic analogue of GroMM with shorter fatty acids.197 Bhowruth et al. 
separated a lipid extract of M. bovis BCG showing GroMM as one of  four lipid fractions, which 
showed an ability to induce high levels of some pro-inflammatory cytokines (IL-12 and TNF-α).174  
The synthesis of GroMM using single synthetic mycolic acids will result in a rich knowledge 
of the nature of the cell wall of M. tuberculosis, and hence give a better understanding of 
their effects in the immune system.197  
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The development of such a novel class of synthetic lipids would be suitable for presence in 
vaccines to investigate their use in humans. Such synthetic GroMMs with a R-glycerol 
component (Scheme 5) have been reported by M. Sahb.203,204 They were prepared by two 
methods (Scheme 5). In the first, the TBDMS protected MA was coupled with acetonide (B) 
promoted by DCC and DMAP. In the second, the unprotected acid was coupled with tosylate 
(F) in the presence of cesium hydrogen carbonate. 
Scheme 5: Reagents & conditions: (i) DMAP, DCC; (ii) TFA, CH2Cl2; (iii) CsHCO3; (iv) HCl, THF, H2O.203 
In order to determine whether the biological activitiy of the GroMMs is dominated by the 
S-glycerol unit or the mycolic acid unit, a series of GroMMs containing single enantiomers 
of synthetic mycolic acids were prepared. This will allow the biological activity of these 
compounds to be compared to those of the previously synthesised R-glycerol esters. 
 
 
 
Chapter 1                                                                                                                 Introduction 
30 
 
1.12 TB Detection 
TB infection can be detected through several existing methods; these all meet the WHO’s 
standards, but they still have disadvantages such as high cost, being time consuming, 
inaccurate results, interference by BCG vaccination and their inability to distinguish between 
latent and active TB. A brief description of the tests is given below: 
❖ Bacterial Culture: This method is considered as a gold standard for detecting active 
TB,205 and it has one of the highest sensitivities (sensitivity is defined as the 
proportion of actual positive samples correctly detected by the antigen to the total TB-
positive sera) among TB diagnostics. It can also distinguish TB patients with drug 
resistant strains from those with non-drug resistant strains,206 providing valuable 
information for the treatment of the disease. This method does however take around 3 
to 8 weeks to obtain a result.207,208 
 
 
❖ Tuberculin Skin Test: The tuberculin skin test (TST) was one of the earliest diagnostic 
tools developed against the disease, and it requires 2 to 3 days to obtain a result.206 One 
drawback is that it does not distinguish between latent and active TB; moreover, it cannot 
distinguish an active TB patient from one that was previously infected by the disease.209 
False negative samples include patients co-infected with HIV, while false positive 
samples include patients vaccinated with BCG.207,210,211,212,213,214  
❖ Sputum Smear Microscopy: This is a simple, cheap and fast method of diagnosing 
TB, and relies on direct observation of mycobacteria under a light microscope. It 
cannot however distinguish TB from other mycobacterial diseases.206 An advantage of 
this method over bacterial culture is that the time required for the result is much 
shorter, the staining process being performed in less than 1 hour,215 making this 
valuable as a quick screening method for mycobacterial disease.216,217  
❖ Interferon γ-Release Assay: The principle of the IFN-γ assay is the stimulation of T-
cells to produce IFN-γ when they re-encounter the antigen of M.tb.218 This method 
detects both latent and active TB and again cannot distinguish between them.209,219 It 
is also reasonably fast, with results available in 24 h; no false positive samples are 
seen caused by BCG vaccination. One disadvantage however is there is only a limited 
amount of clinical and laboratory experience with this assay. 220,221,222 
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❖ Nucleic Acid Amplification Test: Detects the presence of the M.tb complex, but 
cannot distinguish the individual mycobacteria. This method does however have low 
limits of detection, and the results are obtained in 2.5 to 3.5 h.223,224  
There are some newly available tests which are simple, faster, less expensive and give better 
results such as: 
• Biosensor Detection of TB: The principle of this method depends on the binding of 
the host antibody to specific antigens such as mycolic acids, cord factors or their 
corresponding thiolated compounds. The main advantages of this method include high 
levels of detection, it is simple to use and very fast.225,226,227 
• Serodiagnostic assays: ELISA assays for the detection of TB are used to detect 
antibodies produced against M.tb. However, the WHO has strongly recommended that 
the current assays are not to be used for the detection of TB. It does however indicate 
that an assay of this kind which does meet its criteria would be valuable. 225,228 
 
1.13 ELISA in the serodiagnosis of TB 
A number of natural mixtures of cord factors and mycolic acids have been shown to have 
strong effects on the immune system and have been used in ELISA (Enzyme-linked 
immunosorbent assay) to investigate both their biological activity and diagnosis applications 
for the serodiagnosis of TB.229,230,231 ELISA is widely used in clinical medicine to detect 
many infectious diseases such as TB. The principle of the method is based on the detection of 
the antibodies in an infected sample through antibody–antigen reaction which produces a 
detectable signal. The test is a rapid and simple screening method.232 ELISA tests have been 
used for TB detection because M.tb has many different antigens which were widely used for 
detection; however, it suffers from low sensitivity and specificity (specificity is the 
proportion of actual negative samples correctly detected by the antigen to the total TB-
negative sera).233 Schleicher et al., used ELISA to try and detect anti-mycolic acid antibodies 
from M.tb in serum samples from patients infected with TB and HIV, and from patients 
infected with TB alone. They used natural mycolic acids, isolated from M.tb, as antigens and 
they showed that the antibody levels were pointedly higher for TB positive sera than for TB 
negative sera and that antibody levels remained largely unchanged between HIV-positive and 
HIV-negative samples, signifying that antibody responses to mycolic acids are also preserved 
in patients who have tested HIV-positive.234 Beukes et al. used synthetic mycolic acids 
Chapter 1                                                                                                                 Introduction 
32 
 
prepared by Al Dulayymi et al. and natural mycolic acids extracted from M.tb to compare the 
antibody responses, in addition to examining their corresponding methyl esters.235 They 
proved that in the case of free mycolic acids the antibody recognition is much higher than 
their corresponding methyl esters, signifying that the carboxylic acid unit of the mycolic 
acids either has a large contribution to the binding of the mycolic acids to the antibodies, or 
that they stabilise a particular antigen conformation. They also established that oxygenateD-
mycolic acids are more antigenic than alpha-mycolic acids. However, none of the 
synthetically produced mycolic acids could reproducibly distinguish TB positive sera from 
TB negative sera.235 
1.15 Overall Aim of this Research: 
The aim of this study was to synthesise two different glycolipids related to the mAG 
complex, as well as, glycerol mycolates, which are present in the cell wall of mycobacteria. 
In particular, the synthesis of:  
1- Di-Mycolyl-Di-Arabino-L-Glycerol (DMAG). 
2- Di-Mycolyl Tri-Arabino-L-Glycerol (DMTAG). 
3- Glycerol Mono-Mycolates (GroMM) with S-stereochemistry of the glycerol 
component, to compare the biological activity of R-GroMM. 
The object of this work was to ascertain if these fragments (Figure 22) have any capacity for 
the stimulation of the production of co-stimulatory molecules and certain pro-inflammatory 
cytokines (e.g. TNF-α, IL-1β, IL-6), in addition to investigating their antigenicity for the 
detection of TB and other mycobacterial infections. 
Figure 22: Structures of target molecules. 
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Chapter 2 
Results and Discussion 
Section 1 
2.1 Synthesis of a single enantiomer of di-mycolyl di-arabinofuranosyl 
glycerol (DMAG) 
2.1.1 The aims of this part 
• Synthesis of di-arabino-glycerol (DAG), 2',3'-di-O-benzyl-L-glycerol-(1'→1)-2,3-di-
O-benzyl-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-α-D-arabinofuranoside. 
 
Figure 23: Structure of the glycan (DAG). 
• Esterification of the above glycan (DAG) with simple fatty acids as model 
glycolipids.  
• Preparation of a number of di-mycolyl di-arabino glycerol (DMAG) esters through 
esterifying the glycan moiety with common classes of synthetic mycolic acids (MAs). 
• Investigation of the biological activity of the synthetic compounds.  
2.1.2 Synthesis of 2',3'-di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-α-D-arabinofuranoside (DAG)  
In the glycosidation reaction, a new stereogenic centre is created at the C-1 position on the 
ring and as a result two different diasteromeric products can be obtained (Figure 24). Thus, 
control of stereochemistry at the anomeric position has been a challenge to organic chemists. 
In nature, glycosidic linkages are formed through reactions catalysed by enzymes 
(glycosyltransferases). The biosynthesis is a highly stereoselective processes due to the specificity 
of the enzymes.236  
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Figure 24: Glycosylation using a donor with a nonparticipating group at C-2. 
In this part of the study, the preparation of the target glycan molecules was undertaken, which 
contains both α- and β- arabinofuranosyl linkages (Figure 25). Formation of the α-glycosidic 
bond can be directly achieved by using neighbouring group participation of the 2-O-acyl 
functionalities in the donor species. The leaving group at the anomeric centre of the donor 
departs by the activation of the promoter to form an oxocarbenium ion, which is immediately 
attacked by the protecting group 2-O-acyl to generate a dioxolenium ion intermediate. The 
dioxolenium ion blocks one face of the molecule and hence, the acceptor has to attack the 
anomeric centre from the less sterically hindered face, through a process that is kinetically 
favoured. Discrimination between α- and β- isomers was achieved using NMR data, 
particularly the δC-1 and 3JH-1,H-2 values. For the β-isomer, δC-1 = 97 – 103 ppm and 3JH-1,H-2 = 
3 – 5 Hz, whereas for the α-isomer, δC-1= 104 –111 ppm and 3JH-1,H-2 = 0 – 2 Hz.237  
 
Figure 25: Glycosidic linkages in the target molecule. 
The synthesis of the DMAG’s acceptor (60) began with commercially available D-arabinose 
(45) as starting material (Scheme 5A). Fischer glycosylation of (45) in methanol under 
kinetic control provided a mixture of methyl-α,β-arabinofuranoside (46). The crude product 
was suspended in dry pyridine without further purification, before acetic anhydride was 
added, to give triacetate (47) in 80% yield. Methyl glycoside (47) was stereoselectively 
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transformed to the α-thioglycoside (48) as the principal product upon reaction with p-
thiotoluene in the presence of boron trifluoride dietherate in CH2Cl2 in 65% yield. 
Subsequent treatment of (48) with NaOCH3 in methanol afforded thioglycoside triol (49) in 
89% yield, which was converted to silyl-protected arabino-thioglycoside (50) in one step. All 
data was identical to those of the authentic samples reported in the literature.238  
Scheme 5A: Synthesis of compound (50): Reagents & conditions: (i) MeOH, HCl, 78%; (ii) Ac2O, pyridine. 0 0C, 80%; 
(iii) p-CH3C6H4SH, BF3.Et2O, CH2Cl2, 0 ºC/R.T., 8 h, 65%; (iv) NaOCH3, MeOH:CH2Cl2 (1:1), R.T., 3 h, 89%; (v) 
TIPDSCl2, pyridine, 6 h, 0 ºC/R.T., 76%. 
Subsequently, benzoyl chloride was used under standard conditions to protect the hydroxyl 
group of (50) at the C-2 position on the sugar ring affording silyl, benzoyl-protected arabino-
thioglycoside (51) in 89% yield (Scheme 6).239  
 
Scheme 6: Reagents & conditions: (a) BzCl, pyridine, 0 ºC/R.T., 89%. 
The initial step in the synthetic route was to construct the previously prepared L-glycerol 
moiety in DMAG’s acceptor and in order to achieve that the silyl benzoyl-protected arabino- 
thioglycoside (51) was subjected to a glycosidation reaction with 2,3-di-O-benzyl-L-glycerol 
(51G) 247 using N-iodosuccinimide (NIS) and silver triflate (AgOTf) in dichloromethane (CH2Cl2) 
at -36 °C (Scheme 7). 
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Scheme 7: Reagents & conditions: (b)        , NIS/AgOTf, CH2Cl2, -36 ºC, 91%. 
This type of glycosidation is highly efficient and highly stereoselective due to the neighbouring 
group participation (benzoyl group at the C-2 position on the glycan ring), thus, only the α-
isomer (1,2-trans isomer) was obtained in an excellent yield of 91% for the fully-protected 
arabiofuranosyl-glycerol (52). The 1H-NMR spectrum showed the α-anomer glycosidic linkage, 
which appeared as the only product, one downfield signal occurring as a broad doublet at 
4.98 ppm (J 1.0 Hz) for the proton at the anomeric centre, while the 13C-NMR showed a peak 
at  105.6 ppm due to the carbon at the C-1 position on the glycan ring (Figure 26), both 
indicating that only the α-anomer was present.  
 
Figure 26: HSQC-NMR of compound (52). 
Deprotection of the benzoyl ester-protecting group of the glycan (52) under Zemplén 
conditions using methanol and a catalytic amount of sodium methoxide afforded (53) in 89% 
yield (Scheme 8).  
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Scheme 8: Reagents & conditions: (c) NaOCH3, CH3OH: CH2Cl2 (1:1), R.T.,1 h, 89%. 
The next step was the protection of the free hydroxyl group at the C-2 position using an allyl 
(All) group. This was achieved through reaction with allyl bromide (AllBr) and NaH in dry 
DMF at 0 ºC to give (54) in 75% yield (Scheme 9).  
 
Scheme 9: Reagents & conditions: (d) NaH, AllBr, DMF, 0 ºC/R.T., 1 h, 75%. 
Removal of the silyl group (tetra-isopropyldisiloxane) was achieved using fluoride ion 
[tetrabutylammonium fluoride solution 1.0 M (TBAF)] in dry THF. This gave two free 
hydroxyl groups at the C-3 and C-5 positions (55) in 95% yield (Scheme 10). 
 
Scheme 10: Reagents & conditions: (e) TBAF, THF, 0 ºC/R.T., 16 h, 95%. 
Two different protecting groups were required at the C-3 and C-5 positions of the DMAG’s 
acceptor. The presence of a p-methoxybenzyl (PMB) protecting group at the C-5 position on 
the acceptor is found to give good β-selectivity when coupling with the donor to form a 
disaccharide.144 In order to obtain this, the hydroxyl group at the C-5 position in (55) was 
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firstly protected using tert-butyldiphenylsilyl ether (TBDPS) to afford (56) in 65% yield, 
followed by protection of the hydroxyl group at the C-3 position with a benzyl (Bn) group 
using benzyl bromide (BnBr) and sodium hydride in DMF at 0 ºC to give (57) in 72% yield. 
De-silylation using TBAF to give a free hydroxyl group at the C-5 position was then carried out 
affording (58) in 91% yield, which was then treated with sodium hydride and freshly prepared 
p-methoxybenzyl bromide (PMBBr) in dry DMF to give (59) in 76% yield (Scheme 11). The 
formation of all these compounds (50-59) was proved by NMR and I.R spectroscopy and mass 
spectrometry. 
Scheme 11: Reagents & conditions: (f) t-BuPh2SiCl, imidazole, DMF, 0 ºC/R.T., 1/2 h, 65%; (g) NaH, BnBr, 
DMF, 0 ºC/R.T., 2 h, 72%; (h) TBAF, THF, 0 ºC/R.T.,16 h, 91%; (i) NaH, PMBBr, DMF, 0 ºC/R.T., 2 h, 76%.  
The final step to prepare the target acceptor was the removal of the allyl protecting group at 
the C-2 position, which was successfully achieved by stirring 59 in a mixture of 
CH3OH:CH2Cl2 and adding 0.2 equivalents of PdCl2 to give the target molecule, the 
DMAG’s acceptor (60) in 84% yield (Scheme 12).  
 
Scheme 12: Reagents & conditions: (j) PdCl2, CH3OH:CH2Cl2 (1:1), R.T., 16 h, 84%. 
Formation of the target acceptor (60) was confirmed by 1H-NMR, which showed one 
downfield signal as a broad singlet at δ 5.03 corresponding to the proton attached to the C-1 
position on the sugar, while the 13C-NMR spectrum showed a signal at δ 109.3 corresponding 
to the C-1 position on the glycan ring. Figure (27 A) shows the correlation of these signals 
by HSQC-NMR. 
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Figure 27 A: HSQC-NMR of the DMAG’s acceptor compound (60). 
The structure of (60) was also confirmed by mass spectrometry. Nano Electrospray Ionization 
(NSI) mass technique, was used to reduce fragmentation and enhance the abundance of the 
intact molecular ion. The [NSI–Found (M+NH4)+: 632.3209; C37H46O8N, requires: 632.3218] 
(Figure 27 B), and the specific rotation which was []
22
D +41.7 (c 1.6, CHCl3) for (59) 
changing to []
22
D +60.0 (c 4.6, CHCl3) for the target molecule (60). 
 
Figure 27 B: Mass spectrum of the DMAG’s acceptor compound (60). 
 
Chapter 2                                            Results &Discussion                                           DMAG 
40 
 
2.1.3 Coupling the donor and the acceptor 
As mentioned earlier, good β-selectivity can be obtained in the case of glycosylation of active 
acceptors and armed donors.145 Active acceptors are species that are not sterically hindered and 
possess electron-donating protecting groups and thus are more nucleophilic, while armed 
donors are referred to as those protected with electron-rich ethers. The next step was the 
coupling of the newly synthesized active acceptor (60), and the armed donor (61), which was 
prepared as reported in the literature,145 to afford the di-saccharide (62) (Scheme 13).  
 
Scheme 13: Reagents & conditions:(k) NIS/AgOTf, CH2Cl2, -78 ºC, 86%. 
The reaction of the 5-O-p-methoxybenzylated glycosyl acceptor (60) and thioglycoside donor 
(61) was carried out in dry CH2Cl2 by cooling the reaction mixture to -78 ºC. Then NIS and 
AgOTf were added and the reaction was warmed to - 60 ºC over 60 _ 90 min. The reaction was 
quenched with trimethylamine and after work-up afforded the desired disaccharide (62) in 
86% yield with excellent β-selectivity, as confirmed by the 1H, 13C and 2D-NMR spectra.  
It was desirable to carry out the coupling reaction between the acceptor and the donor at low 
temperature (-78 ºC) in order to obtain an oxocarbenium ion pair, instead of the free 
oxocarbenium ion intermediate. It has been suggested that at higher temperatures, it is 
possible that this ion pair would dissociate quickly to give the free oxocarbenium ion, which 
would give mixtures of products. This suggested pathway is consistent with earlier studies on 
the glycosylation of fully protected arabinofuranosyl chlorides (Scheme 14).240 
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Scheme 14: Possible mechanism of the glycosylation from the low temperature activation of thioglycosides. 
The 1H-NMR spectrum (Figure 28A) of the new di-saccharide (62) indicated the presence of two 
different anomeric hydrogens due to the two signals downfield at δ 4.96 (br. s) and at δ 4.79 
(br.d, J 4.3 Hz) corresponding to the protons at the α- and β-anomeric centres respectively. The 
13C-NMR spectrum (Figure 28B) confirmed the presence of glycosidic linkages in the glycan due 
to the signals at δ 106.2 and δ 100.6 ppm belonging to the two carbons at the α- and β-anomeric 
centres respectively.   
 
Figure 28 A: 1H-NMR of the di-saccharide (62). 
Chapter 2                                            Results &Discussion                                           DMAG 
42 
 
 
Figure 28 B: 13C-NMR of the di-saccharide compound (62). 
The HSQC-NMR spectrum (Figure 29 A) confirmed the structure of (62), where the acetal 
proton signals were correlated to their carbons. 
 
Figure 29 A: HSQC-NMR of the di-saccharide compound (62). 
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The structure of (62) was also confirmed by mass spectrometry [NSI–Found (M+NH4)+: 
1162.6495; C63H100O13Si3N, requires: 1162.6497] (Figure 29 B). 
 
Figure 29 B: Mass spectrum of the di-saccharide compound (62). 
Since the di-arabino glycerol (DAG) derivative was planned to be used as precursor for a 
range of mono- and di-substituted glycolipids, two orthogonal protecting groups were 
required for the primary hydroxyl groups in the C-5 positions of the arabinosyl residue. This 
would allow one protecting group to be removed in the presence of the other, later in the 
synthesis, so that symmetrical or unsymmetrical glycolipids could be prepared. This will be 
discussed in more detail later (see page 73).  
Subsequently, the cyclic siloxane-protecting group in the pure β-anomer (62) was removed 
by reacting with TBAF for 6 h in dry THF to give the tri-ol (63) in 95% yield (Scheme 15).  
 
Scheme 15: Reagents & conditions: (l) TBAF, THF, 0 ºC/R.T., 6 h, 95%. 
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The first primary hydroxyl group (in the bottom arabinose molecule) has been successfully 
protected with a PMB group, through the synthesis of the DMAG’s acceptor. The new primary 
hydroxyl group (in the top arabinose molecule) needed to be protected with a different group, 
and in order to achieve that, compound (63) was protected with a TBDPS group, in the 
presence of imidazole in dry pyridine at 0 ºC, to afford (64) in 77% yield (Scheme 16).  
 
Scheme 16: Reagents & conditions: (m) t-BuPh2SiCl, imidazole, DMF, 0 ºC/R.T., 2 h, 77%. 
The structure of this compound was confirmed by NMR spectroscopy and mass spectrometry. 
Figures 30 and 31 show the proton and HSQC-NMR where the key peaks corresponding to the two 
different protecting groups (i.e. TBDPS and PMB) at the primary carbons (C-5 positions) of 
each arabinose molecule are shown.   
 
Figure 30: 1H-NMR of the di-saccharide compound (64). 
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Figure 31: HSQC-NMR of the di-saccharide compound (64). 
The next step was the protection of the free hydroxyl groups at the C-2 and C-3 positions (in 
the top arabinose molecule) of compound (64) by reaction with benzyl bromide (BnBr) and 
NaH in dry DMF at 0 ºC  R.T for 2 h to afford (65) in 90% yield (Scheme 17). This 
compound is a key intermediate for the preparation of the glycolipids selectively as will be 
illustrated later (see page 73). 
 
Scheme 17: Reagents & conditions: (n) NaH, BnBr, DMF, 0 ºC/R.T., 2 h, 90%. 
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Having successfully synthesised (65), the next step was to investigate the coupling of the 
disaccharide with commercially available simple fatty acids. In order to achieve this, de-protection 
of the two hydroxyl groups at the C-5 positions was required. Firstly, the TBDPS group on the 
top arabinose molecule was removed by subjecting compound (65) to TBAF in dry THF at 0 ºC, 
affording (66) in 93% yield (Scheme 18).  
 
Scheme 18: Reagents & conditions: (p) TBAF, THF, 0 ºC/R.T., 6 h, 93%. 
After the first de-protection, the alcohol (66) was treated with cerium ammonium nitrate (CAN) 
in a mixture of CH3CN:H2O (9:1) at 0 ºC to R.T for 1h to remove the PMB group, when TLC 
indicated the conversion had finished. The mixture was diluted with chloroform, washed with 
aq. NaHCO3, dried (MgSO4) and the solvent was evaporated under reduced pressure, the 
product was purified to afford the di-ol (67) in 89% yield (Scheme 19).  
 
Scheme 19: Reagents & conditions: (q) Cerium ammonium nitrate (CAN)/ CH3CN:H2O (9:1), 0 ºC/R.T., 1h, 89%. 
Finally, the benzyl-protected diol (67) was treated with methanesulfonyl chloride (MsCl) in 
dry pyridine and catalytic 4-dimethylaminopyridine (DMAP) at room temperature to activate 
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the free primary hydroxyl groups, affording the mesylate benzyl-protected di-saccharide (68) 
in 85% yield (Scheme 20).  
 
Scheme 20: Reagents & conditions: (r) CH3SO2Cl, DMAP, Pyr. 16 h, 85%. 
Once again, the structure of (68) was confirmed by NMR spectroscopy, which gave the signals 
illustrated in Table 2. These assignments were made based on literature values for the 
arabinoglycerol fragment,241 and a detailed analysis of the HSQC-NMR spectrum for the top 
arabinose (Figure 33). 
       Table 2: 1H and 13C-NMR data analysis of the mesylate compound (68). 
 
 
 
The structure of (68) 
was also confirmed by 
mass spectrometry 
[MALDI–Found 
(M+Na)+: 985.3109; 
C50H58NaO15S2, 
requires: 985.3115].  
 
 
 
 
Proton Shift H's Multiplicity J/Hz Carbon δ/ppm 
H-aromatic 7.27 25 m - C1-alpha 106.4 
Hb 5.01 1 br.d 4.4 C2 81.1 
Ha 4.93 1 br. s - C3 83.5 
H-Bn 4.70 1 d 11.7 C4 85.9 
H-Bn 4.67 1 d 11.7 C5 69.9 
H-Bn 4.63 2 br.s - C6 37.5 
H-Bn 4.58 1 d 11.7 C1’’-beta 101.2 
H-Bn 4.51 1 d 11.7 C2’’ 78.4 
H-Bn 4.46 4 br.s - C3’’ 80.9 
Hh 4.32 1 br. q 4.6 C4’’ 83.5 
Hi, I’, n, n’,f 4.20 5 m - C5’’ 69.8 
Hg,j,k 4.10 3 m - C6’’ 37.4 
Hm 4.00 1 br.dd 4.4, 6.9  C-Bn 72.7 
Hc 3.80 1 dd 5.2, 10.3  C-Bn 72.6 
Hd 3.74 1 br. p 5.1 C-Bn 72.4 
Hc’, e, e’ 3.56 3 br. dd 4.6, 7.2  C-Bn 72.3 
(CH3)p 2.85 3 s - C-Bn 73.4 
(CH3)p’ 2.84 3 s - C1` 69.0 
- - - - - C2` 76.9 
- - - - - C3` 67.3 
Figure 32: Structure of the 
mesylate (68). 
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The specific rotation of (67) was []
21
D - 4.3 and changed to []
22
D +2.8 for the target molecule (68). 
 
Figure 33: HSQC-NMR of the mesylate compound (68). 
For the initial series of analogues, fatty acids that are commercially available were chosen, as 
it was expected that they would be easy to connect to the glycan (hydroxylated or mesylated) 
by esterification. Two different methods were used to achieve the esterification:  
1. An alkylative coupling using cesium hydrogen carbonate (CsHCO3) after mesylation of 
the primary hydroxyl groups in the glycan; this method was employed when using free 
simple fatty acids or unprotected mycolic acids (i.e. those with a free hydroxyl group at 
the -position). 
2. Direct coupling of the glycan alcohol with the fatty acid using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI); this coupling method was used when the 
mycolic acids were protected (i.e. did not have a free hydroxyl group at the -position). 
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2.1.4 Esterification of the glycan (68) with simple fatty acids using the CsHCO3 method  
The di-mesylate (68) was reacted with three different simple fatty acids (69a-c), and a model β-
hydroxy acid (69d) via the alkylative esterification strategy, using caesium hydrogen carbonate 
as a coupling reagent in dry THF:DMF (5:1) at 70 ºC for 4 days, to give the expected fully 
protected di-esters (70a-d) in 92, 89, 87 and 55% yield respectively (Scheme 21). Mass 
spectrometry of the products confirmed the structures (as expected) as did I.R. and NMR 
spectroscopy.  
 
Scheme 21: Synthesis of fully protected DMAG glycolipid analogues (70 a-d): Reagents & conditions: (s) 
CsHCO3, THF: DMF (5:1), 70 ºC 3 days, 92, 89, 87 and 55% respectively. 
As an example, the 1H-NMR spectrum for the fully protected di-stearyl di-arabino-glycerol 
(70b), showed two downfield signals at δ 5.01 (br.d J 4.2 Hz) and δ 4.95 (br.s) corresponding 
to the protons of the glycan at the - and -anomeric centers respectively. Protons 
corresponding to the CH2 of the five-benzyl groups appeared between δ 4.69 – 4.38. The 
remaining 15 protons on the sugar moiety and the glycerol appeared in the range from δ 4.30 – 
3.55. Four protons corresponding to the CH2 adjacent to the carbonyl groups in the acid came 
around δ 2.32 as a triplet (J 7.6 Hz) and δ 2.18 as a double triplet (J 1.9, 7.4 Hz) respectively. 
The CH2 chain ranged from δ 1.69 – 0.95 and the protons of the terminal CH3 of the acid part 
came up-field around δ 0.85 as a triplet (J 6.8 Hz). 
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Figure 34: 1H-NMR of fully protected DMAG analogue compound (70b). 
The 13C-NMR spectrum showed two carbonyl signals at δ 173.5 and δ 173.3. Signals for the 
carbon at the -anomeric centre was at δ 106.1 while that at the -anomeric centre was at δ 
100.4. The remaining sugar and glycerol carbons were in the region of δ 85.5 – 63.7.         
The carbons for the CH2 chain ranged from δ 34 - 22 and the carbons of the CH3 came up-
field around δ 14.1. The specific rotation of (68) was []
22
D +2.8 changing for the protected di-
ester (70b) to []
22
D -14.6. The I.R. spectrum of (70b) gave bands for the two carbonyl groups 
at 1740 and 1731 cm-1.  
 
Figure 35: 13C-NMR of fully protected DMAG analogue compound (70b). 
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The protected esters (70a-d) were then subjected to hydrogenolysis to afford the target 
DMAG glycolipid analogues (71a-d) (Scheme 22). 
 
Scheme 22: Synthesis of DMAG glycolipid analogues (71 a-d): Reagents & conditions: (t) (Pd(OH)2-C/20%), 
H2 atmosphere, CH3OH:CH2Cl2 (1:1), R.T., 36 h, 82, 81, 87 and 74% respectively.  
The debenzylation was achieved by stirring (70a-d) in dry CH2Cl2:MeOH (1:1) in the 
presence of Pd(OH)2 (0.75 eq. fold by weight) under a hydrogen atmosphere (using a 
hydrogen filled balloon). Once again, mass spectrometry, I.R. and NMR spectroscopy proved 
the formation and the structure of the products (71a-d). The 1H-NMR spectrum of (71b) for 
example, showed clearly the disappearance of those signals corresponding to the methylene 
protons of the benzyl groups between δ 4.69 – 4.38, and the aromatic protons between δ 7.32 
– 7.15. Two downfield signals appearing as a broad doublet at δ 5.01 (J 4.3 Hz) and a broad 
singlet at δ 5.00, corresponded to the protons at the - and -anomeric centers respectively. 
The remaining protons on the glycan moiety and the glycerol appeared in the range from δ 
4.35 – 3.51. The CH2 adjacent to the carbonyl groups in the acid came around δ 2.33 as a 
triplet (J 7.5 Hz). The CH2 chain ranged from δ 1.7 – 0.90 and the protons of the terminal 
CH3 of the acid part came up-field around δ 0.86 as a triplet (J 6.3 Hz). The 13C-NMR 
spectrum showed two carbonyl signals at δ 174.3 and δ 174.0, while the -anomeric centre 
appeared at δ 105.8 and that of the -anomeric centre at δ 101.9. The remaining sugar and 
glycerol carbons were in the region of δ 88.5 – 63.3. The carbons of the CH2 chain ranged 
from δ 34.0 – 22.0 and the carbons for the CH3 groups came up-field around δ 14.0.  
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Figure 36: 1H and 13C-NMR of DMAG analogue compound (71b). 
The 2D-NMR spectrum (Figure 37) for (71b) showed the acetal proton signals were 
correlated to their carbons.  
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Figure 37: HSQC-NMR of DMAG analogue compound (71b). 
The specific rotation of (70b) was []
22
D -14.6 changing for the target DMAG glycolipid analogue 
(71b) to []
25
D -3.4. The MS gave the correct mass ion, and the I.R. spectrum of (71b) gave a 
broad absorbance at 3430 cm-1 for the five hydroxyl groups and a band for the carbonyl groups at 
1737 cm-1.  
2.1.5 Comparison of the NMR data for the glycan part of the synthetic and natural DMAG 
After successfully synthesising the DMAG analogues, a comparison of the synthesised DMAG 
glycolipid analogue (particularly the sugar part) with that reported for the natural mixture (as 
DMAG per-acetate) was needed to confirm the structure of the synthetic DMAG. Therefore, the 
five free hydroxyl groups in (71c) were acetylated with acetic anhydride in anhydrous pyridine at 
0 ºC to give the penta-acetate (72) in 83% yield (Figure 38).  
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Figure 38: Structure of synthetic DMAG penta-acetate analogue compound (72). 
The NMR data for (72) gave the signals illustrated in Table 3. 
Table 3: A comparison of di-arabino-glycerol fragment of carbon and proton NMR spectra of synthetic and natural 
DMAG penta-acetates.  
  Natural DMAG peracetate81 Synthetic DMAG penta-acetate 
analogue (72) 
G
ly
ce
ro
l 
13C 
δ/ppm 
1H 
Shift, Class, J/Hz 
1H 
 Shift, Class, J/Hz  
13C 
δ/ppm 
C1’ 65.3 3.60 (dd, J 4.5, 11.0), 
3.80 (dd, J 5.2, 11.0) 
3.60 (dd, J 4.5, 11.0), 
3.80 (dd, J 5.2, 11.0) 
65.3 
C2’ 69.8 5.20 5.21(m) 69.8 
C3’ 62.8 4.25 (dd, J 4.0, 11.7), 
4.17 (dd, J 5.2, 11.7) 
4.37 (dd, J 4.6, 11.6), 
4.20 (m) 
62.6 
A
ra
b
in
o
se
 B
 
C1 99.5 5.39 (d, J 4.7) 5.40 (br.d, J 4.7) 99.4 
C2 77.2 4.98 (dd, J 4.7, 6.6) 4.95 (br.dd, J 4.7, 6.6) 77.5 
C3 75.4 5.34 (dd, J 5.1, 6.6) 5.34 (dd, J 5.3, 6.3) 75.6 
C4 79.0 4.12 (dt, J 4.6, 5.1, 7.8) 4.12 (m) 79.1 
C5 65.2 4.38 (dd, J 4.6, 11.6), 
4.22 (dd, J 7.8, 11.6) 
4.37 (dd, 4.6, 11.6), 
4.20 (m) 
65.2 
A
ra
b
in
o
se
 A
 
C1’’ 105 4.91 (s) 4.91 (br.s) 105 
C2’’ 84.0 4.22 (m) 4.21 (m) 84.0 
C3’’ 77.5 4.98 4.95 (br.dd, J 4.7, 6.6) 77.5 
C4’’ 80.8 4.17 4.17 (m) 80.6 
C5’’ 63.8 4.18, 4.30 
(dd, J 2.7,10.3) 
4.18 (m) 63.6 
 
The 2D-NMR spectrum (Figure 39) for (72) also showed the acetal proton signals were 
correlated to their carbons. 
Chapter 2                                            Results &Discussion                                           DMAG 
55 
 
 
Figure 39: HSQC-NMR of DMAG penta-acetate analogue compound (72). 
The comparison of the reported data for the natural mixture (containing a mixture of mycolic acids) 
with that of the synthetic compound, confirmed the structure of the DMAG core and showed a very 
good agreement between the signals for the di-arabino-glycerol fragments of the natural and 
synthetic molecules (Figure 40). 
 
Figure 40: A comparison of 1H-NMR spectra of synthetic DMAG penta-acetate analogue (72) with that 
reported for the natural mixture.81 
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2.1.6 Esterification of the glycan (68) with synthetic methoxy-MA (73) using the CsHCO3 method   
Having secured a successful method for synthesizing model analogues of DMAG containing 
simple fatty acids, an attempt to prepare the desired DMAG containing a mycolic acid by the 
same method as above was undertaken. Firstly, the structurally defined synthetic MA (73) 
provided by Dr. Al Dulayymi,110 a methoxy-cis-cyclopropane with a 22 carbon α-alkyl chain, 
which is present in nature in M. kansasii, was reacted with the mesylate (68), using cesium 
hydrogen carbonate (10 eq.) in dry DMF:THF (1:5) at 70 ºC for 4 days to afford (74) in 54% 
yield (Scheme 23). This yield was lower than those observed when preparing DMAG 
glycolipids with simple fatty acids (70a-c); a possible reason for this may be due to the 
presence of more functional groups in the methoxy-MA chain and also due to there being 
more steric hindrance. 
Scheme 23: Synthesis of fully protected DMAG glycolipid (74). 
The success of the esterification was demonstrated by mass spectrometry, I.R and 1H-NMR 
spectroscopy, where the characteristic signals corresponding to the protons at the - and -
anomeric centres appeared as a broad singlet at δ 4.93 and broad doublet at δ 4.97 (J 4.3 Hz) 
respectively. The region of interest is between δ 0.61 and - 0.36 (cyclopropane reigon), which 
corresponds to the eight protons of the two cis-cyclopropane rings. The proton Ha (Figures 
41 & 42) gave a doublet of triplets, the broadness of this signal shown at δ 0.56 to 0.48 is 
possibly because Hc and Hc` are not magnetically equivalent and the signal observed is 
actually a double doublet of doublets. However, due to the signals being at a nearly identical 
chemical shift it appears as a doublet of triplets. The proton Hb should show a doublet of 
triplets. However, due to the difference of Hc and Hc` the signal at δ - 0.3 to - 0.4 is distorted 
and it appears as a broad quartet. Protons Hc and Hc` again showed a distorted multiplet at δ 
0.67 to 0.57 for the same reason. A singlet at δ 3.31 corresponded to the methoxy group in 
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the MA. The α-proton Hd exhibits a multiplet at δ 2.42 – 2.32, which is not consistent with 
the expected splitting pattern (should be a doublet of triplets), due to the complexity of the 
ring the signal was distorted. Hf is seen as a doublet of triplets at δ 2.95 – 2.90 due to it being 
adjacent to the methoxy group, and the splitting pattern observed is consistent with the 
expected splitting pattern. Signals corresponding to the benzylic protons were seen as three 
doublets at δ 4.41, 4.58, 4.67 (the coupling constant for each signal being 11.6 Hz) and two 
multiplets at δ 4.47 and 4.63.  All the remaining protons on the glycan moiety and the 
glycerol part appeared in the range from δ 4.30 – 3.50.  
 
Figure 41: Structure of fully protected DMAG compound (74). 
 
Figure 42: 1H -NMR of fully protected DMAG compound (74). 
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The 13C-NMR spectrum showed two carbonyls at δ 175.04 and δ 175.03 with a slight 
downfield shift, the carbon of the -anomeric centre appeared at δ 105.9 and that of the -
anomeric centre at δ 100.4. The remaining sugar and glycerol carbons were in the region of δ 
85.5 – 63.7, and the methoxy group at δ 57.7, The carbons of the CH2 chain ranged from δ 
35.0 – 22.0 and the carbons of the CH3 came up-field at around δ 14.0 (Figure 43).  
 
Figure 43: 13C-NMR of fully-protected DMAG compound (74). 
Debenzylation of (74) was achieved by the method described previously to give the target 
DMAG (75) in 73% yield (Scheme 24).  
 
Scheme 24: DMAG glycolipid of methoxy-MA (75). 
Once again, the 1H and 13C-NMR spectra for (75) showed the disappearance of those signals 
corresponding to the methylene group of the benzyl groups, as well as, the aromatic signals. 
All the remaining signals corresponding to the glycan core, the glycerol and the methoxy-MA 
are similar to those of (74) as discussed before. 
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Figure 44: 13C-NMR of DMAG compound (75). 
2.1.7 Esterification of the glycan (67) with different synthetic MAs using the EDCI method  
In order to explore another route for esterification and to produce a series of DMAG 
glycolipids from the most common classes of synthetic mycolic acids, a direct esterification 
method was undertaken using the EDCI method. The advantage of this is that it avoids 
protecting the primary hydroxyl groups of the sugar and gives a good yield. According to the 
literature, direct esterification between the primary hydroxyl group of α-D-Araf and a 
carboxyl group in natural MA was achieved in a low yield (30%) due to the tendency of the 
hydroxy acid to undergo self-condensation; however, by using a MA protected at the -
position (the secondary hydroxyl group) with tert-butyldimethylsilyl (TBDMS), the yield of 
the coupling was raised to 97%. Therefore, the direct condensation of the sugar-diol (67) with 
three different protected synthetic MAs (76f-h) was investigated, using EDCI as an activating 
agent and DMAP as catalyst in dry CH2Cl2 and stirring for five days at room temperature, to 
give the fully protected DMAG’s (77f-h) (Scheme 25).  
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Scheme 25: Synthesis of fully protected DMAG glycolipids (77f-h). 
 
Confirmation of the formation of (77f-h) was achieved by mass spectrometry, I.R and NMR 
spectroscopy. The NMR spectra for (77f) (Figure 45) showed characteristic signals for both 
the glycan and keto-MA illustrated in Table 4. 
 
Figure 45: Structure of compound (77f). 
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Table 4: The 1H and 13C-NMR data analysis of compound (77f). 
Proton Shift H's Class J/Hz Carbon δ/ppm 
H-aromatic 7.30 25 m - C6 215.2 
H () 5.03 1 br.d 4.2 C7 174.3 
H () 4.97 1 br. s - C7’’ 174.1 
H-Bn 4.72 1 d 11.6 C1-alpha 105.9 
H-Bn 4.68 3 d 11.6 C1’’-beta 100.2 
H-Bn 4.62 1 d 11.7 C4 84.9 
H-Bn 4.52 4 m - C4’’ 84.6 
H-Bn 4.43 1 d 11.7 C3 83.6 
H 4 4.37 1 br. q 4.6 C3’’ 83.3 
H (3’’, 4’’, 5’’, 5) 4.20 6  m - C2 80.1 
H 2 4.06 1 t 6.0 C2’’ 79.1 
H 2’’ 4.00 1 br.dd 4.3, 6.5 C2` 77.1 
H Ha, 3’, 1’ 3.88 4 m - C-Bn 73.4 
H 2’ 3.78 1 br.p 4.7, 9.7 C8 73.1 
H 3, 1’, 3’ 3.60 3 br.dd 4.4, 10.4 (C-Bn) x2 72.5 
H 11 2.53 4 sextet 6.8 C-Bn 72.4 
H b, c 2.42 4 dt 1.0, 7.2 C-Bn 72.2 
(CH2-Chain) 1.35 288 m - C1` 70.3 
(CH3)-12 1.06 6 d 6.9 C3` 67.2 
(CH3)-14 0.89 12 t 6.8 C5 66.3 
H (tert-butyl)-16 0.86 9 s - C5’’ 64.3 
H (tert-butyl)-16’ 0.84 9 s - C9 51.5 
H d,d’ 0.67 4 m - C10 51.4 
He’ 0.57 2 dt 4.1, 8.4 C11 46.3 
(CH3)-16 0.04 3 s - C11’’ 41.1 
(CH3)-16 0.03 3 s - C12 16.4 
(CH3)-16’ 0.02 3 s - C13 15.8 
(CH3)-16’ 0.01 3 s - C14 14.1 
H e - 032 2 br.q 5.1 C15 10.9 
 
 
Figure 46: 1H-NMR of compound (77f). 
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Figure 47: HSQC of compound (77f). 
2.1.7.1 Deprotection of TBDMS groups from the MAs core: 
Compounds (77f-h) were then de-protected in two steps. Firstly, removal of the TBDMS 
group from the -position of the MA part by using TBAF in dry THF at 0 °C – R.T under 
nitrogen atmosphere for 16 hr gave (78f-h) in 38, 64 and 31% yield respectively (Scheme 26).  
 
Scheme 26: Removing of TBDMS group from compounds (78f-h). 
For example, the 1H-NMR spectrum for (78f) confirmed the disappearance of the signals for 
the TBDMS groups at  0.86 and  0.84 ppm corresponding to two tert-butyl groups, and 
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between  0.04 – 0.01 ppm corresponding to four methyl groups, which confirmed that the 
deprotection was successful.   
 
Figure 48: Structure of compound (78f). 
 
Figure 49: 1H-NMR of compound (78f). 
Secondly, the removal of the benzyl groups (hydrogenolysis) from (78f-h) was accomplished 
by stirring in dry CH2Cl2:MeOH (1:1) in the presence of Pd(OH)2 under a hydrogen 
atmosphere leading to the target DMAG glycolipids (79f-h) in 71, 70 and 72% yield 
respectively (Scheme 27).  
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Scheme 27: Hydrogenolysis of compounds (79f-h). 
The 1H-NMR spectrum (Figure 51) for (79f) showed the disappearance of the signals for the 
aromatic protons at  7.20 ppm, as well as, the complete loss of the signals for the CH2 of the 
benzyl groups between  4.71 – 4.45 ppm, which confirmed the success of the 
hydrogenolysis.  
The 13C-NMR spectrum showed the anomeric carbon signals at 105.8 and 101.5 ppm for the 
 and  anomers respectively. The remaining NMR data for the sugar and MAs appeared 
approximately similar to that of (78f).  
 
Figure 50: Structure of compound (79f). 
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Figure 51: 1H and 13C-NMR of compound (79f). 
The HSQC-NMR spectrum (Figure 52) for (79f) showed the acetal proton signals were 
correlated to their carbons. 
 
Figure 52: HSQC of compound (79f). 
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2.1.7.2 Esterification of the glycan (67) with -MA (76g) using the EDCI method  
The Synthetic α-MA (76g)109 was esterified with the glycan (67) using EDCI to give (77g) 
(Scheme 25).  
 
Figure 53: Structure of compound (77g). 
The 1H-NMR spectrum of this compound showed 4 singlets at δ 0.04, 0.02, 0.01 and -0.01 
for 12 protons corresponding to the TBDMS group, and the two protons at the β-position to 
the carboxylic group in the two MAs as a multiplet at δ 3.97 – 3.80. The signal for the proton 
at the α-position in the MA appeared as a multiplet at δ 2.63 – 2.46 for two protons. The 
signals of the cyclopropane protons were seen as a broad quartet (4H) at δ - 0.32 (J 5.1 Hz), a 
doublet of triplets (4H) at δ 0.57 (J 4.1, 8.5 Hz) and a multiplet (8H) at δ 0.80 – 0.59. Signals 
corresponding to the glycan moieties were similar to those of the previously prepared 
DMAG’s. Formation of (77g) was proved by the 13C-NMR spectrum, which showed two 
signals for the carbonyls at δ 174.3 and δ 174.1, and the anomeric carbons at the - and β- 
positions which resonated at δ 105.9 and δ 100.2 respectively.  
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Figure 54: 1H and 13C-NMR of compound (77g). 
This compound was then deprotected to remove the TBDMS groups using the same 
conditions as before, to give (78g) in 64% yield (Figure 55).  
 
Figure 55: Structure of compound (78g). 
The 1H-NMR spectrum for (78g) confirmed the complete disappearance of the signals for the 
TBDMS group, which confirmed that the de-silylation had been successful. 
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The hydrogenolysis of this compound by the method described before afforded (79g). 
 
Figure 56: Structure of compound (79g). 
Confirmation of the formation of (79g) was achieved by 1H-NMR spectroscopy. Signals for the 
cyclopropane appeared at approximately the same chemical shift as those in the spectrum of (78g). 
The 13C-NMR spectrum showed two ester carbonyls at δ 175.1 and 175.0. Two signals at δ 
105.9, 100.4 corresponded to the carbons at the positions -and -in the glycan respectively. 
The remaining sugar carbons were in the region of δ 87 – 52. The CH2 chain ranged from δ 
35 – 22 and the CH3 came up-field to around δ 14.0. 2D-NMR was used to provide further 
proof of the structure. Figure 57 shows the HSQC spectrum of (79g) where the acetal proton 
signals were correlated to their carbons. 
 
Figure 57: HSQC of compound (79g). 
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2.1.7.3 Esterification of the glycan (67) with keto-MA (76h) using the EDCI method  
The keto-MA with a trans-cyclopropane (76h)111 has been found in the cell wall of M. tuberculosis. 
The sugar-diol (67) was coupled with this synthetic keto-MA by the method described above to 
prepare (77h) (Figure 58) in 91% yield.  
 
Figure 58: Structure of compound (77h). 
The most interesting signals in the 1H-NMR spectrum (Figure 59) for each MA in this 
compound were in the area between δ 0.50 and δ 0.06 and corresponded to the four protons 
directly bound to the trans-cyclopropane. The region between δ 0.35 – 0.05 contained signals 
for the three different hydrogens. This is because Ha and Ha` are non-equivalent and each has 
three couplings, each signal splitting to give a double doublet of doublets (8 lines), which 
leads to 16 lines. Hb should give a double double doublet of doublets of doublets (32 lines) as 
it is coupled to five non-equivalent protons; however, due to overlap with the signals for Ha 
and Ha`, Hb cannot be resolved fully at δ 0.24 – 0.18. Hc, represented by the broad multiplet at      
δ 0.50 – 0.38, should give a doublet of doublets of doublets of doublets (16 lines). However, 
a complex broad multiplet is observed due to the presence of four similar coupling constants 
leading to the overlapping of peaks. The β-chiral centre proton Hg gave a doublet of triplets at 
δ 2.42 ppm (J 1.0, 7.5 Hz). The -proton He and the CH2 group adjacent to the distal position 
appeared as a multiplet at δ 2.53. The region between δ 0.91 – 0.87 (9H, including a triplet at 
0.89 with J 7.5 Hz) corresponding to the three terminal methyl groups and the doublet at       
δ 1.06 (J 6.9 Hz) corresponds to the other α-methyl groups.  
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Figure 59: 1H-NMR of compound (77h). 
The 13C-NMR of compound (77h) (Figure 60) showed characteristic signals illustrated in Table 5. 
 
Figure 60: 13C-NMR of compound (77h). 
Table 5: The 13C-NMR data analysis of (77h). 
 
This compound then was de-silylated by using the method described previously to give (78h) 
(Figure 61). 
Cn C1 / C1’’ C2 / C2’’ C3 / C3’’ C4 / C4’’ C5 / C5’’ C6 / C6’’ C7 C8 C9 C10 C11 
δ/ 
ppm 
105.9/ 
100.1 
80.1/ 
79.1 
83.6/ 
83.3 
84.9/ 
84.6 
67.2/ 
66.3 
174.3/ 
174.1 
14.1 72.4 18.6 26.1 10.5 
Cn C12 C13 C14 C15 C16 C17 C18 C1’ C2’ C3’  
δ/ 
ppm 
38.1 19.7 215.2 46.3 16.4 14.1 51.5 70.3 77.2 67.2 
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Figure 61: Structure of compound (78h). 
The 1H and 2D-NMR spectrum for this compound showed the success of the de-protection 
through the disappearance of the signals belong to TBDMS group (Figure 62 and 63). 
 
Figure 62: 1H-NMR of compound (78h). 
 
Figure 63: 2D-NMR of compound (78h). 
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Hydrogenolysis of (78h) was achieved as above to afford (79h) (Figure 64). 
 
Figure 64: Structure of compound (79h). 
Once again, compound (79h) showed characteristic NMR signals (Figure 65) between δ 0.51 
to 0.05 for the protons of the trans-cyclopropane. The signals for protons on the - and -
anomeric centres appeared as a broad singlet at δ 5.03 and a broad doublet at δ 5.04 
respectively. The remaining 17 protons on the glycerol and the glycan moieties, as well as the 
proton at the -hydroxy position of the MAs, appeared between δ 4.54 - 3.58. 
 
Figure 65: 1H-NMR of compound (79h). 
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Section 2 
Orthogonal protection 
2.2 Selective esterification at each primary alcohol position 
As mentioned earlier, the strategy in the synthesis of the glycan di-arabino glycerol was to 
put two different protecting groups at the primary hydroxyl group (C-5) of each arabinose 
molecule. This was achieved successfully by having a PMB group on the lower arabinose 
molecule through the synthesis of the DMAG’s acceptor, and after coupling the donor and 
acceptor, a TBDPS group was also added to the top arabinose molecule (65). The reason for 
having two different protecting groups, was to allow selective esterification with different 
acids at each primary alcohol position, and control the synthesis of either mono- or di-
(symmetrical or unsymmetrical) glycolipids. Thus, if the esterification process is carried out 
before removal of the PMB group, a mono-mycolyl di-arabino-glycerol can be produced, 
esterifing only on the top arabinose, which could then be selectively acylated on the lower 
arabinose as illustrated in (scheme 28). 
Scheme 28: Selective esterification to make mono and symmetrical di-glycolipid. 
Reagents and conditions: (i) TBAF, THF, 0 ºC/R.T., 6 h, 93%; (ii) EDCI, RCOOH, CH2Cl2, DMAP, R.T., 48 h, 85%.; 
(iii) Cerium ammonium nitrate (CAN), CH3CN:H2O:THF (9:1:0.2), 0 ºC-R.T., 16 h, 83%; (iv) EDCI, R1COOH, 
CH2Cl2, DMAP, R.T., 72 h, 50%.  
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2.2.1 Selective esterification of the glycan (66) with behenic acid  
After removing the TBDPS group from (65) using TBAF to give (66), direct condensation 
with behenic acid was carried out using EDCI as a coupling reagent and DMAP as catalyst in 
dry CH2Cl2 for 2 days to give the expected mono-ester (80a) in 85% yield (Figure 66).  
 
Figure 66: Structure of compound (80a). 
The NMR data confirmed the formation of the mono-ester (80a) and appeared similar to that 
of the DMAG analogue (70c) but with only half of the behenate integration as expected. The 
1H-NMR spectrum included two downfield signals at δ 7.15 (d J 8.6 Hz) and δ 6.77 (d J 8.5 
Hz) corresponding to the protons of the PMB ring, and two downfield signals at δ 5.00 (br.d J 
4.1 Hz) and δ 4.95 (br.s) corresponding to the glycan protons at the - and -anomeric 
centres respectively. The protons of the methoxy group of the PMB in the glycan gave a 
singlet at δ 3.72; the presence of this singlet and the two-doublets mentioned above for the 
PMB ring, is good evidence that the PMB group remains within the glycan structure. Twelve 
protons corresponding to the CH2 of five benzyl groups, and one methylene of the PMB 
appeared between δ 4.61 – 4.25. The remaining 15 protons of the sugar moiety and the 
glycerol part appeared in the range from δ 4.25 – 3.47. Two protons corresponding to the CH2 
adjacent to the carbonyl group in the acid came around δ 2.13 as a double triplet (J 3.6, 7.7 
Hz). The CH2 chain ranged from δ 1.53 – 1.02 and the protons of the terminal CH3 group of 
the acid part came up-field around δ 0.81 as a triplet (J 6.7 Hz).  
The 13C-NMR spectrum showed a characteristic signal at δ 173.4 due to one carbonyl group, 
and the four CH groups of the PMB ring were seen in the region δ 130.2 and δ 113.7 ppm. 
Carbons corresponding to the - and -anomeric centres appeared at δ 106.0 and δ 100.5 
respectively, while the remaining carbons of the sugar and glycerol part were seen in the region 
of δ 85.9 – 66.0. The carbons of the CH2 chain ranged from δ 34.0 – 22.7 and the carbons of the 
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CH3 came up-field around δ 14.1. All the signals described above are shown in the HSQC-NMR 
spectrum (Figure 67), which confirmed the structure of the compound.  
 
Figure 67: 1H, 13C and HSQC-NMR of compound (80a). 
De-protection of (80a), removing the PMB group, was carried out by using ceric ammonium 
nitrate (CAN) in a mixture of CH3CN: H2O (9:1) and stirring at 0 ºC R.T for 1 h. to afford 
(81a) in 62% yield (Figure 68).  
 
Figure 68: Structure of compound (81a). 
 

Chapter 2                                            Results &Discussion                                           DMAG 
76 
 
Once again, the formation of this compound was proved by mass spectrometry and NMR 
spectroscopy (1H and 13C), which showed approximately similar signals for the glycan and the 
acid to those of (80a), except those signals corresponding to the PMB group (Figure 69). The 
I.R. spectrum of (81a) gave characteristic bands for the hydroxyl group at 3414 and the 
carbonyl group at 1737 cm-1.  
 
Figure 69: 1H-NMR of mono-ester alcohol compound (81a). 
Now, by utilising the same coupling conditions as before, compound (81a) and a second 
molecule of behenic acid were coupled again to make a model glycolipid. This time the 
reaction mixture was stirred for 72 h, and afforded a symmetrical fully protected DMAG 
analogue compound (82a) in 50% yield (Figure 70).  
 
Figure 70: Structure of compound (82a). 
The 1H-NMR spectrum (Figure 71) of this compound showed signals and integration 
corresponding to the glycan and the acid part moieties that were identical to those of the 
previously prepared and discussed compound (70c) (Scheme 21).  
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Figure 71: 1H-NMR of a symmetrical fully protected DMAG analogue compound (82a). 
2.2.2 Selective esterification of the glycan (66) with a protected keto-MA (76f)  
The glycan (66) was coupled with a TBDMS-protected synthetic keto-MA (76f)111 by the 
same method described above to prepare (80b) in 86% yield (Figure 72).  
 
Figure 72: Structure of compound (80b). 
This showed characteristic NMR signals (Figure 73 and 74); all the signals corresponding to 
the glycerol glycan part were approximately similar to those of (80a) and the signals 
belonging to the mycolic acid were identical to those discussed before for the keto-MA.  
 
Figure 73: 1H-NMR of compound (80b). 
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Figure 74: HSQS-NMR of compound (80b). 
Next, ceric ammonium nitrate (4 eq.) was used, this time in a mixture of CH3CN: H2O: THF 
(9:1:0.2) and stirring at room temperature for 16 h, to remove the PMB group. Surprisingly, 
this resulted in the removal of both the PMB group from the lower arabinose molecule, as 
expected, and also the TBDMS group from the -position of the mycolic acid core, to afford 
(81b) in 83% yield (Figure 75).  
 
Figure 75: Structure of compound (81b). 
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The 1H-NMR spectrum showed characteristic signals for the glycan and the acid part similar 
to those of (80b), apart from those signals corresponding to the PMB and TBDMS groups 
(Figure 76). 
 
Figure 76: 1H-NMR of compound (81b). 
To examine the coupling at the free hydroxyl group on the bottom arabinose molecule, and to 
avoid the complexity of the 1H-NMR for the resulting product, a second esterification of 
(81b) with a second protected keto-MA (same MA) was achieved by the method given 
previously, and afforded (82b) in 50% yield (Figure 77). The low yield in comparison to the 
previous method, may be related to the sterically hindred structure of (82b).  
 
Figure 77: Structure of compound (82b). 
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Compound (82b) showed characteristic NMR signals for the glycan and the acid part, again 
similar to those for (81b) with double integration, and new signals for the protected mycolic 
acid. Figure 78 shows the 1H-NMR spectrum of (82b) which confirmed the structure of the 
compound.  
 
Figure 78:1H-NMR of compound (82b). 
The 13C-NMR spectrum of (82b) showed characteristic signals at  215.2 for the keto-MAs and 
at  175.0 and 174.4 for the ester carbonyls.  
It is worth mentioning that by esterifying the DMAG in two separate steps, this will allow 
unsymmetrical DMAG’s, with two different MAs, to be prepared. This may be useful for the 
biological assays, and may lead to compounds with improved biological activity.   
 
2.2.3 Summary 
In this part of the thesis, the following targets have been achieved successfully: 
1. The glycan moiety di-arabino glycerol (DAG) incorporating L-glycerol was 
synthesised with the correct stereochemistry. 
2. Esterification of the above moiety with three different simple fatty acids to make the 
DMAG glycolipid analogues has been carried out.  
3. A model DMAG using a -hydroxy acid coupled to DAG, was prepared. 
4. Esterification with four common classes of synthetic mycolic acids, to make the DMAG 
glycolipids has been achieved. The synthesised glycolipids are shown below (Figure 79).  
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Figure 79: Structures of synthesised DMAG glycolipids. 
5. The penta-acetate analogue of the DMAG of behenic acid was prepared to compare it 
with the natural mixture. This proved and confirmed the structure and stereochemistry 
of this novel sugar of the DMAG glycolipid to be --di-arabino-furanosyl glycerol. 
 
Figure 80: Structure of synthetic DMAG penta-acetate analogue (72). 
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6. Selective esterification with different acids at each primary alcohol position was 
carried out, to produce prepared mono or symmetrical di-glycolipids. The prepared 
mono- and di-glycolipids are shown below (Figure 81). 
Figure 81: Structures of selective mono- and di-symmetrical protected glycolipids. 
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Section 3 
2.3.1 Synthesis of di-mycolyl tri-arabinofuranosyl glycerol (DMTAG) 
2.3.2 The aims of this part 
• To prepare the glycan tri-arabinofuranosyl glycerol (TAG) (Figure 82), which is 2',3'-
di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-α-D-arabinofuranosyl-(1→3)-[2,3-di-O-
benzyl-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl -α-D-arabinofuranoside. 
 
Figure 82: Structure of the glycan (TAG). 
• To prepare a model glycolipid formed by the esterification of TAG with a simple fatty acid. 
• To prepare a series of DMTAG glycolipids, through esterification of the above glycan 
with structurally defined synthetic MAs. 
• To investigate the biological activity of the synthesised compounds, as they are 
important components of the cell wall of mycobacteria. In particular, their 
antigenicity will be studied.   
2.3.3 Synthesis of fully protected tri-arabino-furanosyl glycerol (TAG) 
Although the methyl tri-saccharide of D-arabinofuranoside had been prepared and esterified 
with different fatty acids, such as behenic, palmatic and butyric acids earlier,144 there is no 
report of the synthesis of tri-arabinofuranosyl-L-glycerol.  The target tri-saccharide structure 
(86) has three α-glycosidic linkages, and can be assembled readily from the following 
building blocks, the donor (84)242 and the diol acceptor (85) (Scheme 29).  
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Scheme 29: Synthesis of fully protected glycan tri-arabino glycerol (TAG) (86). 
2.3.3.1 Synthesis of the donor (84) 
The synthetic route to the 2,3-O-benzoyl protected thioglycosyl donor (84) started from 
thioglycoside triol (49). The primary hydroxyl group at the C-5 position was protected by 
treating (49) with TBDPS in dry DMF in the presence of a catalytic amount of imidazole to 
afford (83) in 82% yield. In order to protect the two secondary hydroxyl groups at the C-2 
and C-3 positions, compound (83) was suspended in pyridine before benzoyl chloride was 
added, to give (84) in 85% yield. The NMR data of (84) were identical to the literature 
(Scheme 30).242 
 
Scheme 30: Synthesis of the TAG’s donor (84). 
2.3.3.2 Synthesis of the acceptor (85) 
Having the donor target in hand, the exploration of the synthesis of the acceptor (85) was 
carried out. The initial step in the synthetic route, was preparing the fully protected 
arabinofuranosyl glycerol (52) from D-arabinose as described earlier (Scheme 7), then, removal 
of the silyl group using TBAF in dry THF gave two free hydroxyl groups at the C-3 and C-5 
positions respectively, affording the target acceptor (85) in 95% yield (Scheme 31). 
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Scheme 31: Synthesis of TAG’s acceptor (85). 
The structure of the acceptor (85) was confirmed by mass spectrometry [NSI–Found 
(M+Na)+: 531.2; C29H32NaO8, requires: 531.2]. The 2D-NMR spectrum (Figure 83) showed 
the -anomeric proton was correlated to its carbon.  
 
Figure 83: HSQC-NMR spectrum for TAG’s acceptor (85). 
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2.3.3.3 Coupling the donor and the acceptor 
Lowary et al. have used NIS/AgOTf in dry CH2Cl2 to couple the thioglycoside donor (84) 
with a 2-O-benzylated diol acceptor but not with the acceptor (85) used here. In order to 
investigate the effect of the protecting group at the C-2 position, the 5-silylated thioglycoside 
donor (84) and the new 2-O-benzoylated acceptor (85) were reacted under the reported 
conditions to give the desired glycan (86) as mentioned earlier (Scheme 29). The tri-arabino-
glycerol (86) was obtained in 91% yield, which was similar to that reported by Lowry, when 
using the 2-O-benzylated acceptor with a methoxy group at the anomeric centre rather than a 
glycerol as described here. The 1H-NMR spectrum of (86) showed three signals downfield 
corresponding to the three protons at the anomeric centre of each ring, as broad singlets at 
δ 5.61, 5.31 and 5.22. The 13C-NMR spectrum (Figure 84) established the presence of the 
glycosidic linkages in the tri-arabinofuranosyl glycerol (86), with the signals at δ 106.1 and 
105.2 ppm belonging to the three carbons at the anomeric centers. Those signals together 
confirmed the three α-glycosidic linkages in the glycan.   
 
Figure 84: 13C-NMR spectrum for fully protected tri-arabino glycerol (86). 
 
The HSQC-NMR of (86) confirmed the structure of the compound (Figure 85), the spectrum 
showed three significant peaks corresponding to the acetal protons, at δ 5.61, 5.31 and 5.22, 
correlated to their carbons, which confirmed that the coupling between the donor (84) and the 
acceptor (85) was successful.   
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Figure 85: HSQC-NMR spectrum for tri-arabino glycerol (86). 
The structure of (86) was also confirmed by mass spectrometry (Figure 86). 
 
Figure 86: Mass spectrum of the tri-saccharide compound (86). 
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The tri-saccharide (86) was deprotected with sodium methoxide to give (87) as a thick oil in 
83% yield. Formation of the penta-hydroxy saccharide (87) was confirmed by 1H-NMR, 
where all the signals corresponding to the protons on the carbon adjacent to the benzoyl ester 
were shifted up-field. The 13C-NMR spectrum showed the disappearance of the carbonyl 
signals which indicated the success of the hydrolysis. Compound (87) was benzylated to 
protect the five secondary hydroxyl groups using benzyl bromide and sodium hydride in dry 
DMF to give (88) in 65% yield, followed by de-protection of the two primary hydroxyl groups 
using TBAF to afford (89) in 87% yield (Scheme 32).  
Scheme 32: Synthesis of compounds (87-89). 
The material obtained, (89), was split into two portions, each portion being used in different 
esterification methods as follows (cf. DMAG section): 
1. An alkylative coupling using cesium hydrogen carbonate after mesylation of the 
primary hydroxyl groups in the glycan.  
2. Direct coupling of the sugar alcohol with the fatty acid using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDCI).  
In order to use the CsHCO3 method, the two primary hydroxyl groups in the first portion of 
(89) were activated, by treating with MsCl in dry pyridine in the presence of catalytic DMAP 
in dry CH2Cl2 at 0 ºC to afford the corresponding mesylate (90) in 87% yield (Scheme 33).
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Scheme 33: Structure of the tri-arabino-glycerol di-mesylate (90). 
The structure of (90) was confirmed by mass spectrometry and NMR spectroscopy. The 1H-NMR 
spectrum of (90) (Figure 87) showed the expected signals, including two singlets at δ 2.94 and 2.89 
for the CH3 of the mesylate groups.  
 
Figure 87: 1H-NMR spectrum for compound (90). 
The 13C-NMR spectrum Figure 88 showed two signals at δ 37.6 and 37.5 for the carbons of 
the mesylate groups. The assignments of the signals were made by comparison with literature 
values reported for the methoxy tri-arabinose compound, which is identical to (90) except for 
the absence of the glycerol moiety.241 
 
Chapter 2                                          Results &Discussion                                           DMTAG 
90 
 
 
Figure 88: 13C-NMR spectrum for compound (90). 
The 2D-NMR Figure 89 confirmed the structure of (90) and showed the signals of the CH3 
groups and the acetal protons correlated to their carbons.  
 
Figure 89: 2D-NMR spectrum for compound (90). 
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2.3.4 Esterification of lipids with the glycan tri-arabino glycerol (90) 
2.3.4.1 Esterification with a simple fatty acid 
Having prepared the mesylate (90), the exploration of coupling with behenic acid to make a 
model analogue, was now undertaken. The fully protected di-behenoyl-tri-arabino-glycerol 
(91) was prepared by coupling the mesylate (90) with behenic acid through the alkylative 
esterification strategy using cesium hydrogen carbonate in dry THF: DMF at 70 ºC for 3 days 
and afforded (91) in 80% yield (Scheme 34).   
 
Scheme 34: Synthesis of a model analogue of fully protected di-behenoyl tri-arabino glycerol (91). 
The formation of (91) was confirmed by NMR spectroscopy. The region of the 1H-NMR 
spectrum which was of most interest was between δ 5.15 – 4.90, which corresponds to the 
three protons at the anomeric centres on the glycan rings. Signals at δ 5.09, 5.06 and 4.97, 
integrating to one proton each, occurred as broad singlets. The CH2 groups adjacent to the 
carbonyls gave a triplet at δ 2.17 (J 7.6 Hz) integrating to 4 protons. The terminal methyl 
group showed a triplet signal at δ 0.81 (J 6.8 Hz) integrating to 6 protons.  
 
Figure 90: 1H-NMR spectrum for compound (91). 
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The 13C-NMR spectrum showed two signals at δ 173.6 and 173.5 for the carbonyl groups. Signals 
corresponding to the carbon at the anomeric centre for the three rings appeared at δ 106.5, 106.2 
and 105.5. The carbon of the CH2 group adjacent to the carbonyl in the acid appeared at δ 34.1. The 
CH2 chain ranged from δ 32 - 22 and the CH3 came up-field at δ 14.1.  
 
Figure 91: 13C-NMR spectrum for compound (91). 
All the signals described above are shown in the HSQC-NMR spectrum, where the anomeric 
protons and the behenic acid (the CH2 adjacent to carbonyl and the terminal CH3) signals 
were correlated to their carbons (Figure 92). 
 
Figure 92: 2D-NMR spectrum for compound (91). 
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Compound (91) was debenzylated by stirring vigorously in a suspension of Pd(OH)2 in dry 
CH2Cl2:MeOH (1:1) under an atmosphere of hydrogen for 36 h to give the target DMTAG 
analogue (92)  in 82% yield (Scheme 35).  
 
Scheme 35: Synthesis of a model analogue of di-behenoyl tri-arabino glycerol (92). 
The 1H-NMR spectrum (Figure 93) of compound (92) confirmed the success of the 
hydrogenolysis, and showed three broad singlets at  5.01, 4.97 and 4.90 ppm for the three -position 
protons respectively, the remaining 20 protons of the sugar and glycerol moieties appeared 
between  4.30 – 3.50 ppm. The four protons next to the two carbonyls gave a triplet at  2.30 
ppm (J 7.6 Hz), while the terminal CH3 appeared at  0.83 ppm as a triplet (J 6.5 Hz). 
 
Figure 93: 1H-NMR spectrum for compound (92). 
The 13C-NMR spectrum obtained for the glycolipid analogue (92) gave signals illustrated in 
(Figure 94), which were essentially identical to those for an analogue in the literature,241 
bearing a methoxy substituent at C-1 rather than the glycerol substituent in compound (92), 
and are assigned on that basis (See Table 6).   
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Figure 94: 13C-NMR spectrum for compound (92). 
Table 6: The 1H and 13C-NMR data analysis of the glycolipid compound (92) 
Proton Shift H's Class J/Hz Carbon δ/ppm 
H11 5.01 1 br. s - C16 174.05 
H6 4.97 1 br. s - C6, 11 108 
H1 4.90 1 br. s - C1 107.7 
H10, 3 4.24 2 br.dd 3.2, 11.7 C3 83.3 
H15, 1’’, 13 4.17 3 br.dd 5.0, 11.8 C14 83.0 
H15` 4.12 1 br.d 4.3 C9 82.4 
H10` 4.09 1 m - C4 81.8 
H4 4.04 1 br.q 5.5 C12 81.3 
H2, 7, 9 3.95 3 br.m - C7 80.7 
H5` 3.94 1 dd 3.6, 11.5 C2 79.0 
H5, 2’, 8  3.79 3 m - C8 77.6 
H1’ 3.73 1 br.dd 4.8, 10.1 C13 75.8 
H3’’ 3.64 1 m - C2’ 69.9 
H3’, 12 3.60 2 br.d 3.1 C1’ 69.1 
H14 3.54   1 m - C3’ 66.4 
CH2-Next to carbonyl 2.30  4 t 7.6 C5 63.9 
CH2-Chain 1.39 83 m - C10 63.7 
CH3-Terminal 0.83  6 t 6.5  C15 63.5 
- - - - - C17 34.0 
- - - - - C18 13.9 
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2.3.5 Esterification of the glycan (89) with mycolic acids (76f-h) using the EDCI method 
2.3.5.1 Esterification of the glycan (89) with keto-MA (76f) 
Having secured a successful method for preparing a model analogue, the tri-arabinosyl glycerol 
di-behenate (92), now, the glycan (89) was used to explore the coupling with three common 
classes of structurally defined synthetic MAs (76f-h).111 First, the glycan (89) was coupled with 
the synthetic keto-MA (76f) using the EDCI method as before (see Scheme 24, Section 1), and 
afforded (93) in 51% yield (Scheme 36). 
Scheme 36: Synthesis of fully protected DMTAG of keto-MA (93). 
This compound showed NMR signals for the keto-MA and the glycan similar to those 
discussed before (Figure 95). 
 
Figure 95: HSQC-NMR spectrum for compound (93). 
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To improve the percentage yield of the de-silylation of (93), an alternative method was used, 
compared to that used with the DMAG glycolipids (see Scheme 25, Section 1). This time, the 
TBDMS group at the β-position in the keto-mycolic acid was removed using hydrogen 
fluoride-pyridine complex (~70% HF) in dry THF, stirring the reaction mixture at 43 ºC for 24 h 
to afford (94) in 76 % yield (Scheme 37), (Figure 96).  
 
Scheme 37: Synthesis of fully protected DMTAG (94). 
 
Figure 96: 1H-NMR spectrum for compound (94). 
Hydrogenolysis of (94) by stirring it in dry CH2Cl2:MeOH (1:1) in the presence of Pd(OH)2 
and under a hydrogen atmosphere gave (95) in 86% yield (Scheme 38).  
 
Scheme 38: Synthesis of DMTAG of keto-MA (95). 
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Compound (95) gave NMR signals (Figure 97) corresponding to the keto-MA and the glycan 
moiety similar to those discussed before.  
 
Figure 97: 1H-NMR spectrum for compound (95). 
2.3.5.2 Esterification of the glycan (89) with -mycolic acid (76g) 
The TBDMS-protected α-MA with a 24 carbon α-alkyl chain (76g),109 was reacted with the 
sugar-diol (89) by the EDCI method, and afforded (96) in 84% yield (Scheme 39). 
Scheme 39: Synthesis of fully protected DMTAG of -MA (96). 
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The 1H-NMR spectrum showed the success of the coupling between the tri-arabino-glycerol 
and the -MA (Figure 98).  
 
Figure 98: 1H-NMR spectrum for compound (96). 
Removal of the silyl group from the -position in the -mycolic acid was achieved by the 
same method described previously (using hydrogen fluoride-pyridine complex), and afforded 
(97) in 51% yield (Scheme 40). 
 
 
Scheme 40: Synthesis of compound (97). 
The 1H-NMR spectrum (Figure 99) of this compound showed the disappearance of signals 
corresponding to the TBDMS groups and gave characteristic NMR signals for the -MA and 
the glycan moiety (Table 7). These were assigned by comparison to values reported for the 
methoxy tri-arabino-dimycolate,241 which is essentially identical to the DMTAG shown here. 
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Figure 99: 1H-NMR spectrum for compound (97). 
Table 7: The 1H and 13C-NMR data analysis of compound (97). 
Proton Shift H's Class J/Hz Carbon δ/ppm 
H1 5.16 1 br. s - C16 175.1 
H6 5.13 1 br. s - C16’ 175.0 
H11 5.05 1 br. s - C1 106.3 
H3, 10, 10`, 15, 15`, 9 4.29 6 m - C6 106.2 
H14 4.17 1 br.dd 3.7, 6.9 C11 105.5 
H4 4.11 1 dd 2.7, 4.4 C2 88.2 
H7 4.07 1 br. d 2.1 C7 88.0 
H12 3.98 1 m - C12 87.9 
H5`,2 3.91 2 m - C8, 13 83.6 
H13, 8 3.86 2 br.dd 4.6, 10.3 C4 80.7 
H2’ 3.79 1 br.p 4.8 C3 80.3 
H5 3.72 1 m - C14 79.3 
H1’,3’,18 3.61 5 br.d 5.3 C9 79.2 
H17 2.41 2 m - C2’ 77.2 
H21 0.89 12 t 8.1 C18 72.2 
H19 0.65 8 m - C1’ 67.1 
H20’ 0.57 4 dt 4.2, 8.5 C5 65.4 
H20 -0.32 4 br.q 4.9 C15, 10 63.1 
PhCH2O 4.67 2 br.s - C3’ 63.0 
PhCH2O 4.55 1 d 11.9 C17 51.9 
PhCH2O 4.50 8 m - C17’ 51.8 
PhCH2O 4.46 2 d 11.8 C19 15.8 
PhCH2O 4.41 1 d 11.9 C21 14.1 
Ph-aromatic × 7 7.29 35 m - C20 10.9 
- - - - - PhCH2 73.4 
- - - - - PhCH2 72.4 
- - - - - PhCH2  × 2 72.0 
- - - - - PhCH2 71.9 
- - - - - PhCH2 71.7 
- - - - - PhCH2 70.3 
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Hydrogenolysis of (97) was achieved by the method given previously, and afforded (98) in 
88% yield (Scheme 41).  
 
Scheme 41: Synthesis of DMTAG of -MA (98). 
Confirmation of the formation of (98) was achieved by 1H-NMR (Figure 100), which 
showed the disappearance of the signals corresponding to the benzyl protons. Signals of the 
glycan moiety and the α-MA appeared similar to those discussed before.  
 
Figure 100: 1H-NMR spectrum for compound (98). 
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2.3.5.3 Esterification of (89) with trans-cyclopropane keto-MA (76h) 
The sugar-diol (89) was esterified with the keto-MA with a trans-cyclopropane (76h)111 by 
the same method as before, and afforded (99) in 46% yield (Scheme 42).  
Scheme 42: Synthesis of fully protected DMTAG of trans-keto-MA (99). 
All the 1H-NMR signals belonging to the MAs appeared in the same area as discussed before, 
as did the signals for the tri-arabino glycerol. The 1H and 13C-NMR spectra for (99) are 
shown in Figure 101.  
 
Figure 101: 1H and 13C-NMR spectra for compound (99). 
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De-silylation of (99) was carried out next to remove the TBDMS group from -position 
in the MAs by the same method mentioned above, and afforded (100) in 66% yield 
(Scheme 43, Figure 102). 
 
Scheme 43: Synthesis of DMTAG of trans-keto-MA (100). 
 
Figure 102: 1H-NMR spectrum for compound (100). 
Compound (100) was hydrogenolysed by a similar method to that discussed before, to give 
(101) in 82% yield (Scheme 44).  
 
Scheme 44: Synthesis of DMTAG of trans-keto-MA (101). 
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Compound (101) showed 1H-NMR signals for the glycan and the keto-MA, similar to those 
obtained before. The disappearance of the signals corresponding to the benzylic protons and 
the protons in the aromatic area, confirmed the successful of hydrogenolysis (debenzylation).  
 
Figure 103: 1H-NMR spectrum for compound (101). 
2.3.6 Summary: 
In this part of the thesis, the preparation of DMTAG glycolipids was described, and the 
following targets have been achieved successfully: 
1. The first synthesis of the glycan moiety tri-arabino glycerol (TAG) incorporating L-
glycerol has been achieved. 
2. Esterification of the above moiety with a simple fatty acid to prepare the DMTAG 
glycolipid analogue has been done.  
3. Esterification with three common classes of synthetic mycolic acids, to make the 
DMTAG glycolipids has been achieved. No literature data are available for DMTAGs, 
so it will be interesting in future work to have authentic samples for comparison.  
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Figure 104: Structures of the target DMTAG glycolipids. 
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Section 4 
2.4 Synthesis of Glycerol Mono-mycolate (GroMM) 
2.4.1 The aims of this part 
• Synthesis of benzyl protected glycerol [(4-methylbenzenesulfonyl)-2,3-di-O-benzyl-S-glycerol]. 
• Synthesis of a model glycolipid through esterification with a simple fatty acid. 
• Synthesis of a series of GroMM esters through esterification of the benzyl protected 
S-glycerol with different synthetic MAs. 
• Investigate the biological activity of the synthetic S-glycerol esters and compare it to 
those of the R-glycerol esters to determine whether the stereochemistry matters. 
2.4.2 Synthesis of 1-O-p-toluenesulfonyl-2,3-di-O-benzyl-S-glycerol (102)  
The overall aim of this part of the work was the preparation of 2,3-di-O-benzyl-S-glycerol 
(51G), which could first be esterified with a simple fatty acid as a model, then with a number 
of different synthetic MAs from common classes. The protected S-glycerol (51G) was 
synthesized from D-mannitol as reported in the literature.243,244,245,246,247. For the synthesis of 
glycerol mono-mycolate (GroMM) (Scheme 45) from benzyl protected S-glycerol (51G) and 
fatty or mycolic acids (103 a-f), it was necessary to convert the free hydroxyl group at the C-
1 position in the benzyl protected S-glycerol into a good leaving group. The free hydroxyl 
group was therefore converted to a tosylate by reaction with p-toluenesulfonyl chloride 
(TsCl) in dry pyridine and catalytic DMAP in dry CH2Cl2 at 0 ºC to afford the tosylate (102) 
in 62% yield. The synthesis of this compound was confirmed and all the data obtained were 
consistent with the literature.248 
Scheme 45: Synthesis of GroMM incorporating S-glycerol. 
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2.4.3 Esterification of the tosylate (102) with a simple fatty acid 
Compound (102) was reacted with behenic acid (103a) via the alkylative esterification 
strategy, using cesium hydrogen carbonate (10 eq.) in dry DMF:THF (1:5) at 70 ºC for 2 days 
to give protected ester (104a) in 83% yield (Scheme 46).  
 
Scheme 46: Synthesis of protecteD-glycerol behenate (104a). 
The 1H-NMR spectrum (Figure 105) confirmed the formation of (104a), which showed six 
signals in region δ 4.61-3.53 belonging to the glycerol. The protons corresponding to the CH2 
group of the two benzyl groups appeared as two broad singlets at δ 4.61 and 4.49 respectively, 
and the two doublets of doublets at δ 4.25 (J 4.2, 11.7 Hz) and 4.12 (J 5.8, 11.7 Hz) respectively 
corresponded to the CH2 protons adjacent to the carboxylic group. The multiplet at δ 4.75 
belonged to the CH group on the glycerol, while the CH2 group on the glycerol appeared as a 
muliplet at δ 3.53. The protons corresponding to the CH2 adjacent to the carbonyl group in 
the acid came around δ 2.2 as a triplet (J 7.6 Hz) and the three protons in the terminal 
position of the acid chain appeared as an up-field triplet at δ 0.83 (J 6.8 Hz).  
 
Figure 105: 1H-NMR spectrum for compound (104a). 
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The 13C-NMR spectrum (Figure 106) of (104a) showed a carbonyl signal at δ 173.6, the 
aromatic carbons at δ 138 – 127, the remaining glycerol ester carbons at δ 75 – 63, the CH2 
chain ranged from δ 34 – 22 and the terminal CH3 came up-field at around δ 14.0.  
 
Figure 106: 13C-NMR spectrum for compound (104a). 
Debenzylation of (104a) was achieved by stirring in dry CH2Cl2:MeOH (1:1) in the presence 
of Pd(OH)2 (0.15 eq. fold by weight) under a hydrogen atmosphere to give (105a) in 70% 
yield (Scheme 47).  
 
Scheme 47: Synthesis of glycerol behenate (105a). 
Once again, the formation of this compound was proven by 1H-NMR spectroscopy, which 
clearly showed the disappearance of those signals corresponding to the benzyl groups 
between δ 4.6 – 4.5. Two doublets of doublets at δ 4.07, (J 3.6, 9.9 Hz) and 4.03 (J 4.4, 9.9 Hz) 
corresponded to the CH2 adjacent to the carboxylic group, a multiplet at δ 3.80 belonged to 
the CH group on the glycerol core, while the CH2 group on the glycerol appeared as two 
doublets of doublets at δ 3.57 (J 4.1, 11.5 Hz) and 3.48 (J 6.1, 11.5 Hz).  
The 13C-NMR spectrum (Figure 107) showed a carbonyl at δ 174.4, the remaining glycerol 
ester carbons appeared at δ 70 – 63, the CH2 chain ranged from δ 34 – 22 and the terminal 
CH3 came up field around δ 14.0.  
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Figure 107: 13C-NMR spectrum for compound (105a). 
2.4.4 Esterification of the tosylate (102) with synthetic mycolic acids (103b-f) 
2.4.4.1 Esterification of the tosylate (102) with the keto-mycolic acid (103b) 
Keto-MAs are the major oxygenated MAs in the cell wall of mycobacteria. Synthetic keto-MA 
(103b) is present in nature in M. kansasii. Keto-MAs encourage the growth of the bacterial cell. 
Their formation in the cell increases during growth in macrophages and at low oxygen 
concentrations.249 The α-chain of the keto-MA in M. tuberculosis has 24 carbons. Having 
secured a successful method for synthesising a model of the S-glycerol behenate (105a), the 
coupling of the tosylate (102) with a synthetic mycolic acid was now undertaken. The synthetic 
material of keto-mycolic acid (103b)111, was provided by Dr. Al Dulayymi. Firstly, this 
compound was esterified with the tosylate (102) to give the corresponding protected glycerol 
mycolate (104b) in 59% yield using the same procedure as above (Scheme 48).  
 
Scheme 48: Synthesis of protecteD-glycerol-keto-mycolates (104b). 
The success of the esterification was demonstrated by the 1H-NMR spectrum (Figure 108). 
The region of most interest is between δ 0.56 and - 0.40, which corresponds to the four 
protons of the cis-cyclopropane ring. The proton Hp gave a doublet of triplets; the broadness 
of this signal shown at δ 0.52 to 0.45 is possibly because Hn and Hn’ are not magnetically 
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equivalent and the signal observed is actually a double doublet of doublets, but due to the 
signals being at a nearly identical chemical shift it appears as a doublet of triplets. The proton 
Hq should show a doublet of triplets; however, due to the magnetic inequivalence of Hn and 
Hn’ the signal at δ - 0.35 to - 0.45 is distorted and appears as a broad quartet. Protons Hn and 
Hn’ again showed a distorted multiplet at δ 0.65 to 0.54 for the same reason. The α-proton Hh 
exhibits a multiplet seen at δ 2.45 – 2.38. More proton and 13C-NMR data (Figure 109) of 
protected ester (104b) was analysed as shown in Table 8.  
 
Figure 108: 1H-NMR spectrum for compound (104b). 
 
Figure 109: 13C-NMR spectrum for compound (104b). 
Table 8: The 1H and 13C-NMR data analysis of compound (104b). 
Proton Ha Ha’ Hb Hc Hd He Hf,f’,g Hh,OH Hi,j,k Hl Hm Hn,n
’ 
Hp Hq 
Shift 4.60 4.57 4.47 4.35 4.14 3.75 3.52 2.43 2.35 0.98 0.81 0.56 0.49 -0.40 
H's 1 1 2 1 1 1 3 2 3 3 6 2 1 1 
Class d d br.s dd dd m br.dd m dt d t m dt br.q 
J/Hz 11.8 11.8 - 4.0, 11.7 5.5, 11.7 - 1.4, 5.4 - 5.4, 7.9 6.9 6.7 - 4.0, 8.5 5.1 
Carbon C1 C2 C3 Ca,a’ / Cb C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 
δ/ppm 215.1 175.4 75.7 73.4/ 72.2 72.0 69.5 63.4 51.3 46.2 41.0 16.3 15.7 14.0 10.8 
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Hydrogenolysis of (104b) was achieved by the method described previously to give (105b) in 
87% yield (Scheme 49).  
Scheme 49: Synthesis of glycerol-keto-mycolates (105b). 
Compound (105b) showed characteristic NMR signals (Figure 110) corresponding to the 
cyclopropane protons and glycerol moiety approximately similar to those signals of (104b) 
without the benzylic protons, which confirm the success of the debenzylation.  
 
Figure 110: 1H and 13C-NMR spectra for compound (105b). 
2.4.4.2 Esterification of the tosylate (102) with α-MAs (103c,d) 
The α-MA type is the most abundant among MAs in M. tuberculosis, and characterized by 
containing two cis-cyclopropanes. This acid was reported by Minnikin and Polgar to be the 
major mycolic acid of M. tuberculosis var hominis.99 The absolute stereochemistry of the cis-
cyclopropane in the MA has not been proven, i.e. the (S, R) or (R, R) or (S, S) or (R, S) 
configurations respectively, therefore the two of the four possible structures were used in this 
study.  
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Synthesising MA esters may provide valuable information for determining the stereochemistry 
of naturally occurring MAs, which subsequently may provide further understanding of the 
biosynthetic pathway. The structurally defined synthetic MAs (103c,d) reported by                 
Al Dulayymi et al.109, were reacted with tosylate (102), using the conditions mentioned earlier 
to give (104c) in 58% yield, and compound (104d) in 71% yield (Scheme 50). 
 
Scheme 50: Synthesis of protecteD-glycerol--mycolates (104c,d). 
The 1H-NMR spectrum (Figure 111) of (104c) showed a broad doublet of doublets at δ 3.60 
(J 1.6, 5.4 Hz) for the proton at the β-position. The signal corresponding to the proton at the 
α-position in the MA appeared as a broad doublet of doublets at δ 2.43 (J 3.8, 10.5 Hz). Protons 
corresponding to the cyclopropane appeared as a 2H broad quartet at δ - 0.32 (J 5.2 Hz), a 2H 
doublet of triplets at δ 0.57 (J 3.9, 8.4 Hz), and a 4H multiplet at δ 0.73 – 0.60. Signals corresponding 
to the glycerol moiety were approximately similar to those of the previously prepared glycerol-
mycolates. Formation of (104c) was proven by the 13C-NMR spectrum which showed a signals for 
the carbonyl ester at δ 175.4, and the carbon on the β-hydroxy acid position at δ 72.3.  
 
Figure 111: 1H-NMR spectrum for compound (104c). 
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Hydrogenolysis of (104c,d) using the same method mentioned earlier afforded (105c,d) in 74% 
and 92% yield respectively (Scheme 51).  
 
Scheme 51: Synthesis of glycerol--mycolates (105c,d). 
Confirmation of the formation of (105c) was achieved by 1H-NMR. Two doublets of doublets 
at δ 4.21 and δ 4.10 (J 4.3, 11.4 and 6.4, 11.5 Hz respectively) correspond to the 2 protons 
attached to the C-4 of the glycerol core. The remaining protons of the glycerol moiety were 
approximately similar to those of the previously prepared glycerol-mycolates. The α-proton in 
the MA appeared as a doublet of doublet of doublets at δ 2.39. Signals for the cyclopropane 
appeared at approximately the same chemical shift as those in the spectrum of compound 
(104c). The 13C-NMR spectrum showed a carbonyl at δ 175.5, and the remaining glycerol 
carbons in the region of δ 83 – 54. The β-hydroxy carbon appeared at δ 72.6. The CH2 chain 
ranged from δ 37 – 22.5 and the CH3 came up-field to around δ 14.0. The MA α-carbon 
resonated at δ 52.6. 2D-NMR (Figure 112) was used to provide further proof of the structure of 
the glycerol mycolate (105c). 
 
Figure 112: HSQC-NMR spectrum for compound (105c). 
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2.4.4.3 Esterification of the tosylate (102) with the methoxy-MAs (103e,f) 
Methoxy-MAs in M. tuberculosis increase in stationary phase cells and in addition, the 
oxygenated mycolates in M. tuberculosis affect the growth rate of intramacrophages.249 In order 
to probe the biological effects of varying the α-alkyl chain length, methoxy-MAs with 22 and 24 
carbon α-chains, were used to obtain glycerol mycolates (104e,f). Firstly, the structurally defined 
synthetic MA reported by Al Dulayymi et al.110, a methoxy-cis-cyclopropane with 22 carbon α-
alkyl chain (103e), which is present in nature in M. kansasii, was reacted with the tosylate (102), 
using the same procedure as above, giving compound (104e) in 62% yield. The tosylate (102) 
was coupled with (103f) by the same method as above to prepare compound (104f) (Figure 113) 
in 72% yield (Scheme 52); this showed NMR signals as shown in Table 9. These assignments 
were made by comparison to the data reported for the R-GroMM compounds.203 
 
Scheme 52: Synthesis of protecteD-glycerol-methoxy-mycolates (104e,f). 
 
Figure 113: Structure of protecteD-glycerol-methoxy mycolates (104e,f) 
 
 
 
. 
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Table 9: The 1H and 13C-NMR data analysis of compounds (104e). 
Proton Shift H's Class J/Hz Carbon δ/ppm 
Ha-Bn 4.62 1 d 11.8 C1 175.4 
Ha’-Bn 4.58 1 d 11.8 C2 85.3 
Hb-Bn 4.48 2 br.s - C3 75.7 
Hc 4.36 1 dd 4.1, 11.7 Ca-Bn 73.4 
Hc’ 4.15 1 dd 5.5, 11.7 C4 72.2 
Hd 3.76 1 m - Cb-Bn 72.0 
He,e’ 3.53 3 br.dd 1.6, 5.4 C5 69.5 
(OCH3)7 3.28 3 s - C6 63.4 
Hf 2.90 1 m - (OCH3)7 57.6 
Hg,h 2.37 2 m - C8 51.3 
(CH3)11 0.83 6 t 6.8 C9 15.7 
(CH3)10 0.79 3 d 6.9 (CH3)10 14.8 
Hi,i’ 0.60 2 m - (CH3)11 14.0 
Hj 0.50 1 dt 4.0, 8.4 C12 10.8 
Hk -0.39 1 br.q 5.2 - - 
 
 
Figure 114: 1H-NMR spectrum for compounds (104e). 
Hydrogenolysis of (104e,f) by the same method as above afforded (105e,f) in 85 and 92% 
yield respectively (Scheme 53).  
 
Scheme 53: Synthesis of glycerol-methoxy-mycolates (105e,f). 
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Once again, compounds (105e,f) showed characteristic NMR signals (Figure 115) 
corresponding to the cyclopropane protons and the remaining protons in the methoxy-MA 
and glycerol moiety were approximately the same to those previously discussed. 
 
Figure 115: 1H and 13C-NMR spectra for compound (105e). 
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2.4.5 Summary  
In this part of the thesis, five examples of GroMM esters (105b-f) were prepared based on the 
three common classes of synthetic MAs, and one linear alkyl acid as a model (105a). The 
prepared GroMMs are shown below (Figure 116). 
 
Figure 116: Structures of the target glycerol mono-mycolates (GroMMs 105a-f). 
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2.5 DMAGs as antigens in the serodignosis of bovine tuberculosis 
2.5.1 ELISA assay 
The use of ELISA as a tool for diagnosing TB is attractive for a number of reasons, in 
particular it is a relatively simple, cheap and quick technique. However, the results obtained 
from ELISA predominately depend on how well the antibodies in the TB patient’s blood 
sample are detected by the antigens used. MAs and their derivatives are the dominant lipids 
in the mycobacterial cell wall, and are considered to be among the best antigens. Being able 
to use this method of detection for TB would mean patients would not need to spend time in 
quarantine and would be able to receive anti-TB therapy more quickly.229,230,231,232 
 
According to the literature, DMAG showed applicability for serodiagnosis of Mycobacterium 
avium-intracellulare complex (MAI) infection by ELISA.175,176,177 Recently, Rombouts and 
co-workers identified DMAG in large quantities in slow growing pathogenic species, e.g. 
M.tb, M. bovis, BCG and M. Scrofulaceum, identifying this glycolipid as more biologically 
potent and possibly important in mycobacterial pathogenesis. 
 
One purpose of synthesizing the DMAG compounds described in this thesis is that their 
antigenic activity can be studied by ELISA. Investigating the antigenic activity of specific 
synthetic DMAG antigens could lead to the development of improved methods for the 
detection and diagnosis of mycobacterial diseases such as bovine TB. It is possible that single 
synthetic antigens could give a better distinction between TB+ and TB- serum samples, 
compared to a natural mixture, which contains a number of different homologues.  
 
Preliminary ELISA assays, using the synthetic DMAG glycolipids (71a), (71b), (71c), (71d), 
(75), (79f), (79g) and (79h) as antigens, have been carried out by Mr. Paul Mason at the 
School of Chemistry, Bangor University. A synthetic keto TDM (AD132) known to 
distinguish active TB was also used as a control antigen. For these initial assays bovine serum 
samples were used at a 1 in 40 dilution in Casein / PBS buffer and an anti-bovine IgG Fc 
specific HRP secondary antibody was used. This was visualised by adding a colour reagent 
(OPD/H2O2 solution), and the absorbance was measured at 492 nm. A detailed method for the 
assay can be seen in the Appendix. 
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These initial assays were carried out to determine whether any response was observed to 
samples obtained from the Veterinary Laboratories Agency (VLA) that were known to be 
infected with bovine TB. Two samples that were believed to be free from bovine TB were 
also run as negative controls. (Figure 117). 
 
Figure 117: Response of 14 samples - 12 infected with bovine TB (red) and 2 samples free from bovine TB 
(blue) to a range of DMAG antigens. Green – blank / control. 
As can be seen from Figure 1 the model DMAG antigens (simple esters) 71a, 71b, 71c and 71d 
have a very low response to all serum samples, both positive and negative, with the values being 
comparable to those observed for the blank / control wells. The DMAG antigens that have a 
mycolic acid attached to the diarabinoglycerol did however show a response to the serum 
samples, with 3 of the antigens, 79f, 79g and 79h showing a distinction between the positive and 
negative samples. The other antigen 75 also showed a response to some of the serum samples, 
however a number of the positive samples gave responses that were lower than that observed for 
the negative controls. These results therefore suggest that the mycolic acid moiety of the DMAG 
plays a role in the antigenicity of these compounds and that the presence of different types of 
mycolic acid also influences the response observed. In addition a set of Mycobacterium Avium 
subspecies Paratuberculosis (MAP) infected and uninfected samples, obtained from the 
Veterinary and Agrochemical Research Centere, Brussels, were also tested (Figure 118). 
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Figure 118: Response of 7 samples - 5 infected with MAP (red) and 2 uninfected (blue) to a range of DMAG 
antigens. Green – blank / control. 
As was the case with the previous assay, apart from 1 sample, a poor response was again 
observed with the model DMAG antigens 71a, 71b, 71c and 71d. The other antigens all gave 
a response, however in this case there was not such a good distinction between the positive 
and negative samples. 
 
These initial results show that the DMAG antigens 75, 79f, 79g and 79h do give a response to 
bovine serum samples infected with bovine TB and MAP, while the model DMAG antigens 
71a, 71b, 71c and 71d give no response, this suggesting that the mycolic acid moiety plays a 
role in the recognition. For the samples obtained from the VLA some of the antigens 79f, 79g 
and 79h show some distinction between the positive and negative samples. Although these 
results are encouraging they are only for a very small set of serum samples, therefore a much 
larger sample set needs to be tested in order to see whether these observations are real. It will 
also be interesting to test these antigens using TB+ and TB- human serum samples to 
determine whether they show a distinction between the two sets and could thus be used for 
the detection of TB. Based on these intial results, the use of DMAGs in serodiagnosis of such 
infections shows promise and is being further studied.  
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2.5.2 TNF-α cytokine stimulation 
Many mycobacterial components have been demonstrated to be strong adjuvants. For 
example, natural TDM is able to stimulate the immune system so it will produce a range of 
chemokines (e.g. IL-8) and cytokines (e.g. TNF-α).250 Another component which induced 
high levels of TNF-α is the lipid extract from Mycobacterium avium-intracellulare complex 
(MAI).175  
 
TNF-α is stimulated from the cells of macrophages or monocytes in response to organisms 
such as M. tuberculosis, M. bovis BCG, and Listeria monocytogenes, in addition, some 
glycolipids can also release TNF-α.  
 
TNF-α has been proven to be a significant inflammatory mediator, that can affect different 
kinds of cells. Studies in mice infected with M. bovis BCG and L. monocytogenes, and 
injected with anti-TNF-α antibody, showed inhibition of granuloma production in the host 
organs, and widespread growth of organisms in vivo.251 It has been widely shown that 
activation of dendritic cells (DCs) is required to initiate immune responses. Presently, one of 
the suggested mechanisms for the route of DCs after activation, is that these cells are 
programmed to respond to certain activators. This process stimulates the production of co-
stimulatory molecules and certain pro-inflammatory cytokines (e.g., TNF-α, IL-12, IL-6).252 
As described in the Introduction (Section 1.9), natural mixtures of DMAG show very strong 
effects on a number of immune system responses. 
 
Biological assay experiments using the synthetic DMAG glycolipids (71a), (71b), (71c), (71d), 
(75), (79f), (79g) and (79h) against the production of certain pro-inflammatory cytokines (e.g TNF-α), 
were carried out by Dr. Andy Chancellor, University of Southampton, UK.   
 
To study the stimulation of the TNF-α different concentrations were used (10, 50 and 100 
µg/mL). The TNF-α signal was measured for these synthetic DMAG glycolipids and compared 
to that of a control sample. (Figure 119). As can be seen, some of the compounds show a good 
stimulation of TNF-α compared to the control sample, with compound (OTA 79g) showing a 
very high level of TNF-α production at all concentrations. These initial results clearly indicate 
that synthetic single glycolipids show a selectivity in the inducing the TNF-α cytokine, and 
show an improved stimulation compared to the control.  
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Figure 119: TNF-α stimulation. 
 
 
Figure 120: Structure of synthetic DMAG models used for TNF-α stimulation. 
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Figure 121: Structure of synthetic DMAGs used for TNF-α stimulation. 
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Chapter 3 
Conclusion and further work 
3.1 Conclusions: 
This work involved the successful synthesis of: eight Di-Mycolyl-Di-Araf-Glycerol (DMAG) 
compounds, which had the L-stereochemistry of the glycerol component; four Di-Mycolyl-
tri-Araf-Glycerol (DMTAG) compounds; and finally, a range of Glycerol-Mono-Mycolates 
(GroMM), with S- stereochemistry of the glycerol component. All the synthetic MAs used in 
this project were provided by researchers within the Prof. M. S. Baird group. 
The first aim of this project was the synthesis for the first time of single enantiomers of 
DMAG from structurally defined synthetic MAs. These compounds will be assayed for their 
capability to stimulate a variety of cytokines in the immune system as well as being tested for 
their antigenicity in the detection of TB disease through ELISA assays. 
The synthesis of DMAG was carried out by firstly preparing the glycan moiety of DMAG 
with L-stereochemistry of the glycerol component. 
 
An efficient route to prepare the DMAG glycan moiety as a single anomer in excellent β-
selectivity and a very good yield was successfully developed. This was achieved by having a 
benzyl protecting group and a PMB protecting group on the C-3 and C-5 positions, 
respectively, in the acceptor. The armed donor was prepared according to the literature.145 
Such coupling reactions have been reported to produce a mixture of α- and β-anomer, 
however, the synthesis of this di-saccharide has not previously been reported. After 
synthesising the di-saccharide unit in a large quantity, it was followed by the preparation of 
three new model analogues of DMAG, and one model using a -hydroxy acid coupled to the 
glycan.  
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Finally, a series of four compounds of DMAG glycolipids was prepared based on the three 
common classes of synthetic MAs. The following compounds were successfully synthesised: 
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The main target of this part was to compare the NMR data for the synthesised compound 
with that reported for the naturally occurring compound. The NMR data for the penta-acetate 
derivative of compound (72) was compared directly with that in the literature for the per-
acetate of the natural mixture. This comparison gave a very good agreement between the 
signals for the di-arabino-glycerol fragments of natural and synthetic molecules, and 
confirmed the structure and stereochemistry of this novel sugar of the DMAG glycolipid to 
be --di-arabino-furanosyl glycerol. 
 
Natural DMAG has been found in the cell wall of M. tuberculosis in a high quantity and has 
been shown to be biologically active. Testing the effects of the synthetic DMAG glycolipids 
on a range of cytokines involved in the immune system, together with ELISA assays for the 
detection of TB, are expected to be carried out, which will give a further insight into the 
initial results discussed above. 
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The second part of this project involved the first synthesis of DMTAG, which is an important 
component in the cell wall of mycobacteria as a potential stimulator of some pro-inflammatory 
cytokines (e.g TNF-α). This glycolipid was reported in the literature;80 however, it has never 
been synthesised. This part started by preparing the tri-Araf-glycerol (86), which involved 
preparing the donor (84) according to the literature methods with slight modifications in some 
of the steps, while the acceptor (85) has been synthesised for the first time by an efficient route 
and in a large quantity. Coupling the donor and the acceptor to prepare the desired glycan was 
carried out using known conditions. One type of tri-Araf-glycerol, which contained three α- 
glyosidic linkages in its form, was prepared in high yield. 
 
Having the glycan core, the preparation of a model through esterifying with commercially 
available behenic acid was carried out. A series of three DMTAG compounds were then 
prepared based on the three common classes of MAs. The following compounds were 
successfully synthesised: 
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Methyl Tri-Araf-Di-Mycolate (MTADM) compounds derived from a natural mixture of MAs 
have been reported in the literature and showed a very high response in the stimulation of 
TNF-α cytokines. The synthesis of the above set of DMTAG glycolipids, from single 
enantiomers of MAs, will therefore allow the effects of the individual components to be 
investigated. The assessment of the ELISA assay for detection of TB employing these 
compounds will also be carried out.  
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The final part of the project entailed the synthesis of GroMM, which required synthesis of 
the glycerol with (S) stereochemistry, prior to it being coupled to different MAs to produce a 
single enantiomer of GroMM compounds. According to the lietrature,197 glycerol esters of 
complex mixtures of natural mycolic acids have strong effects in the immune system. GroMM has 
been observed to have adjuvant activity in murine models, and showed an ability to induce high 
levels of some pro-inflammatory cytokines (e.g IL-12 and TNF-α).174 
In this part, a model of GroMM was synthesised, a series of five compounds was also 
prepared based on the three common classes of synthetic MAs. The following compounds 
were successfully synthesised: 
 
 
 
 
Chapter 3                                                                                       Conclusion & Further work 
129 
 
 
 
 
The above series of compounds were prepared from single synthetic enantiomers of MAs to 
investigate the differences in their biological activity, in contrast with that of the R-GroMM 
esters.  
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3.2 Further Work: 
Further work which needs to be investigated, or could be undertaken: 
1. Studies on the natural DMAG glycolipid that is obtained from the cell wall of several 
mycobacterial species, including M. tuberculosis, showed that it possesses very high 
biological activity. Preparing a large amount of the DMAG glycan with the L-glycerol 
component, and finding an efficient way of coupling it with synthetic MAs has been 
carried out. Hence it would be interesting to synthesise the DMAG with D-glycerol in 
order to obtain a range of compounds and compare their biological activities. 
 
2. Selective esterification with different acids at each primary alcohol position was 
carried out to produce mono or symmetrical di-glycolipids similar to synthetic TDM 
and TMM which have shown promising results in the ELISA assays for the detection 
of TB. Therefore, synthesising a series of mono and symmetrical or unsymmetrical 
DMAG glycolipids would be valuable to use them in different assays to test their 
biological activity. 
  
3. Natural Arabino-mycolates extracted from the cell wall of mycobacteria contain a 
number of different components with very complex mixtures of MAs, hence 
preparing DMTAG with different MAs within the same compound will be valuable, 
as it is unlikely that the two MAs will be the same, in the same compound, in nature. 
This will then allow the biological activity of these mixed compounds to be studied.  
 
4. Finally, the synthesis of Penta-Araf Tetra-Mycolates (PATM) is another item of 
further work which must be done. Again, penta-Araf coupled with a natural mixture 
of MAs has been reported in the literature and was shown to have a high biological 
activity. Preparing the glycan unit and esterifying it with different synthetic MAs, 
followed by testing their biological activities using the previously discussed assays, 
will be valuable. This will also complete the set of different fragments of the mAGP. 
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Chapter 4 
Experimental 
4.1 General considerations: 
All chemicals were purchased from commercial suppliers. THF was distilled over sodium and 
benzophenone under nitrogen, while dichloromethane was distilled over calcium hydride. Petrol 
refers to the fraction b.p 40–60 °C. Organic solutions were dried over anhydrous magnesium 
sulfate (MgSO4). All glassware used in anhydrous reactions was dried for not less than 6 h in a 
250 °C oven. Reactions carried out under inert conditions were under a slow stream of nitrogen. 
Those carried out at low temperatures were cooled using a bath of methylated spirits and liquid 
nitrogen. Silica gel and silica gel plates used for column chromatography and thin layer 
chromatography (TLC) were obtained from Aldrich. Infra-red (IR) spectra were carried out on a 
Perkin-Elmer 1600 F.T.I.R. spectrometer as liquid films or KBr disc (solid). Optical rotations 
were measured as solutions in chloroform of known concentration using a Polar 2001 automatic 
polarimeter. Nuclear magnetic resonance (NMR) spectra were recorded on Bruker Avance 500 
and 400 spectrometer in CDCl3 or CD3OD if not differently indicated; 
1H spectra were normally 
run at 400MHz, and 13C spectra were run at 101 MHz. Chemical shifts are quoted in δ relative to 
the trace resonance of proton chloroform (δH 7.27 ppm, δC 77.0 ppm), and the resonances of 
methanol (δH 4.87 and 3.31 ppm, δC 49.00 ppm). Mass spectrometry data was obtained from the 
EPSRC UK National Mass Spectrometry Facility at Swansea University and Dr Paul Gates 
(Bristol University). A laboratory book was filled in including chemical safety information 
following COSHH regulations. 
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4.2 Experiments: 
p-Cresyl 2-O-benzoyl-3,5-O-(tetraisopropylsiloxane-1,3-diyl)-α-D-arabinofuranoside (51):239 
 
Benzoyl chloride (5.0 g, 4.2 mL, 0.035 mol) was added dropwise to a stirred solution of p-cresyl 
3,5-O-(tetraisopropylsiloxane-1,3-diyl)-α-D-arabinofuranoside (50) (16.2 g, 0.0324 mol) in 
anhydrous pyridine (25 mL) at 0 ºC under nitrogen. The mixture was allowed to reach room 
temperature and stirred for 6 h, when TLC showed no starting material was left. The solvent 
was evaporated under reduced pressure. The residue was diluted with ethyl acetate (100 mL), 
washed with water (2×50 mL), 1 M aqueous HCl (2×50 mL), sat. aq. NaHCO3 (1×50 mL) 
and brine (1×50 mL). The organic layer was dried over (MgSO4), then the solvent was 
evaporated under reduced pressure. The residue was purified by column chromatography on 
silica eluting with hexane/ethyl acetate (10:1) to give the title compound (51) as a colourless 
thick oil (17 g, 89%) [MALDI–Found (M+Na)+: 625.2; C31H46NaO6SSi2, requires: 625.2]; []
22
D +20 
(c 4.2, CHCl3), which showed δH (400 MHz, CDCl3): 8.08 – 8.01 (2H, d, J 7.9 Hz), 7.59 (1H, t, J 
7.4 Hz), 7.52 – 7.42 (4H, m), 7.10 (2H, d, J 7.9 Hz), 5.59 (1H, br.dd, J 3.8, 5.3 Hz), 5.47 (1H, 
br.d, J 3.7 Hz), 4.57 (1H, dd, J 5.3, 7.9 Hz), 4.23 (1H, m), 4.10 (1H, dd, J 3.2, 12.7 Hz), 4.03 
(1H, dd, J 4.4, 12.7 Hz), 2.32 (3H, s), 1.21 – 0.86 (28H, m); δC (101 MHz, CDCl3): 165.4, 
137.5, 133.3, 132.2, 129.7, 129.6, 129.4, 128.4, 89.6, 83.2, 80.9, 75.5, 61.4, 31.6, 22.6, 21.1, 
17.4, 17.3, 17.0, 16.9, 16.85, 13.5, 13.2, 12.8, 12.5; νmax: 3445, 3022, 2947, 2869, 1718,1468, 
1045, 861 cm-1.  
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-Benzoyl-3,5-O-(tetraisopropylsiloxane-1,3-diyl)-α-D-
arabinofuranoside (52): 
 
Molecular sieves 4 Å (5.6 g) were added to a stirred solution of α-D-arabinofuranoside (51) 
(15.4 g, 0.0255 mol) and 2',3'-di-O-benzyl-L-glycerol (51G) (6.9 g, 0.025 mol) in dry CH2Cl2 
(25 mL) at room temperature under nitrogen. The reaction mixture was stirred for 30 min 
then cooled to -35 oC and N-iodosuccinimide (9.38 g, 0.0383 mol) was added, followed by 
the addition of silver trifluoromethanesulfonate (1.17 g, 0.00460 mol). The mixture was 
stirred at the same temperature until the colour turned a red/dark brown colour and TLC 
showed no starting material was left. The reaction mixture was quenched by the addition of 
triethylamine (2 mL) until became yellow. The mixture was diluted with CH2Cl2 (50 mL) and 
filtered through celite and the solvent was evaporated. The residue was purified by column 
chromatography on silica eluting with hexane/ethyl acetate (10:1) affording the title 
compound (52) as a colourless thick oil (17 g, 91%) [MALDI–Found (M+Na)+: 773.3; 
C41H58NaO9Si2, requires: 773.3]; []
22
D +2.6 (c 4.3, CHCl3), which showed δH (400 MHz, 
CDCl3): 8.01 – 7.97 (2H, m), 7.55 (1H, t, J 7.4 Hz), 7.41 (2H, t, J 7.7 Hz), 7.35 – 7.15 (10H, 
m), 5.41 (1H, br.dd, J 1.4, 4.9 Hz), 4.98 (1H, br.d, J 1.0 Hz), 4.67 (2H, br.s), 4.50 (2H, br.s), 
4.45 (1H, dd, J 5.0, 7.4 Hz), 4.04 – 3.95 (2H, including a broad double doublet J 3.0, 9.9 Hz 
at 3.99), 3.92 (1H, dd, J 5.5, 13.2 Hz), 3.86 – 3.76 (2H, m), 3.67 – 3.59 (2H, including a 
broad double doublet J 4.2, 10.0 Hz at 3.63), 3.58 (1H, dd, J 5.0, 10.2 Hz), 1.32 – 0.75 (28H, 
m); δC (101 MHz, CDCl3): 165.5, 138.7, 138.3, 133.2, 129.7, 128.4, 128.3, 128.2, 127.8, 
127.6, 127.5, 127.4, 105.6, 84.4, 81.2, 76.2, 73.4, 72.3, 70.3, 67.7, 61.8, 31.6, 22.6, 17.5, 
17.4, 17.3, 17.0, 16.9, 13.4, 13.2, 12.8, 12.5; νmax: 3065, 3031, 2945, 2868,1717, 1105, 884, 
712 cm-1. 
 
 
 
 
Chapter 4                                                                                                              Experimental  
134 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-3,5-O-(tetraisopropylsiloxane-1,3-diyl)-α-D-arabinofuranoside (53): 
 
Sodium methoxide in methanol (10 mL, 0.1 M) was added to a stirred solution of compound 
(52) (15.6 g, 0.0207 mol) in dry CH3OH:CH2Cl2 (25 mL, 1:1) at room temperature and the 
mixture was stirred for 0.5 h then TLC showed no starting material was left. The mixture was 
neutralized with Amberlite IR-120 (H+), the resin was filtered off and the solvent was 
removed under reduced pressure to give a residue which was purified by column 
chromatography on silica eluting with petrol/ethyl acetate (5:1) to afford the title compound 
(53) as a thick colourless oil (12 g, 89%) [MALDI–Found (M+Na)+ : 669.3, C34H54NaO8Si2, 
requires 669.3], []
20
D -40 (c 0.10, CHCl3) which showed δH (400 MHz, CDCl3): 7.35 – 7.17 
(10H, m), 4.79 (1H, br.d, J 2.4 Hz), 4.63 (2H, br.s), 4.49 (2H, br.s), 4.14 – 4.04 (2H, m), 3.89 
(1H, dd, J 3.1, 12.7 Hz), 3.86 (1H, br.d, J 3.7 Hz), 3.84 – 3.79 (1H, m), 3.77 (1H, br.dd, J 3.7, 
7.2 Hz), 3.72 (1H, p, J 4.8 Hz), 3.57 (2H, d, J 4.8 Hz), 3.54 (1H, dd, J 4.4, 10.5 Hz), 1.12 – 
0.72 (28H, m); δC (101 MHz, CDCl3): 138.5, 138.4, 128.3, 128.3, 127.8, 127.7, 127.6, 107.5, 
82.6, 80.8, 76.9, 73.4, 72.2, 70.2, 67.9, 61.4, 31.6, 22.6, 17.4, 17.3, 17.1, 17.05, 17.0, 13.5, 
13.1, 12.8, 12.5; νmax: 3402,3062, 2946, 2867, 1467, 1035, 884, 695 cm-1.  
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-allyl-3,5-O-(tetraisopropylsiloxane-1,3-diyl)-α-D-
arabinofuranoside (54): 
 
A solution of 2',3'-di-O-benzyl-L-glycerol-(1'→1)-3,5-O-(tetraisopropylsiloxane-1,3-diyl)-α-
D-arabinofuranoside (53) (11.9 g, 0.0183 mol) in dry DMF (20 mL) was added dropwise to a 
stirred suspension of NaH (0.88 g, 0.036 mol, 60% w/w, dispersion in mineral oil) at 0 ºC 
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under nitrogen. The mixture was stirred for 10 min then allyl bromide (2.66 g, 1.90 mL, 
0.0220 mol) was added. The mixture was stirred at 0 ºC for 2 h then TLC showed no starting 
material was left. The mixture was quenched by slow addition of CH3OH (1 mL) and the 
solvent was evaporated under reduced pressure to give an oily residue which was diluted with 
ethyl acetate (100 mL), and washed with water (50 mL), brine (50 mL), dried over (MgSO4) 
and the solvent was evaporated under reduced pressure. The residue was purified by column 
chromatography on silica eluting with petrol/ethyl acetate (5:1) to give the title compound 
(54) as a colourless thick oil (9.5 g, 75%) [MALDI–Found (M+Na)+: 709.3, C37H58NaO8Si2, 
requires:709.3], []
22
D +72 (c 0.10, CHCl3) which showed δH (400 MHz, CDCl3): 7.44 – 7.05 
(10H, m), 5.81 (1H, ddt, J 5.4, 10.6, 17.3 Hz), 5.20 (1H, dd, J 1.6, 17.3 Hz), 5.09 (1H, dd, J 
1.4, 10.6 Hz), 4.84 (1H, br.d, J 2.4 Hz), 4.63 (2H, br.s), 4.49 (2H, br.s), 4.14 (1H, dd, J 6.0, 
8.3 Hz), 4.05 – 3.93 (2H, m), 3.92 – 3.81 (3H, m), 3.80 – 3.77 (2H, including a broad double 
doublet J 3.5, 8.5 Hz at 3.78), 3.76 – 3.70 (1H, m), 3.64 – 3.55 (2H, including a broad double 
doublet J 4.1, 10.7 Hz at 3.58), 3.54 (1H, dd, J 3.4, 9.3 Hz), 1.11 – 0.83 (28H, m); δC (101 
MHz, CDCl3): 138.6, 138.3, 134.3, 128.3, 128.2, 127.7, 127.6, 127.55, 127.5, 116.8, 106.0, 
89.5, 80.5, 77.1, 76.1, 73.4, 72.1, 71.4, 70.4, 67.5, 61.5, 17.5, 17.3, 17.2, 17.1, 17.05, 17.0, 
13.5, 13.1, 12.8, 12.5; νmax: 3082, 3069, 2927, 2867, 1465, 1036, 885, 696 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-allyl-α-D-arabinofuranoside (55): 
 
Tetrabutylammonium fluoride (26.2 mL, 0.0904 mol, 1.0 M) was added dropwise to a stirred 
solution of α-D-arabinofuranoside (54) (9.0 g, 0.01 mol) in anhydrous THF (25 mL) at 0 ºC under 
nitrogen. The mixture was allowed to reach room temperature and stirred for 2 h then TLC 
showed no starting material was left, then diluted with ethyl acetate (100 mL), washed with sat. 
aq. NH4Cl (50 mL) and brine (50 mL). The organic layer was dried (MgSO4), and concentrated 
to give a residue which was purified by column chromatography on silica eluting with 
hexane/ethyl acetate (3:1) to give to the title compound (55) as a colourless thick oil (5.5 g, 95%) 
[MALDI–Found (M+Na)+: 467.2, C25H32NaO7, requires: 467.2], []
20
D +80 (c 0.10, CHCl3) 
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which showed δH (400 MHz, CDCl3): 7.33 – 7.19 (10H, m), 5.81 (1H, ddt, J 5.6, 10.8, 17.2 Hz), 
5.22 (1H, dd, J 1.5, 17.2 Hz), 5.14 (1H, dd, J 1.3, 10.8 Hz), 5.00 (1H, br.s), 4.61 (1H, d, J 11.9 
Hz), 4.57 (1H, d, J 11.9 Hz), 4.48 (2H, br.s), 4.04 – 3.92 (4H, m), 3.84 – 3.77 (2H, including a 
broad double doublet J 5.7, 10.3 Hz at 3.81), 3.72 (1H, br.dd, J 4.8, 9.7 Hz), 3.68 (1H, br.d, J 3.1 
Hz), 3.63 (1H, dd, J 3.7, 11.8 Hz), 3.58 – 3.54 (1H, m), 3.53 – 3.49 (2H, including a broad 
doublet J 5.1 Hz at 3.52); δC (101 MHz, CDCl3): 138.1, 137.9, 133.6, 128.4, 128.3, 127.8, 
127.75, 127.7, 117.9, 105.6, 86.9, 86.5, 76.5, 75.3, 73.5, 72.1, 70.6, 69.6, 66.7, 62.4; νmax: 3437, 
3031, 2940, 2867, 1651, 1454, 1055, 668 cm-1. The experiment was repeated on a large scale. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-allyl-5-O-tert-butyldiphenylsilyl-α-D-arabinofuranoside (56): 
 
tert-Butylchlorodiphenylsilane (9.2 g, 0. 033 mol) was added to a stirred solution of α-D-
arabinofuranoside (55) (15 g, 0.033 mol) in dry DMF (100 mL), followed by the addition of 
imidazole (5.7 g, 0.084 mol) at 0 ºC under nitrogen. The mixture was allowed to reach room 
temperature and stirred for 25 min, when TLC showed no starting material was left. The 
mixture was diluted with ethyl acetate (100 mL) and water (25 mL). The organic layer was 
separated, the aqueous layer was re-extracted with ethyl acetate (2×100 mL). The combined 
organic layers were washed with water (100 mL), brine (100 mL), dried (MgSO4) and the 
solvent was evaporated under reduced pressure. The residue was purified by column 
chromatography on silica eluting with hexane/ethyl acetate (4:1) affording the title compound 
(56) as a colourless thick oil (15 g, 65%) [NSI–Found (M+NH4)+: 700.3661; C41H54O7SiN, 
requires: 700.3664]; []
22
D +26.5  (c 1.27, CHCl3), which showed δH (400 MHz, CDCl3): 7.66 
– 7.55 (4H, m), 7.41 – 7.17 (16H, m), 5.77 (1H, ddt, J 5.5, 10.7, 17.2 Hz), 5.18 (1H, dd, J 1.0, 
17.2 Hz), 5.11 (1H, dd, J 0.5, 10.7 Hz), 4.95 (1H, br.s), 4.62 (1H, d, J 12.1 Hz), 4.58 (1H, d, J 
12.1 Hz), 4.48 (2H, br.s), 4.11 – 3.98 (2H, including a broad double doublet J 3.5, 9.6 Hz at 
4.03), 3.97– 3.87 (2H, including a broad doublet J 5.4 Hz at 3.93), 3.83 – 3.75 (3H, including 
a broad double doublet J 5.5, 10.5 Hz  at 3.79), 3.74 – 3.69 (1H, m), 3.66 (1H, dd, J 6.5, 10.2 
Hz), 3.60 – 346 (3H, including a broad quartet J 4.7 Hz at 3.54), 1.02 (9H, s); δC (101 MHz, 
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CDCl3): 138.3, 138.0, 135.6, 135.5, 134.0, 133.3, 133.2, 129.7, 128.4, 128.3, 127.75, 127.7, 
127.65, 127.6, 127.55, 117.3, 106.0, 87.8, 84.9, 76.6, 76.5, 73.4, 72.0, 70.6, 69.9, 66.8, 64.3, 
26.8, 19.2; νmax: 3445, 3069, 3031, 2930, 2859,1590, 1471, 1110, 858, 740 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-allyl-3-O-benzyl-5-O-tert-butyldiphenylsilyl-α-D-
arabinofuranoside (57): 
 
A solution of α-D-arabinofuranoside (56) (9.7 g, 0.014 mol) in dry DMF (100 mL) was added 
dropwise to a stirred suspension of NaH (0.68 g, 0.028 mol, 60% w/w, dispersion in mineral 
oil) at 0 ºC under nitrogen atmosphere. The mixture was stirred for 30 min. then benzyl 
bromide (2.5 mL, 3.6 g, 0.021 mol) in dry DMF (5 mL) was added. The mixture was stirred at 
room temperature for 10 h then quenched slowly with CH3OH (10 mL) and H2O (15 mL). The 
mixture was diluted with ether (200 mL). The organic layer was separated and the aqueous 
layer was extracted with ether (2×100 mL). The combined extracts were washed with water 
(100 mL), brine (100 mL), dried (MgSO4) and the solvent was evaporated under reduced 
pressure. The residue was purified by column chromatography on silica eluting with 
petrol/ethyl acetate (5:1) to give the title compound (57) as a colourless thick oil (8.1 g, 72%) 
[NSI–Found (M+NH4)+: 790.4132; C48H60O7SiN, requires: 790.4134]; []
22
D +28 (c 3.9, 
CHCl3), which showed δH (400 MHz, CDCl3): 7.79 – 756 (4H, including a broad double 
doublet J 3.9, 10.8 Hz at 7.66), 7.47 – 7.14 (21H, m), 5.84 (1H, ddt, J 5.5, 10.7, 17.2 Hz), 5.24 
(1H, dd, J 1.3, 17.2 Hz), 5.16 (1H, dd, J 0.9, 10.7 Hz), 5.01 (1H, br.s), 4.70 (1H, d, J 12.0 Hz), 
4.66 (1H, d, J 12.0 Hz), 4.59 (1H, d, J 11.9 Hz), 4.54 – 4.48 (3H, m), 4.13 (1H, br.q, J 4.6 Hz), 
4.03 – 3.89 (4H, m), 3.85 (1H, dd, J 5.1, 10.2 Hz), 3.82 – 3.73 (3H, including a broad double 
doublet J 4.8, 8.1 Hz at 3.79), 3.67 – 3.56 (3H, m), 1.04 (9H, s); δC (101 MHz, CDCl3): 138.6, 
138.3, 138.0, 135.7, 135.6, 134.1, 133.5, 133.4, 129.6, 129.5, 128.3, 128.2, 127.7, 127.65, 
127.6, 127.55, 127.5, 127.45, 127.4, 117.2, 106.4, 88.0, 77.0, 73.3, 72.1, 72.0, 70.6, 70.3, 67.0, 
63.7, 26.8, 19.3; νmax: 3068, 3031, 2929, 2859, 1588, 1454, 1027, 823, 738 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-allyl-3-O-benzyl-α-D-arabinofuranoside (58): 
 
Tetrabutylammonium fluoride (7.0 mL, 7.0 mmol, 1.0 M) was added dropwise to a stirred solution 
of α-D-arabinofuranoside (57) (5.2 g, 0.0067 mol) in anhydrous THF (50 mL) at 0 ºC under 
nitrogen. The mixture was allowed to reach room temperature and stirred for 16 h then TLC 
showed no starting material was left. The mixture was diluted with ethyl acetate (100 mL) 
and water (50 mL). The organic layer was separated and the aqueous layer was re-extracted 
with ethyl acetate (3×50 mL). The combined organic layers were washed with sat. aq. NH4Cl 
(50 mL), brine (50 mL), dried (MgSO4) and the solvent was concentrated. The residue was 
purified by column chromatography on silica eluting with petrol/ethyl acetate (5:1) to give 
the title compound (58) as a colourless thick oil (3.3 g, 91%) [NSI–Found (M+NH4)+: 
552.2948; C32H42O7N, requires: 552.2956]; []
22
D +36 (c 3.3, CHCl3), which showed δH (400 
MHz, CDCl3): 7.38 – 7.28 (15H, m), 5.87 (1H, ddt, J 5.6, 10.7, 17.2 Hz), 5.27 (1H, dd, J 1.5, 
17.2 Hz), 5.20 (1H, dd, J 1.1, 10.7 Hz), 5.03 (1H, br.s), 4.70 (2H, br.s), 4.66 (1H, d, J 11.8 
Hz), 4.58 – 4.49 (3H, m), 4.13 (1H, br.p, J 3.4 Hz), 4.01 (1H, br.dd, J 4.4, 11.8 Hz), 3.99 – 
3.95 (2H, including a broad doublet  J 10.6 Hz at 3.98), 3.94 (1H, br.dd, J 2.6, 6.2 Hz), 3.86 
(1H, dd, J 5.2, 10.3 Hz), 3.82 (1H, dd, J 5.3, 9.6 Hz), 3.79 (1H, br.d, J 9.7 Hz), 3.67 – 
3.63(2H, including a broad double doublet J 6.3, 7.4 Hz at 3.64), 3.63 – 3.59 (2H, including a 
broad doublet J 10.5 Hz at 3.62); δC (101 MHz, CDCl3): 138.6, 138.2, 137.8, 133.9, 128.4, 
128.35, 128.3, 127.8, 127.75, 127.7, 127.6, 127.5, 117.6, 106.4, 87.6, 82.8, 82.2, 76.9, 73.4, 
72.3, 72.2, 70.7, 70.1, 67.1, 62.2; νmax: 3453, 3063, 3031, 2923, 2870, 1603, 1453, 1064, 850, 
739 cm-1.  
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-allyl-3-O-benzyl-5-p-methoxybenzyl-α-D-arabinofuranoside (59): 
 
A solution of α-D-arabinofuranoside (58) (3.1 g, 0.0057 mol) in dry DMF (10 mL) was added 
dropwise to a stirred suspension of NaH (0.25 g, 0.010 mol, 60% w/w, dispersion in mineral 
oil) at 0 ºC under nitrogen. The mixture was stirred for 30 min. then, freshly prepared,           
p-methoxybenzyl bromide (1.4 g, 0.0069 mol) was added. The mixture was stirred at 0 ºC for 
2 h then TLC showed no starting material was left. The mixture was quenched with slow 
addition of CH3OH (1 mL) and the solvent was evaporated under reduced pressure to give an 
oily residue which was diluted with ethyl acetate (50 mL). The organic layer was washed 
with water (25 mL), brine (25 mL), dried (MgSO4) and the solvent was evaporated under 
reduced pressure. The residue was purified by column chromatography on silica eluting with 
petrol/ethyl acetate (5:1) to give the title compound (59) as a colourless thick oil (2.9 g, 76%) 
[NSI–Found (M+NH4)+: 672.3526; C40H50O8N, requires: 672.3531]; []
22
D +41 (c 1.6, 
CHCl3), which showed δH (400 MHz, CDCl3): 7.37 – 7.26 (15H, m), 7.24 (2H, d, J 8.7 Hz), 
6.86 (2H, d, J 8.6 Hz), 5.86 (1H, ddt, J 5.5, 10.7, 17.2 Hz), 5.25 (1H, dd, J 1.6, 17.2 Hz), 5.18 
(1H, dd, J 1.3, 10.7 Hz), 5.03 (1H, br.s), 4.71 (1H, d, J 12.1 Hz), 4.68 (1H, d, J 12.1 Hz), 4.61 
(1H, d, J 11.9 Hz), 4.54 (3H, br.s), 4.51 (1H, d, J 11.7 Hz), 4.47 (1H, d, J 11.7 Hz), 4.22 – 
4.15 (1H, m), 4.03 – 3.91 (3H, m), 3.88 (1H, dd, J 5.2, 10.5 Hz), 3.86 (1H, br.d, J 6.5 Hz), 
3.84 – 3.75 (4H, including a singlet at 3.8 for OCH3), 3.66 – 3.58 (4H, m), 3.55 (1H, dd, J 
5.2, 10.7 Hz); δC (101 MHz, CDCl3): 138.7, 138.3, 138.0, 134.1, 130.2, 129.4, 128.8, 128.4, 
128.3, 127.75, 127.7, 127.6, 127.5, 127.45, 117.4, 113.7, 106.4, 88.1, 83.7, 80.8, 73.4, 73.0, 
72.2, 70.8, 70.4, 69.3, 67.2, 55.3; νmax: 3064, 3030, 2912, 2864, 1612, 1513, 1454, 1106, 820, 
738 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-3-O-benzyl-5-p-methoxybenzyl-α-D-arabinofuranoside (60): 
  
Palladium (II) chloride (0.30 g, 0.0017 mol) was added to a stirred solution of α-D-
arabinofuranoside (59) (5.7 g, 0.0087 mol) in dry CH2Cl2:MeOH (0.6:5, 5 mL) at room 
temperature. The mixture was stirred for 16 h then TLC showed no starting material was left. 
The mixture was quenched with triethylamine (1 mL) and the solvent was evaporated under 
reduced pressure. The residue was purified by column chromatography on silica eluting with 
petrol/ethyl acetate (4:1) to give the title compound (60) as a pale yellow thick oil (4.5 g, 84%) 
[NSI–Found (M+NH4)+: 632.3209; C37H46O8N, requires: 632.3218]; []
22
D +60 (c 4.6, 
CHCl3), which showed δH (400 MHz, CDCl3): 7.38 – 7.26 (15H, m), 7.23 (2H, d, J 8.5 Hz), 
6.89 (2H, d, J 8.6 Hz), 5.03 (1H, br.s), 4.74 (1H, d, J 12.1 Hz), 4.68 (1H, d, J 12.1 Hz), 4.66 
(1H, d, J 11.9 Hz), 4.58 (1H, d, J 11.9 Hz), 4.51 (2H, br.s), 4.49 (1H, d, J 11.7 Hz), 4.44 (1H, 
d, J 11.7 Hz), 4.26 (1H, br.d, J 2.4 Hz), 4.18 (1H, d, J 10.8 Hz), 3.89 (1H, dd, J 5.4, 10.4 Hz), 
3.87 (1H, br.d, J 3.1 Hz), 3.85 – 3.79 (4H, including a singlet at 3.82 for OCH3), 3.68 – 3.63 
(3H, m), 3.61 (1H, dd, J 5.5, 10.2 Hz), 3.49 (1H, dd, J 2.1, 10.4 Hz), 3.39 (1H, d, J 10.8 Hz); 
δC (101 MHz, CDCl3): 159.5, 138.8, 138.4, 137.8, 129.5, 129.1, 128.4, 128.3, 128.2, 127.75, 
127.7, 127.65, 127.55, 127.45, 127.4, 113.9, 109.4, 85.4, 83.6, 77.5, 76.9, 73.4, 73.3, 72.2, 
71.9, 70.4, 69.4, 67.4, 55.2; νmax: 3433, 3063, 3031, 2912, 2867, 1611, 1513, 1454, 1248, 1098, 
820, 738, 699 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-(triisopropylsilyl)-3,5-O-(tetraisopropylsiloxane-1,3-
diyl)-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-p-methoxybenzyl-α-D-arabinofuranoside (62): 
 
Molecular sieves 4 Å (5 g) was added to a stirred solution of -D-arabinofuranoside (60) (4.3 
g, 0.0069 mol) and  p-tolyl-3,5-O-(tetraisopropylsiloxane-1,3-diyl)-1-thio-2-O-triisopropylsilyl-α-D-
arabinofuranoside (61)3 (11.4 g, 0.0174 mol) in dry CH2Cl2 (50 mL) at room temperature under 
nitrogen. The mixture was stirred for 30 min then cooled to -78 ºC and N-iodosuccinimide (6.4 g, 
0.026 mol) was added followed by the addition of silver trifluoromethanesulfonate (0.71 g, 0.0028 
mol). The mixture was stirred until the colour turned red/dark brown at -60 ºC, when TLC showed 
no starting material was left. The mixture was quenched with triethylamine (4 mL) until the colour 
turned yellow. The mixture was diluted with CH2Cl2 (100 mL) and filtered through celite and the 
solvent was evaporated. The residue was purified by column chromatography on silica eluting with 
hexane/ethyl acetate (4:1) affording the title compound (62) as a yellow thick oil (6.9 g, 86%) 
[NSI–Found (M+NH4)+:1162.6495; C63H100O13Si3N, requires: 1162.6497]; []
22
D +4.5 (c 0.97, 
CHCl3), which showed δH (400 MHz, CDCl3): 7.28 – 7.18 (15H, m), 7.15 (2H, d, J 8.5 Hz), 6.78 
(2H, d, J 8.5 Hz), 4.96 (1H, br.s), 4.79 (1H, br.d, J 4.3 Hz), 4.63 (1H, d, J 12.0 Hz), 4.59 (2H, d, J 
12.0 Hz), 4.44 (2H, br.s), 4.43 (1H, d, J 12.0 Hz), 4.39 (2H, br.s), 4.34 (1H, br.dd, J 5.7, 7.3 
Hz), 4.20 – 4.17 (1H, br.m), 4.15 (1H, dd, J 4.7, 9.2 Hz), 4.12 (1H, br.t, J 5.1 Hz), 3.87 (1H, d, J 
5.7 Hz), 3.86 (1H, d, J 6.8 Hz), 3.84 – 3.76 (3H, m), 3.75 – 3.70 (4H, including a singlet at 3.73 for 
OCH3), 3.56 (1H, dd, J 3.9, 9.7 Hz), 3.53 (1H, br.d, J 5.3 Hz), 3.51 – 3.47 (2H, including a broad 
double doublet J 4.6, 10.5 Hz at 3.49), 3.45 (1H, dd, J 5.9, 10.8 Hz), 1.04 – 0.92 (49H, m); δC 
(101 MHz, CDCl3): 159.1, 138.8, 138.4, 138.0, 130.2, 129.3, 128.3, 128.25, 128.2, 127.7, 127.65, 
127.6, 127.5, 127.4, 127.3, 113.7, 106.2, 100.6, 85.9, 84.4, 82.0, 81.5, 79.4, 79.1, 77.05, 73.3, 72.9, 
72.2, 72.15, 70.6, 69.8, 67.4, 66.6, 55.2, 18.0, 17.95, 17.6, 17.5, 17.4, 17.3, 17.2, 17.1, 17.0, 16.9, 
13.4, 13.3, 13.0, 12.7, 12.4; νmax: 3064, 3031, 2943, 2867, 1513,1248, 736, 695 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-p-methoxybenzyl-α-D-
arabinofuranoside (63): 
 
Tetrabutylammonium fluoride (17.1 mL, 0.0202 mol, 1.0 M) was added dropwise to a stirred 
solution of α-D-arabinofuranoside (62) (6.5 g, 0.0056 mol) in dry THF (100 mL) at 0 ºC under 
nitrogen. The mixture was allowed to reach room temperature and stirred for 6 h. When TLC 
showed no starting material was left, the mixture was diluted with ethyl acetate (100 mL) and 
water (10 mL). The organic layer was separated and the aqueous layer was re-extracted with 
ethyl acetate (3×25 mL). The combined organic layers were washed with sat. aq. NH4Cl (25 mL), 
brine (25 mL), dried (MgSO4) and the solvent was concentrated to give a residue which was 
purified by column chromatography on silica eluting with dichloromethane /methanol (20:1) 
to give the title compound (63) as a colourless thick oil (4.0 g, 95%) [NSI–Found (M+NH4)+: 
764.3639; C42H54O12N, requires: 764.3641]; []
24
D +16 (c 0.50, CHCl3), which showed δH 
(400 MHz, CDCl3): 7.28 – 7.17 (15H, m), 7.15 (2H, d, J 8.6 Hz), 6.79 (2H, d, J 8.6 Hz), 4.96 
(1H, br.s), 4.94 (1H, br.d, J 4.7 Hz), 4.60 (2H, br.s), 4.56 (1H, d, J 11.9 Hz), 4.44 (3H, br.s), 
4.40 (1H, d, J 11.6 Hz), 4.33 (1H, d, J 11.6 Hz), 4.23 (1H, m), 4.06 (1H, br.p, J 3.6 Hz), 4.01 
(1H, dd, J 2.7,  6.1 Hz), 3.95 (1H, t, J 7.2 Hz), 3.87 (1H, br.dd, J 5.9, 10.6 Hz), 3.79 (1H, 
br.dd, J 4.8, 10.5 Hz), 3.76 (1H, br.dd, J 3.3, 6.8 Hz), 3.73 – 3.69 (4H, including a singlet at 
3.7 for OCH3), 3.61 – 3.47 (6H, m), 3.39 (1H, dd, J 3.9, 10.9 Hz); δC (101 MHz, CDCl3): 
159.3, 138.5, 138.2, 137.8, 129.8, 129.7, 128.4, 128.35, 128.3, 127.8, 127.7, 127.6, 127.55, 
127.5, 113.8, 106.2, 101.0, 86.5, 82.9, 82.4, 81.2, 78.1, 76.9, 75.0, 73.4, 73.1, 72.3, 72.2, 70.1, 
68.6, 67.3, 62.3, 55.3; νmax: 3430, 3063, 3031, 2923, 2868, 1612, 1514, 1100, 740, 699 cm-1.  
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-5-O-tert-butyldiphenylsilyl-β-D-arabinofuranosyl-(1→2)-3-O-
benzyl-5-p-methoxybenzyl-α-D-arabinofuranoside (64): 
 
tert-Butylchlorodiphenylsilane (1.39 mL, 1.47 g, 0.00535 mol) was added to a stirred 
solution of α-D-arabinofuranoside (63) (4.0 g, 0.005 mol) in dry DMF (5 mL), followed by 
the addition of imidazole (0.73 g, 0.010 mol) at 0 ºC under nitrogen. The mixture was 
allowed to reach room temperature and stirred for 30 min, when TLC showed no starting 
material was left. The mixture was diluted with ethyl acetate (25 mL) and water (5 mL). The 
organic layer was separated, and the aqueous layer was re-extracted with ethyl acetate (2×25 mL). 
The combined organic layers were washed with water (10 mL), brine (10 mL), dried (MgSO4) 
and the solvent was evaporated under reduced pressure. The residue was purified by column 
chromatography on silica eluting chloroform/methanol (20:1) affording the title compound (64) 
as a colourless thick oil (4.1 g, 77%) [NSI–Found (M+NH4)+: 1002.4816; C58H72O12SiN, 
requires: 1002.4818]; []
22
D -6.3 (c 0.38, CHCl3), which showed δH (400 MHz, CDCl3): 7.69 – 
7.63 (4H, m), 7.46 – 7.16 (21H, m), 7.11 (2H, dd, J 2.9, 6.5 Hz), 6.85 (2H, d, J 8.6 Hz), 5.03 (1H, 
br.d, J 4.5 Hz), 5.02 (1H, br.s), 4.69 (1H, d, J 12.0 Hz), 4.66 (1H, d, J 12.0 Hz), 4.56 – 4.48 (4H, 
m), 4.45 (1H, d, J 11.6 Hz), 4.40 (1H, d, J 11.6 Hz), 4.31 – 4.29 (1H, m), 4.25 (1H, d, J 11.7 Hz), 
4.14 (1H, br.p, J 5.1 Hz), 4.01 – 3.84 (4H, m), 3.82 (1H, br.dd, J 3.8, 9.1 Hz), 3.79 – 3.75 (4H, 
including a singlet at 3.77 for OCH3), 3.71 (1H, dd, J 6.6, 10.0 Hz), 3.65 – 3.60 (3H, including a 
broad double doublet J 4.9, 8.9 Hz at 3.63), 3.54 (1H, dd, J 3.3, 10.8 Hz), 3.46 (1H, dd, J 4.9, 
10.8 Hz), 2.43 (1H, d, J 9.4 Hz), 2.16 (1H, d, J 2.7 Hz), 1.07 (9H, s); δC (101 MHz, CDCl3): 
159.2, 138.6, 138.3, 137.8, 135.8, 135.7, 135.6, 135.5, 133.1, 133.0, 130.0, 129.95, 129.9, 129.6, 
129.5, 128.4, 128.35, 128.3, 128.2, 128.0, 127.9, 127.85, 127.8, 127.7, 127.65, 127.6, 127.55, 
127.5, 113.8, 106.3, 100.8, 85.9, 83.8, 81.6, 81.4, 78.2, 77.4, 77.0, 73.4, 73.0, 72.3, 72.2, 70.2, 
69.1, 67.3, 66.1, 55.3, 26.9, 19.2; νmax: 3438, 3067, 3031, 2930, 2859, 1612, 1513, 1248, 739, 700 
cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-tert-butyldiphenylsilyl-β-D-
arabinofuranosyl-(1→2)-3-O-benzyl-5-p-methoxybenzyl-α-D-arabinofuranoside (65): 
 
A solution of α-D-arabinofuranoside (64) (4.0 g, 0.0040 mol) in dry DMF (5 mL) was added 
dropwise to a stirred suspension of NaH (0.39 g, 0.016 mol, 60% w/w, dispersion in mineral 
oil) at 0 ºC under nitrogen. The mixture was stirred for 0.5 h then benzyl bromide (1.44 mL, 2.08 g, 
0.012 mol) in dry DMF (5 mL) was added. The mixture was stirred at room temperature for 10 h 
and then quenched with CH3OH (1 mL) and H2O (5 mL). The mixture was diluted with ether 
(25 mL). The organic layer was separated and the aqueous layer was extracted with ether 
(2×25 mL). The combined extracts were washed with water (25 mL), brine (25 mL), dried 
(MgSO4) and the solvent was evaporated under reduced pressure. The residue was purified by 
column chromatography on silica eluting with petrol/ethyl acetate (4:1) to give the title compound 
(65) as a colourless thick oil (4.3 g, 90%) [NSI–Found (M+NH4)+: 1182.5751;  C72H84O12SiN, 
requires: 1182.5757]; []
22
D -11 (c 0.38, CHCl3), which showed δH (400 MHz, CDCl3): 7.68 – 7.64 
(4H, m), 7.42 – 7.16 (31H, m), 7.08 (2H, dd, J 1.6, 7.5 Hz), 6.85 (2H, d, J 8.6 Hz), 5.08 (1H, d, J 
4.4 Hz), 5.04 (1H, br.s), 4.70 (1H, d, J 12.1 Hz), 4.66 (1H, d, J 12.1 Hz), 4.64 (2H, br.s), 4.56 (1H, 
d, J 11.7 Hz), 4.52 (2H, br.s), 4.48 (1H, d, J 11.7 Hz), 4.44 (2H, d, J 11.5 Hz), 4.41 (2H, d, J 11.5 
Hz), 4.29 (1H, br.d, J 1.9 Hz), 4.20 (1H, br.d, J 5.9 Hz), 4.17 (2H, br.dd, J 5.0, 6.1 Hz), 4.11 (1H, 
br.q, J, 6.5 Hz), 4.05 (1H, br.dd, J 4.5, 6.1 Hz), 3.89 (1H, dd, J 5.2, 10.4 Hz), 3.84 – 3.78 (6H, 
including a singlet at 3.79 for OCH3), 3.61 (3H, br.dd, J 4.8, 9.4 Hz), 3.53 (1H, br.dd, J 2.8, 9.5 
Hz), 3.49 (1H, br.dd, J 4.7, 9.5 Hz), 1.05 (9H, s);   δC (101 MHz, CDCl3): 159.1, 138.7, 138.4, 
138.2, 137.9, 137.7, 135.6, 135.5, 133.2, 133.1, 130.3, 129.8, 129.3, 128.4, 128.3, 128.2, 128.1, 
127.9, 127.8, 127.75, 127.7, 127.6, 127.55, 127.5, 127.4, 113.7, 106.0, 100.3, 85.4, 84.6, 84.1, 84.0, 
82.0, 81.6, 77.1, 73.3, 72.8, 72.4, 72.3, 72.25, 72.2, 70.4, 69.9, 67.2, 66.2, 55.2, 26.8, 19.2; νmax: 
3065, 3031, 2930, 2860, 1612, 1513, 1248, 738, 699 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-p-
methoxybenzyl-α-D-arabinofuranoside (66): 
 
Tetrabutylammonium fluoride (3.5 mL, 0.0038 mol, 1.0 M) was added dropwise to a stirred 
solution of α-D-arabinofuranoside (65) (4.1 g, 0.0035 mol) in dry THF (25 mL) at 0 ºC 
under nitrogen. The mixture was allowed to reach room temperature and stirred for 6 h. When 
TLC showed no starting material was left, the mixture was diluted with ethyl acetate (15 mL) and 
water (5 mL). The organic layer was separated and the aqueous layer was re-extracted with ethyl 
acetate (3×50 mL). The combined organic layers were washed with sat. aq. NH4Cl (25 mL), brine 
(25 mL), dried (MgSO4) and the solvent was concentrated to give a residue which was purified by 
column chromatography on silica eluting with petrol /ethylacetate (5:2) to give the title 
compound (66) as a colourless thick oil (3.0 g, 93%) [NSI–Found (M+NH4)+: 944.4574; 
C56H66O12N, requires: 944.4580]; []
22
D -7.1 (c 0.79, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.29 – 7.18 (25H, m), 7.16 (2H, d, J 8.7 Hz), 6.78 (2H, d, J 8.7 Hz), 4.97 (1H, d, J 4.5 
Hz), 4.95 (1H, br.d, J 1.1 Hz), 4.64 (1H, d, J 11.7 Hz), 4.60 (2H, br.s), 4.53 (1H, d, J 11.5 Hz), 
4.51 (1H, d, J 11.5 Hz), 4.47 – 4.43 (4H, m), 4.39 (1H, d, J 11.9 Hz), 4.38 (1H, d, J 11.9 Hz), 
4.35 (1H, d, J 11.7 Hz), 4.21 (1H, br.dd, J 1.4, 3.5 Hz), 4.18 (1H, d, J 6.8 Hz), 4.09 (1H, br.p, J 
4.1 Hz ), 4.02 (1H, br.dd, J 3.5, 6.5 Hz), 3.95 (1H, dd, J 4.5, 7.3 Hz), 3.93 – 3.88 (1H, m), 3.79 
(1H, dd, J 5.2, 10.4 Hz), 3.74 – 3.68 (4H, including a singlet at 3.71 for OCH3), 3.59 – 3.50 (5H, 
m), 3.48 (1H, br.d, J 3.7 Hz), 3.43 (1H, dd, J 4.9, 10.8 Hz), 2.22 (1H, br.dd, J 5.1, 7.8 Hz); δC 
(101 MHz, CDCl3): 159.2, 138.6, 138.3, 138.1, 137.9, 137.6, 130.0, 129.5, 128.5, 128.45, 128.4, 
128.3, 128.2, 128.0, 127.9, 127.8, 127.75, 127.7, 127.65, 127.6, 127.55, 127.5, 113.8, 106.1, 
100.1, 86.3, 84.1, 83.3, 82.0, 81.0, 80.7, 77.0, 73.4, 73.0, 72.6, 72.4, 72.2, 70.3, 69.1, 67.4, 63.4, 
55.2; νmax: 3491, 3063, 3031, 2925, 2869, 1612, 1513, 1454, 1248, 738, 699 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-α-D-
arabinofuranoside (67): 
 
Cerium ammonium nitrate (CAN) (3.5 g, 0.0064 mol) was added to a stirred solution of α-D-
arabinofuranoside (66) (2.0 g, 0.002 mol) in CH3CN:H2O (9:1,15 mL) at 0 ºC. The mixture 
was allowed to reach room temperature and stirred at ambient temperature for 1 h then TLC 
indicated the conversion had finished. The mixture was diluted with chloroform (25 mL), 
washed with aq. NaHCO3 (15 mL), dried (MgSO4) and the solvent was evaporated under 
reduced pressure. The residue was purified by column chromatography on silica eluting with 
petrol/ethyl acetate (5:2) to give the title compound (67) as a colourless thick oil (1.5 g, 89%) 
[NSI–Found (M+Na)+: 829.4; C48H54NaO11, requires: 829.4]; []
21
D -4.3 (c 0.83, CHCl3), which 
showed δH (400 MHz, CDCl3): 7.64 – 6.67 (25H, m), 4.97 (1H, br.d, J 4.6 Hz), 4.95 (1H, br.s), 
4.67 (1H, d, J 11.6 Hz), 4.64 (2H, br.s), 4.62 (1H, d, J 11.6 Hz), 4.55 (1H, d, J 11.6 Hz), 4.50 
– 4.46 (5H, m), 4.2 – 4.17 (2H, broad double doublet J 5.6, 8.1 Hz), 4.16 (1H, br.dd, J 2.2, 
5.6 Hz), 4.09 – 4.04 (1H, m), 4.00 (1H, dd, J 4.6, 7.3 Hz), 3.97 – 3.92 (1H, m), 3.80 (1H, dd, 
J 5.2, 10.2 Hz), 3.76 (1H, br.d, J 6.4 Hz), 3.73 (1H, br.dd, J 3.9, 8.3 Hz), 3.63 (1H, dd, J 2.9, 
10.2 Hz), 3.60 – 3.48  (5H, m); δC (101 MHz, CDCl3): 138.5, 138.2, 137.9, 137.8, 137.4, 
128.5, 128.4, 128.35, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.65, 127.6, 127.55, 127.5, 
106.3, 100.5, 86.4, 84.0, 83.0, 82.7, 81.9, 80.4, 76.9, 73.3, 72.6, 72.5, 72.3, 72.2, 70.1, 67.2, 
63.2, 62.0; νmax: 3463, 3063, 3031, 2922, 2872, 1454, 1107, 738, 698 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-methanesulfonyl-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-5-O-methanesulfonyl-α-D-arabinofuranoside (68): 
 
Methanesulfonyl chloride (1.98 g, 1.36 mL, 0.0171 mol) and DMAP (0.10 g, 0.86 mmol) 
were added to a stirred solution of α-D-arabinofuranoside (67) (1.4 g, 0.0017 mol) in dry 
pyridine (10 mL) under nitrogen at room temperature. The mixture was stirred for 16 h then 
TLC showed no starting material was left. The mixture was quenched by the addition of H2O 
(3 mL), the organic layer was separated by decanting and diluted with CH2Cl2 (10 mL). The 
mixture was washed with 1N aq. HCl (4×10 mL), sat. aq. NaHCO3 (4×10 mL), dried 
(MgSO4), filtered and the solvent was evaporated under reduced pressure to give a thick oil 
residue which was purified by column chromatography on silica eluting with petrol/ethyl 
acetate (4:1) to afford the title compound (68) as a colourless thick oil (1.4 g, 85%) [NSI–Found 
(M+Na)+: 985.3109; C50H58NaO15S2, requires: 985.3115]; []
22
D +2.8 (c 1.3, CHCl3), which showed 
δH (400 MHz, CDCl3): 7.36 – 7.16 (25H, m), 5.01 (1H, br.d, J 4.4 Hz), 4.93 (1H, br.s), 4.70 
(1H, d, J 11.7 Hz), 4.67 (1H, d, J 11.7 Hz), 4.63 (2H, br.s), 4.58 (1H, d, J 11.7 Hz), 4.51 (1H, 
d, J 11.7 Hz), 4.46 (4H, br.s), 4.32 (1H, br.q, J 4.6 Hz), 4.25 – 4.13 (5H, m), 4.13 – 4.07 (3H, 
m), 4.00 (1H, br.dd, J 4.4, 6.9 Hz), 3.80 (1H, dd, J 5.2, 10.3 Hz), 3.74 (1H, br.p, J 5.1 Hz), 
3.60 – 3.50 (3H, including a broad double doublet J 4.6, 7.2 at 3.56), 2.85 (3H, s), 2.84 (3H, 
s); δC (101 MHz, CDCl3): 138.5, 138.2, 137.7, 137.6, 137.2, 128.6, 128.5, 128.4, 128.35, 
128.3, 128.1, 128.0, 127.95, 127.9, 127.8, 127.75, 127.7, 127.6, 127.55, 127.5, 106.4, 101.2, 
85.9, 83.5, 81.1, 80.9, 78.4, 76.9, 73.3, 72.7, 72.6, 72.4, 72.3, 69.9, 69.8, 69.0, 67.3, 37.5, 
37.4; νmax: 3087, 3031, 2929, 2867, 1606, 1454, 1046,738, 697 cm-1.  
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-alkanoate-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-5-O-alkanoate-α-D-arabinofuranoside (70a-d): 
 
General procedure: 
Cesium hydrogencarbonate was added to a stirred solution of α-D-arabinofuranoside (68) and 
fatty acids (69a-d) in dry THF:DMF (5:1, 1 mL) at room temperature under nitrogen . The mixture 
was stirred at 70 ºC for 4 days then TLC showed no starting material was left. The suspension was 
diluted with ethyl acetate (25 mL) and water (5 mL). The organic layer was separated and the 
aqueous layer was re-extracted with ethyl acetate (2×10 mL). The combined organic layers 
were washed with water (10 mL) and brine (10 mL), dried (MgSO4) and filtered. The filtrate 
was evaporated under reduced pressure to give a thick oil residue which was purified by 
column chromatography on silica eluting with hexane/ethyl acetate (5:1) to afford the title 
compounds (70a-d). 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-palmitate-β-D-arabinofuranosyl-(1→2) -
3-O-benzyl-5-O-palmitate-α-D-arabinofuranoside (70a): 
 
Cesium hydrogencarbonate (66 mg, 0.34 mmol), α-D-arabinofuranoside (68) (33.0 mg, 0.034 
mmol) and plamitic acid (69a) (22 mg, 0.085 mmol); to give (70a) as a colourless thick oil (41 mg, 
92%) [NSI–Found (M+Na)+: 1305.8; C80H114NaO13, requires: 1305.8]; []
22
D -7.6 (c 0.58, CHCl3), 
which showed δH (400 MHz, CDCl3): 7.37 – 7.16 (25H, m), 5.01 (1H, d, J 4.2 Hz), 4.95 (1H, 
br.s), 4.66 (1H, d, J 11.6 Hz), 4.63 (3H, br.s), 4.56 (1H, d, J 11.6 Hz), 4.48 (1H, d, J 11.6 Hz), 
4.47 (2H, br.s), 4.45 (1H, d, J 11.8 Hz), 4.41 (1H, d, J 11.8 Hz), 4.30 (1H, br.d, J 2.0 Hz), 4.25 – 4.15 
(3H, m), 4.11 (1H, br.dd, J 3.1, 6.6 Hz), 4.09 – 4.01 (3H, m), 3.99 (1H, dd, J 4.3, 6.6 Hz), 3.90 
(1H, br.dd, J 2.5, 5.8 Hz), 3.82 (1H, dd, J 5.2, 10.4Hz), 3.74 (1H, br.p, J 5.0 Hz), 3.61 – 3.50 
(3H, including a broad double doublet J 4.7, 8.5 Hz at 3.56), 2.33 – 2.21 (2H, m), 2.18 (2H, 
dt, J 2.1, 7.4 Hz), 1.64 – 1.01 (52H, m), 0.84 (6H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 173.5, 
173.4, 138.6, 138.3, 137.8, 137.7, 137.4, 128.5, 128.4, 128.35, 128.3, 128.0, 127.8, 127.75, 
127.7, 127.65, 127.6, 127.5, 106.1, 100.5, 85.6, 84.3, 83.8, 82.5, 80.1, 78.9, 73.4, 72.6, 72.5, 
72.4, 72.3, 70.2, 67.3, 66.0, 63.7, 34.0, 31.9, 29.7, 29.65, 29.6, 29.5, 29.4, 29.35, 29.3, 29.25, 
29.2, 29.1, 24.9, 24.8, 22.7, 14.1; νmax: 3065, 3031, 2924, 2853, 1741, 1732, 1455, 1114, 737, 
698 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-stearate-β-D-arabinofuranosyl-(1→2)-3-O-
benzyl-5-O-stearate-α-D-arabinofuranoside (70b): 
 
Cesium hydrogencarbonate (80 mg, 0.41 mmol), α-D-arabinofuranoside (68) (40 mg, 0.041 
mmol) and stearic acid (69b) (30 mg, 0.10 mmol); to give (70b) as a colourless thick oil (49 
mg, 89%) [NSI–Found (M+NH4)+: 1356.9227; C84H126O13N, requires: 1356.9224]; []
22
D -4.6 (c 
0.44, CHCl3), which showed δH (400 MHz, CDCl3): 7.36 – 7.14 (25H, m), 5.01 (1H, d, J 4.2 Hz), 
4.95 (1H, br.s), 4.66 (2H, d, J 11.5 Hz), 4.63 (2H, br.s), 4.56 (1H, d, J 11.5 Hz), 4.52 – 4.43 
(4H, m), 4.41 (1H, d, J 11.6 Hz), 4.31 (1H, br.d, J 1.8 Hz), 4.25 – 4.16 (3H, m), 4.14 – 4.02 
(4H, m), 3.99 (1H, dd, J 4.3, 6.6 Hz), 3.90 (1H, br.dd, J 2.4, 5.7 Hz), 3.82 (1H, dd, J 5.2, 10.4 
Hz), 3.74 (1H, br.p, J 4.9 Hz), 3.62 – 3.52 (3H, including a broad double doublet J 4.8, 7.6 Hz at 
3.56), 2.23 (2H, t, J 7.6 Hz), 2.18 (2H, dt, J 1.9, 7.4 Hz), 1.31 – 1.14 (60H, m), 0.85 (6H, t, J 
6.8 Hz); δC (101 MHz, CDCl3): 173.5, 173.3, 138.6, 138.3, 137.8, 137.7, 137.4, 128.5, 128.4, 
128.3, 128.2, 128.0, 127.8, 127.75, 127.7, 127.65, 127.6, 127.5, 106.1, 100.4, 85.6, 84.3, 
83.7, 82.5, 80.1, 78.8, 77.0, 73.3, 72.6, 72.5, 72.3, 72.2, 70.2, 67.3, 65.9, 63.7, 34.0, 31.9, 
29.7, 29.65, 29.6, 29.5, 29.4, 29.35, 29.3, 29.25, 29.2, 29.1, 24.9, 24.8, 22.7, 14.1; νmax: 3065, 
3032, 2925, 2854, 1740, 1731, 1454, 1116, 734, 697 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-behenate-β-D-arabinofuranosyl-(1→2)-
3-O-benzyl-5-O-behenate-α-D-arabinofuranoside (70c): 
 
Cesium hydrogencarbonate (161 mg, 0.830 mmol), α-D-arabinofuranoside (68) (80 mg, 0.083 
mmol) and behenic acid (69c) (71 mg, 0.20 mmol); to give (70c) as a colourless thick oil 
(0.11 g, 87%) [NSI–Found (M+Na)+: 1474.0; C92H138NaO13, requires: 1474.0]; []
22
D -4.2 (c 1.1, 
CHCl3), which showed δH (400 MHz, CDCl3): 7.30 – 7.15 (25H, m), 4.97 (1H, br.d, J 4.2 Hz), 
4.91 (1H, br.s), 4.62 (1H, d, J 11.5 Hz), 4.61 (1H, d, J 11.5 Hz), 4.59 (2H, br.s), 4.52 (1H, d, 
J 11.6 Hz), 4.44 (3H, br.s), 4.41 (1H, d, J 11.6 Hz), 4.37 (1H, d, J 11.6 Hz), 4.27 (1H, br.d, J 
2.0 Hz), 4.20 (1H, J 3.5 Hz), 4.16 (1H, J 4.6 Hz), 4.13 (1H, br.dd, J 3.6, 5.8 Hz), 4.10 – 4.04 
(2H, including a broad double doublet J 4.1, 8.2 Hz at 4.06), 4.03 (1H, dd, J 3.7, 9.7 Hz), 
3.99 (1H, d, J 5.2 Hz), 3.95 (1H, dd, J 4.3, 6.7 Hz), 3.86 (1H, dd, J 2.4, 5.9 Hz), 3.78 (1H, dd, 
J 5.2, 10.4 Hz), 3.70 (1H, br.p J 4.8 Hz), 3.57 – 3.48 (3H, including a broad double doublet J 
4.7, 8.3 Hz at 3.52), 2.19 (2H, t, J 7.6 Hz), 2.14 (2H, dt, J 2.7, 7.5 Hz), 1.53 – 1.03 (76H, m), 
0.80 (6H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 173.5, 173.4, 138.6, 138.3, 137.8, 137.7, 137.4, 
128.5, 128.4, 128.35, 128.3, 128.0, 127.8, 127.75, 127.7, 127.6, 127.55, 127.5, 106.1, 100.4, 
85.6, 84.3, 83.8, 82.5, 80.1, 78.9, 77.2, 73.4, 72.5, 72.4, 72.35, 72.3, 70.2, 67.3, 66.0, 63.7, 
34.0, 31.9, 29.7, 29.65, 29.6, 29.55, 29.5, 29.4, 29.3, 29.25, 29.2, 29.1, 24.9, 24.8, 22.7, 14.1; 
νmax: 3063, 3031, 2917, 2850, 1740, 1732, 1467, 1110, 735, 697 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(R)-2-((R)-1-hydroxydocosyl) 
hexacosanoate-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-O-(R)-2-((R)-1-hydroxydocosyl) 
hexacosanoate-α-D-arabinofuranoside (70d): 
 
Cesium hydrogencarbonate (134 mg, 0.691 mmol), α-D-arabinofuranoside (68) (33 mg, 0.034 
mmol) and (R)-2-((R)-1-hydroxydocosyl) hexacosanoic acidc (69d) (50 mg, 0.069 mmol); to give 
(70d) as a colourless thick oil (60 mg, 55%) [NSI–Found (M+Na)+: 2178.7; C140H234NaO15, 
requires: 2178.7]; []
24
D -3 (c 0.9, CHCl3), which showed δH (400 MHz, CDCl3): 7.43 – 7.11 
(25H, m), 5.01 (1H, br.d, J 4.2 Hz), 4.97 (1H, br.s), 4.71 (2H, d, J 11.5 Hz), 4.66 (2H, m), 
4.61 (1H, d, J 11.5 Hz), 4.59 – 4.47 (4H, m), 4.45 (1H, d, J 11.6 Hz), 4.32 (1H, br.d, J 1.8 
Hz), 4.30 – 4.21 (4H, m), 4.17 – 4.08 (3H, including a broad pentet J 5.7 Hz at 4.12), 4.04 – 
3.99 (1H, m), 3.98 – 3.95 (1H, m), 3.84 (1H, dd, J 5.3, 10.2 Hz), 3.79 (1H, br.p, J 5.1 Hz), 
3.72 – 3.52 (5H, including a broad double doublet J 4.5, 10.8 Hz  at 3.59), 2.41 (2H, ddt, J 
4.7, 9.4, 12.7 Hz), 1.80 – 1.04 (174H, m), 0.89 (12H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 
175.0, 138.5, 138.2, 137.7, 137.3, 128.5, 128.4, 128.35, 128.3, 128.25, 128.2, 128.1, 127.9, 
127.8, 127.7, 127.6, 127.5, 105.9, 100.4, 85.5, 84.4, 83.7, 82.8, 80.3, 78.9, 73.4, 72.6, 72.5, 
72.4, 72.2, 72.1, 70.2, 67.2, 66.1, 63.7, 51.9, 51.6, 35.4, 35.3, 31.9, 31.6, 29.7, 29.6, 29.55, 
29.5, 29.45, 29.4, 29.35, 29.3, 27.5, 27.4, 25.7, 25.6, 22.7, 22.6, 14.1; νmax: 3491, 3065, 3031, 
2918, 2850, 1732, 1725, 1468, 1115, 735, 697 cm-1. 
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L-Glycerol-(1'→1)-5-O-alkanoate-β-D-arabinofuranosyl-(1→2)-5-O-alkanoate-α-D-
arabinofuranoside (71a-d): 
 
General procedure: 
Palladium hydroxide on activated charcoal was added to a stirred solution of α-D-
arabinofuranoside (70a-d) in CH2Cl2:MeOH (1:1, 1 mL) at room temperature under hydrogen. 
The mixture was stirred for 36 h then TLC showed no starting material was left. The mixture 
was filtered off through celite and the solvent was evaporated under reduced pressure to give a 
residue which was purified by column chromatography on silica eluting with 
chloroform/methanol (10:1) affording L-glycerol-(1'→1)-5-O-alkanoyl-β-D-arabinofuranosyl-
(1→2)-5-O-alkanoyl-α-D-arabinofuranoside (71a-d). 
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L-Glycerol-(1'→1)-5-O-palmitate-β-D-arabinofuranosyl-(1→2)-5-O-palmitate-α-D-
arabinofuranoside (71a):  
 
(Pd(OH)2-C/20%, 25 mg, 0.75 fold by weight) and α-D-arabinofuranoside (70a) (33 mg, 
0.025 mmol); to give (71a) as a colourless thick oil (18 mg, 82%) [NSI–Found (M+Na)+: 
855.5804; C45H84NaO13, requires: 855.5810]; []
21
D +14 (c 0.30, CHCl3), which showed δH 
(400 MHz, CDCl3+few drops CD3OD): 5.06 (1H, br.d, J 4.5 Hz), 5.02 (1H, br.d, J 1.9 Hz), 
4.45 (1H, dd, J 7.2, 11.9 Hz), 4.38 – 3.30 (1H, m), 4.28 (1H, br.dd, J 4.1, 6.8 Hz), 4.26 – 4.21 
(1H, m), 4.20 – 4.15 (2H, including a broad double doublet, J 1.9, 9.6 Hz at 4.18), 4.15 – 4.10 
(2H, m), 4.07 (2H, including a broad double doublet, J 5.4, 8.3 Hz at 4.07), 4.04 (1H, br.d, J 
7.0 Hz), 4.00 (1H, dd, J 4.8, 10.3 Hz), 3.91 – 3.85 (2H, m), 3.77 (2H, dd, J 6.0, 10.7 Hz), 
3.71 (1H, br.d, J 2.9 Hz), 3.67 (2H, br.t, J 6.0 Hz), 2.36 (4H, t, J 7.6 Hz), 1.46 – 1.08 (53H, 
m), 0.89 (6H, t, J 6.8 Hz); δC (101 MHz, CDCl3+few drops CD3OD): 173.5, 173.4, 138.6, 
138.3, 137.8, 137.7, 137.4, 128.5, 128.4, 128.35, 128.3, 128.0, 127.8, 127.75, 127.7, 127.65, 
127.6, 127.5, 106.1, 100.5, 85.6, 84.3, 83.8, 82.5, 80.1, 78.9, 77.0, 73.4, 72.6, 72.5, 72.4, 72.3, 
70.2, 67.3, 66.0, 63.7, 34.0, 31.9, 29.7, 29.65, 29.6, 29.5, 29.45, 29.4, 29.3, 29.25, 29.2, 29.1, 24.9, 
24.8, 22.7, 14.1; νmax: 3436, 2918, 2850, 1738, 1643, 1469, 1219, 1116, 1041, 927 cm-1. 
 
 
 
 
 
 
 
 
Chapter 4                                                                                                              Experimental  
155 
 
L-Glycerol-(1'→1)-5-O-stearate-β-D-arabinofuranosyl-(1→2)-5-O-stearate-α-D-
arabinofuranoside (71b): 
 
(Pd(OH)2-C/20%, 34 mg, 0.75 fold by weight) and α-D-arabinofuranoside (70b) (45 mg, 0.033 
mmol); to give (71b) as a colourless thick oil (24 mg, 81%) [NSI–Found (M+Na)+: 911.6430; 
C49H92NaO13, requires: 911.6436]; []
25
D -3.4 (c 0.71, CHCl3), which showed δH (400 MHz, 
CDCl3+few drops CD3OD): 5.01 (1H, br.d, J 4.3 Hz), 5.00 (1H, br.s), 4.33 – 4.29 (1H, m), 4.27 
(1H, br.d, J 5.7 Hz), 4.20 – 4.15 (2H, m), 4.13 (1H, br.d, J 7.0 Hz), 4.04 (1H, dd, J 5.9, 10.6 
Hz), 4.00 (1H, br.dd, J 2.6, 6.6 Hz), 3.98 – 3.88 (3H, including a broad double doublet J 4.9, 
9.0 Hz at 3.96), 3.86 – 3.78 (1H, m), 3.74 (1H, dd, J 5.8, 10.6 Hz), 3.63 (1H, br.dd, J 3.9, 11.8 
Hz), 3.6 – 3.53 (2H, including a broad double doublet J 3.0, 10.8 Hz at 3.58), 2.33 (4H, t, J 7.5 
Hz), 1.36 – 1.17 (65H, m), 0.86 (6H, t, J 6.3 Hz); δC (101 MHz, CDCl3): 174.3, 174.0, 138.6, 
138.3, 137.8, 137.7, 137.4, 128.5, 128.4, 128.3, 128.2, 128.0, 127.8, 127.7, 127.65, 127.6, 
127.55, 127.5, 106.1, 100.4, 85.6, 84.3, 83.8, 82.5, 80.1, 78.8, 77.0, 73.4, 72.5, 72.4, 72.3, 72.2, 
70.2, 67.3, 65.9, 63.7, 34.0, 31.9, 29.7, 29.65, 29.6, 29.5, 29.4, 29.35, 29.3, 29.2, 29.15, 29.1, 
24.9, 24.8, 22.7, 14.1; νmax: 3430, 2917, 2849, 1737, 1643, 1467, 1214, 1172, 1041, 719 cm-1. 
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L-Glycerol-(1'→1)-5-O-behenate-β-D-arabinofuranosyl-(1→2)-5-O-behenate-α-D-
arabinofuranoside (71c):   
 
(Pd(OH)2-C/20%, 75 mg, 0.75 fold by weight); (100 mg, 0.0688 mmol) of α-D-
arabinofuranoside (70c); to give (71c) as a colourless thick oil (60 mg, 87%) [NSI–Found 
(M+Na)+: 1023.7682; C57H108NaO13, requires: 1023.7688]; []
22
D -2.3 (c 0.44, CHCl3), which 
showed δH (400 MHz, CDCl3+few drops CD3OD): 4.97 (1H, br.d, J 4.7 Hz), 4.96 (1H, br.s), 
4.30 – 4.21 (2H, including a broad double doublet J 8.4, 11.2 Hz at 4.25), 4.16 (1H, dd, J 3.2, 
11.9 Hz), 4.14 – 4.06 (2H, m), 4.03 – 3.97 (2H, m), 3.96 – 3.88    (3H, m), 3.78 (1H, br.p, J 5.1 
Hz), 3.71 (1H, dd, J 6.0, 10.4 Hz), 3.63 – 3.59 (1H, m), 3.57 (1H, dd, J 4.3, 11.5 Hz), 3.53 (1H, 
dd, J 4.8, 11.2 Hz), 2.31 (4H, t, J 7.6 Hz), 1.34 – 1.14 (81H, m), 0.83 (6H, t, J 6.6 Hz); δC (126 
MHz, CDCl3+few drops CD3OD): 174.2, 173.9, 105.9, 101.9, 88.5, 80.3, 80.1, 75.8, 75.5, 70.4, 
69.5, 65.5, 63.6, 63.2, 34.0, 33.9, 31.8, 29.5, 29.45, 29.4, 29.3, 29.2, 29.15, 29.1, 29.0, 24.7, 
22.5, 13.8; νmax: 3419, 2956, 2917, 1738, 1732, 1464, 1215, 1171, 1048, 881, 720 cm-1. 
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L-Glycerol-(1'→1)-5-O-(R)-2-((R)-1-hydroxydocosyl)hexacosanoate-β-D-arabinofuranosyl-
(1→2)-5-O-(R)-2-((R)-1-hydroxydocosyl)hexacosanoate-α-D-arabinofuranoside (71d):  
 
(Pd(OH)2-C/20%, 23 mg, 0.75 fold by weight) and α-D-arabinofuranoside (70d) (30 mg, 
0.013 mmol); to give (71d) as a colourless thick oil (17 mg, 74%) [NSI–Found (M+Na)+: 
1728.5; C105H204NaO15, requires: 1728.5]; []
22
D +8 (c 0.3, CHCl3), which showed δH (400 
MHz, CDCl3+few drops CD3OD): 4.98 (1H, br.d, J 5.7 Hz), 4.97 (1H, br.s), 4.40 (1H, dd, J 
4.7, 11.6 Hz), 4.34 (1H, dd, J 4.8, 11.4 Hz), 4.22 (1H, dd, J 5.6, 11.6 Hz), 4.20 (1H, dd, J  
6.4, 12.0 Hz), 4.13 (1H, dd, J 6.1, 10.7 Hz), 4.10 (1H, br.q, J 6.9 Hz), 4.05 – 3.98 (4H, 
including a broad doublet J 11.2 Hz at 4.02), 3.85 – 3.76 (1H, m), 3.71 (1H, dd, J 6.4, 10.6 
Hz), 3.68 – 3.62 (2H, br.m), 3.61 (1H, d, J 4.1 Hz), 3.57 (1H, dd, J 4.2, 9.6 Hz), 3.54 (1H, 
br.dd, J 3.2, 10.3 Hz), 2.46 – 2.37 (2H, m), 1.64 – 1.01 (179H, m), 0.86 (12H, t, J 6.8 Hz); δC 
(101 MHz, CDCl3+few drops CD3OD): 175.1, 175.0, 105.8, 101.5, 87.6, 80.7, 79.5, 77.2, 
76.4, 76.1, 72.8, 72.5, 70.4, 69.5, 65.4, 63.7, 63.3, 63.2, 53.3, 52.6, 34.8, 34.7, 31.9, 29.7, 
29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 29.2, 29.1, 27.4, 27.3, 25.4, 25.2, 22.6, 14.0; νmax: 3416, 
2927, 2854, 1728, 1719, 1466, 1215, 1121, 1044, 759, 669 cm-1. 
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2',3'-Di-O-acetyl-L-glycerol-(1'→1)-2,3-di-O-acetyl-5-O-behenate-β-D-arabinofuranosyl-
(1→2)-3-O-acetyl-5-O-behenate-α-D-arabinofuranoside (72): 
 
Acetic anhydride (0.02 g, 0.20 mmol, 0.02 mL) was added to a stirred solution of α-D-
arabinofuranoside (71c) (20 mg, 0.019 mmol) in dry pyridine (2 mL) at room temperature and 
the mixture was stirred at room temperature for 18 hours under nitrogen. The solvent was 
evaporated and the crude product was purified by column chromatography eluting with 
petrol/ethyl acetate (2:1) to afford the title compound (72) (20 mg, 83%) [NSI–Found (M+Na)+: 
1233.8210; C67H118NaO18, requires: 1233.8216]; []
23
D -13 (c 0.62, CHCl3), which showed δH 
(400 MHz, CDCl3): 5.40 (1H, br.d, J 4.7 Hz), 5.34 (1H, dd, J 5.3, 6.3 Hz), 5.21 (1H, br.p, J 4.8 
Hz), 4.95 (2H, br.dd, J 4.7, 6.6 Hz), 4.91 (1H, br.s), 4.37 (1H, dd, J 4.6, 11.6 Hz), 4.29 (1H, dd, 
J 4.4, 7.6 Hz), 4.27 – 4.10 (7H, m), 3.82 (1H, dd, J 5.2, 11.0 Hz), 3.60 (1H, dd, J 4.5, 10.9 Hz), 
2.42 – 2.29 (4H, m), 2.11 – 2.09 (12H, m), 2.08 (3H, s), 1.70 – 0.99 (76H, m), 0.89 (6H, t, J 6.7 
Hz); δC (101 MHz, CDCl3): 173.4, 173.3, 170.6, 170.4, 170.2, 170.1, 169.9, 105.0, 99.4, 83.9, 
80.6, 79.1, 77.5, 75.6, 69.8, 65.3, 65.2, 63.6, 62.5, 34.1, 34.0, 31.9, 31.6, 29.7, 29.65, 29.5, 
29.35, 29.3, 29.2, 24.9, 24.8, 22.7, 22.6, 21.0, 20.8, 20.7, 20.6, 20.4, 14.1; νmax: 2918, 2850, 
1742, 1736, 1466, 1224, 1167, 1045, 755, 721 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(R)-2-((R)-1-hydroxy-18-
((1R,2S)-2-((17S,18S)-17-methoxy-18-methylhexatriacontyl) cyclopropyl) octadecyl) 
tetracosanoate-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-O-(R)-2-((R)-1-hydroxy-18-((1R,2S)-
2-((17S,18S)-17-methoxy-18-methylhexatriacontyl)cyclopropyl)octadecyl)tetracosanoate-α-
D-arabinofuranoside (74): 
 
Cesium hydrogencarbonate (79 mg, 0.40 mmol) was added to a stirred solution of α-D-
arabinofuranoside (68) (20 mg, 0.020 mmol) and (R)-2-((R)-1-hydroxy-18-((1R,2S)-2-
((17S,18S)-17-methoxy-18-methylhexatriacontyl)cyclopropyl) octadecyl)tetracosanoic acid 
(73) (50 mg, 0.040 mmol) in dry THF:DMF (1mL, 5:1) at room temperature under nitrogen. 
The mixture was stirred at 70 ºC for 4 days then TLC showed no starting material was left. 
The suspension was diluted with ethyl acetate (25 mL) and water (5 mL). The organic layer 
was separated and the aqueous layer was re-extracted with ethyl acetate (2×10 mL). The 
combined organic layers were washed with water (10 mL) and brine (10 mL), dried over MgSO4 
and filtered. The filtrate was evaporated under reduced pressure to give a thick oil residue which 
was purified by column chromatography on silica eluting with hexane/ethyl acetate (5:1) to give 
(74) as a colourless thick oil (70 mg, 54%) [NSI–Found (M+Na)+: 3243.9; C214H378NaO17, 
requires: 3243.9]; []
24
D -4.4 (c 0.73, CHCl3), which showed δH (400 MHz, CDCl3): 7.35 – 7.16 
(25H, m), 4.97 (1H, d, J 4.3 Hz), 4.93 (1H, br.s), 4.67 (2H, d, J 11.7 Hz), 4.63 (2H, m), 4.58 (1H, 
d, J 11.7 Hz), 4.52 – 4.44 (4H, m), 4.41 (1H, d, J 11.6 Hz), 4.28 (1H, br.d, J 1.6 Hz), 4.26 – 4.16 
(4H, m), 4.12 – 4.04 (2H, including a broad pentet J 6.5 Hz at 4.08), 4.00 – 3.95 (1H, m), 3.93 
(1H, br.d, J 2.9 Hz), 3.80 (1H, dd, J 5.3, 10.3 Hz), 3.78 – 3.74 – 3.69 (5H, including a broad 
triplet J 6.6 Hz at 3.72), 3.58 – 3.53 (4H, including a broad double doublet J 4.5, 10.7 Hz at 3.55), 
3.31 (6H, s), 2.92 (2H, dt, J 4.1, 7.1 Hz), 2.42 – 2.32 (2H, m), 1.56 – 0.97 (286H, m), 0.85 (12H, 
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t, J 6.8 Hz), 0.82 (6H, d, J 6.9 Hz), 0.65 – 0.58 (4H, m), 0.56 – 0.49 (2H, dt, J 4.0, 8.4 Hz), -0.36 
(2H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3): 175.04, 175.03, 138.5, 138.3, 137.8, 137.3, 128.5, 
128.45, 128.4, 128.35, 128.3, 128.2, 128.1, 127.9, 127.8, 127.75, 127.7, 127.6, 127.5, 105.9, 
100.4, 85.5, 85.4, 84.4, 83.7, 82.8, 80.3, 78.9, 77.1, 73.4, 72.6, 72.5, 72.45, 72.4, 72.2, 72.1, 70.2, 
68.0, 67.2, 66.1, 63.7, 57.7, 51.8, 51.6, 35.3, 32.4, 31.9, 30.5, 30.2, 30.0, 29.9, 29.7, 29.65, 29.6, 
29.5, 29.45, 29.4, 29.3, 28.7, 27.6, 27.4, 26.2, 25.7, 25.6, 22.7, 15.8, 14.9, 14.1, 10.9; νmax: 3522, 
3063, 3031, 2922, 2852, 1744, 1737, 1464, 1101,733, 698  cm-1. 
 
L-Glycerol-(1'→1)-5-O-(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-
methylhexatriacontyl)cyclopropyl)octadecyl)tetracosanoate-β-D-arabinofuranosyl-
(1→2)-5-O-(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-methylhexatriacontyl) 
cyclopropyl)octadecyl)tetracosanoate-α-D-arabinofuranoside (75): 
 
Palladium hydroxide on activated charcoal (Pd(OH)2-C/20%, 33 mg, 0.75 fold by weight) was 
added to a stirred solution of compound (74) (43 mg, 0.013 mmol) in CH2Cl2:MeOH (1:1, 1 mL) 
at room temperature under hydrogen. The mixture was stirred for 36 h then TLC showed no 
starting material was left. The mixture was filtered off through celite and the solvent was 
evaporated under reduced pressure to give a residue which was purified by column 
chromatography on silica eluting with chloroform/methanol (10:1) to give (75) as a colourless 
thick oil (27 mg, 73%) [NSI–Found (M+Na)+: 2793.6; C179H348NaO17, requires: 2793.6]; 
[]
22
D +13 (c 0.36, CHCl3), which showed δH (400 MHz, CDCl3+few drops CD3OD): 4.98 (1H, 
br.d, J 4.7 Hz), 4.82 (1H, br.s), 4.40 (1H, dd, J 4.4, 12.2 Hz), 4.37 – 4.31 (2H, including a broad 
double doublet J 4.7, 11.6 Hz at 4.34), 4.22 (1H, dd, J 5.6, 11.5 Hz), 4.15 (1H, br.dd, J 5.6, 11.7 
Hz), 4.10 (1H, br.dd, J 4.1, 9.0 Hz), 4.07 – 3.94 (6H, br.m), 3.89 (1H, br.dd, J 2.6, 4.7 Hz), 3.85 – 
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3.77 (1H, m), 3.72 (1H, dd, J 5.5, 11.5 Hz), 3.69 – 3.51 (6H, m), 3.38 (1H, dd, J 4.2, 8.5 Hz), 
3.32 (6H, s), 2.99 – 2.90 (2H, m), 2.47 – 2.37 (2H, m), 1.66 – 0.96 (288H, m), 0.86 (12H, t, J 6.9 
Hz), 0.83 (6H, d, J 6.9 Hz), 0.66 – 0.58 (4H, m), 0.53 (2H, dt, J 4.1, 8.6 Hz), -0.36 (2H, br.q, J 
5.1 Hz); δC (101 MHz, CDCl3+few drops CD3OD): 175.1, 175.0, 105.8, 101.5, 87.7, 85.5, 80.6, 
79.5, 77.2, 76.4, 76.0, 72.6, 72.4, 70.3, 69.3, 65.4, 63.3, 63.1, 57.6, 53.2, 52.6, 35.2, 32.2, 31.8, 
30.4, 30.1, 29.8, 29.7, 29.6, 29.5, 29.3, 29.2, 29.1, 29.0, 28.6, 27.4, 27.35, 27.3, 26.0, 25.3, 25.2, 
22.6, 15.6, 14.7, 13.9, 10.8; νmax: 3397,  2920, 2851, 1730, 1467, 1171, 1099, 1046, 721 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-mycolate-β-D-arabinofuranosyl-(1→2)-
3-O-benzyl-5-O-mycolate-α-D-arabinofuranoside (77f-h): 
 
General procedure:  
A solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) in dry 
CH2Cl2 (1 mL) was added to a stirred solution of 2',3'-di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-
benzyl-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-α-D-arabinofuranoside (67); molecular sieves 
4 Å, DMAP and mycolic acids (76f-h) in dry CH2Cl2 (1 mL) at room temperature under 
nitrogen. The mixture was stirred for 5 days. When TLC showed no starting material was left. 
The precipitate was filtered off and washed with CH2Cl2 (10 mL), the solvent was evaporated 
and the residue was purified by column chromatography on silica eluting with 
hexane/ethylacetate (5:1) to afford the compounds (77f-h).  
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(R)-2-((R)-1-((tert-butyldimethylsilyl) 
oxy)-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl)hexadecyl)hexacosanoate-
β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-O-(R)-2-((R)-1-((tert-butyldimethylsilyl)oxy)-
16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl)hexadecyl)hexacosanoate-α-
D-arabinofuranoside (77f): 
 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (77 mg; 0.40 mmol), 
molecular sieves 4 Å (50 mg), α-D-arabinofuranoside (67) (33 mg, 0.040 mmol),  DMAP   
(49 mg; 0.40 mmol) and (R)-2-((R)-1-((tert-butyldimethylsilyl)oxy)-16-((1S,2R)-2-((S)-20-
methyl-19-oxooctatriacontyl)cyclopropyl)hexadecyl) hexacosanoic acid (76f) (108 mg, 
0.0790 mmol); to give (77f) as a colourless thick oil (0.13 g, 97%) [NSI–Found (M+Na)+: 
3496.1; C228H406NaO17Si2, requires: 3496.1]; []
21
D +4.2 (c 0.38, CHCl3), which showed δH 
(400 MHz, CDCl3): 7.38 – 7.18 (25H, m), 5.03 (1H, br.d, J 4.2 Hz), 4.97 (1H, br.s), 4.72 (1H, 
d, J 11.6 Hz), 4.68 (3H, d, J 11.6 Hz), 4.62 (1H, d, J 11.7 Hz), 4.56 – 4.48 (4H, m), 4.43 (1H, 
d, J 11.7 Hz), 4.37 (1H, br.d, J 2.0 Hz), 4.29 – 4.11 (6H, m), 4.06 (1H, t, J 6.0 Hz), 4.00 (1H, 
br.dd, J 4.3, 6.5 Hz), 3.96 – 3.81 (4H, m), 3.78 (1H, br.p, J 4.7 Hz), 3.67 – 3.54 (3H, 
including a broad double doublet J 4.4, 10.4 Hz at 3.60), 2.53 (4H, including a sextet J 6.8 Hz 
at 2.53), 2.42 (4H, dt, J 1.0, 7.2 Hz), 1.61 – 1.12 (288H, m), 1.06 (6H, d, J 6.9 Hz), 0.89 
(12H, t, J 6.8 Hz), 0.85 (9H, s), 0.84 (9H, s), 0.71 – 0.62    (4H, m), 0.57 (2H, dt, J 4.1, 8.4 
Hz), 0.04 (3H, s), 0.02 (3H, s), 0.01 (3H, s), -0.01 (3H, s), -0.32 (2H, br.q, J 5.1 Hz);   δC 
(101 MHz, CDCl3): 215.2, 174.3, 174.1, 138.6, 138.3, 137.9, 137.7, 137.5, 128.5, 128.4, 
128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.65, 127.6, 127.5, 127.4, 105.9, 100.2, 84.9, 
84.6, 83.6, 83.3, 80.1, 79.1, 77.1, 73.4, 73.2, 73.1, 72.5, 72.4, 72.2, 70.3, 67.2, 66.3, 64.3, 
51.5, 51.4, 46.3, 41.1, 33.7, 33.0, 31.9, 30.2, 29.9, 29.85, 29.8, 29.75, 29.7, 29.65, 29.6, 
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29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 28.7, 27.8, 27.7, 27.4, 27.3, 25.9, 25.8, 24.0, 23.9, 23.7, 
22.7, 16.4, 15.8, 14.1, 10.9, -4.4, -4.5, -4.7, -4.8; νmax: 3088, 3063, 2922, 2852, 1739, 1713, 
1465, 1115, 758, 698 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(R)-2-((R)-1-((tert-butyldimethylsilyl) 
oxy)-12-((1S,2R)-2-(14-((1S,2R)-2-icosylcyclopropyl)tetradecyl) cyclopropyl)dodecyl) 
hexacosanoate-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-O-(R)-2-((R)-1-((tert-butyldimethylsilyl) 
oxy)-12-((1S,2R)-2-(14-((1S,2R)-2-icosylcyclopropyl) tetradecyl) cyclopropyl)dodecyl) 
hexacosanoate-α-D-arabinofuranoside (77g): 
 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (83 mg; 0.43 mmol), 
molecular sieves 4 Å (50 mg), α-D-arabinofuranoside (67) (35 mg, 0.043 mmol),  DMAP        (52 
mg; 0.42 mmol) and (R)-2-((R)-1-((tert-butyldimethylsilyl)oxy)-12-((1S,2R)-2-(14-((1S,2R)-2-
icosylcyclopropyl) tetradecyl) cyclopropyl)dodecyl)hexacosanoic acid (76g) (113 mg, 0.0900 
mmol); to give (77g) as a colourless thick oil (0.12 g, 84%) [NSI–Found (M+Na)+: 3295.9; 
C216H382NaO15Si2, requires: 3295.9]; []
22
D -10.2 (c 0.47, CHCl3), which showed δH (400 
MHz, CDCl3): 7.40 – 7.20 (25H, m), 5.04 (1H, br.d, J 4.2 Hz), 4.97 (1H, br.s), 4.73 (1H, d, J 
11.6 Hz), 4.69 (3H, d, J 11.6 Hz), 4.62 (1H, d, J 11.7 Hz), 4.56 – 4.48 (4 H, m), 4.43 (1H, d, J 
11.7 Hz), 4.37 (1H, br.d, J 1.9 Hz), 4.30 – 4.11 (6H, m), 4.07 (1H, t, J 6.0 Hz), 4.00 (1H, br.dd, 
J 4.3, 6.5 Hz), 3.89 (4H, m), 3.78 (1H, br.p, J 4.9 Hz), 3.70 – 3.52 (3H, including a broad 
double doublet  J 4.4, 10.3 Hz at 3.61), 2.62 – 2.48 (2H, m), 1.65 – 1.06 (268H, m), 0.89 (12H, t, J 
6.8 Hz), 0.86 (9H, s), 0.85 (9H, s), 0.71 – 0.61 (8H, m), 0.57 (4H, dt, J 4.1, 8.5 Hz), 0.04 (3H, s), 
0.02 (3H, s), 0.01 (3H, s), -0.01 (3H, s), -0.32 (4H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3): 
174.3, 174.1, 138.6, 138.3, 137.9, 137.7, 137.5, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 
Chapter 4                                                                                                              Experimental  
164 
 
127.7, 127.65, 127.6, 127.5, 127.4, 105.9, 100.2, 84.9, 84.6, 83.6, 83.3, 80.1, 79.1, 77.1, 73.4, 
73.2, 73.1, 72.5, 72.4, 72.2, 70.3, 67.2, 66.3, 64.3, 51.5, 51.4, 33.7, 31.9, 30.3, 30.2, 29.9, 
29.85, 29.8, 29.75, 29.7, 29.65, 29.6, 29.5, 29.4, 28.7, 27.8, 27.7, 27.4, 27.3, 25.9, 25.8, 24.0, 
23.9, 22.7, 18.0, 17.9, 15.8, 14.1, 11.0, 10.9, -4.4, -4.5, -4.7, -4.8; νmax: 3062, 3032, 2922, 2853, 
1740, 1717, 1465, 1116, 733, 698 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-((tert-butyldimethylsilyl) 
oxy)-17-((1S,2R)-2-((22S)-22-methyl-21-oxotetracontan-2-yl)cyclopropyl)heptadecyl)hexacosanoate-β 
-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-O-(2R)-2-((1R)-1-((tert-butyldimethylsilyl)oxy)-17 
-((1S,2R)-2-((22S)-22-methyl-21-oxotetracontan-2-yl)cyclopropyl)heptadecyl) hexacosanoate-α-
D-arabinofuranoside (77h): 
 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (71 mg; 0.37 mmol), 
molecular sieves 4 Å (50 mg), α-D-arabinofuranoside (67) (30 mg, 0.037 mmol),  DMAP (45 mg; 
0.36 mmol) and (2R)-2-((1R)-1-((tert-butyldimethylsilyl)oxy)-17-((1S,2R)-2-((22S)-22-methyl-
21-oxotetracontan-2-yl)cyclopropyl)heptadecyl)hexacosanoic acid (76h) (103 mg, 0.0730 
mmol); to give (77h) as a colourless thick oil (12 mg, 91%) [NSI–Found (M+Na)+: 3580.2; 
C234H418NaO17Si2, requires: 3580.2]; []
22
D +2.3 (c 1.4, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.37 – 7.22 (25H, m), 5.03 (1H, br.d, J 4.2 Hz), 4.97 (1H, br.s), 4.72 (1H, d, J 11.7 Hz), 
4.68 (3H, d, J 11.7 Hz), 4.62 (1H, d, J 11.6 Hz), 4.56 – 4.47 (4H, m), 4.43 (1H, d, J 11.6 Hz), 
4.37 (1H, br.d, J 1.8 Hz), 4.28 – 4.10 (6H, m), 4.06 (1H, br.t, J 5.6 Hz), 4.00 (1H, br.dd, J 4.3, 6.4 
Hz), 3.96 – 3.81 (4H, m), 3.77 (1H, br.p, J 4.9 Hz), 3.66 – 3.55 (3H, including a broad double 
doublet  J 4.4, 10.4 Hz at 3.60), 2.60 – 2.46 (4H, including a sextet J 6.8 Hz at 2.53), 2.42 (4H, dt, 
J 1.0, 7.5 Hz), 1.67 – 1.12 (300H, m), 1.06 (6H, d, J 6.9 Hz), 0.91 – 0.87 (18H, including a triplet 
J 7.5 Hz at 0.89), 0.85 (9H, s), 0.84 (9H, s), 0.75 – 0.62 (2H, m), 0.51 – 0.40 (2H, m), 0.24 – 0.08 
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(6H, m), 0.04 (3H, s), 0.02 (3H, s), 0.01 (3H, s), -0.01 (3H, s); δC (101 MHz, CDCl3): 215.2, 
174.3, 174.1, 138.6, 138.3, 137.9, 137.7, 137.5, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 
127.7, 127.65, 127.6, 127.5, 127.4, 105.9, 100.1, 84.9, 84.6, 83.6, 83.3, 80.1, 79.1, 77.2, 73.4, 
73.2, 73.1, 72.5, 72.4, 72.2, 70.3, 67.2, 66.3, 64.3, 51.5, 51.4, 46.3, 41.1, 38.1, 37.4, 34.5, 33.7, 
33.0, 31.9, 31.6, 30.1, 30.0, 29.9, 29.8, 29.75, 29.7, 29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.35, 
29.3, 27.8, 27.7, 27.4, 27.3, 26.1, 25.9, 25.8, 24.0, 23.9, 23.7, 22.7, 22.6, 19.7, 18.6, 18.0, 17.9, 
16.4, 14.1, 10.5, -4.4, -4.5, -4.7, -4.8; νmax: 3064, 3032, 2922, 2852, 1740, 1714, 1465, 1117, 733, 
698 cm-1. 
 
De-protection of silyl group in mycolic acid (78f-h): 
 
General procedure: 
Tetrabutylammonium fluoride 1.0 M solution in THF was added dropwise to a stirred solution 
of compounds (77f-h) in dry THF (1 mL) at 0 ºC under nitrogen. The mixture was allowed to 
reach room temperature and stirred for 16 h. When TLC showed no starting material was left, 
the mixture was diluted with ethyl acetate (10 mL) and water (1 mL). The organic layer was 
separated and the aqueous layer was re-extracted with ethyl acetate (3×10 mL). The combined 
organic layers were washed with sat. aq. NH4Cl (5 mL), brine (5 mL), dried (MgSO4) and the 
solvent was concentrated to give the residue which was purified by column chromatography on 
silica eluting with hexane /ethyl acetate (10:1) affording the compounds (78f-h). 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(R)-2-((R)-1-hydroxy-16-((1S,2R)-2-
((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl)hexadecyl)hexacosanoate-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-5-O-(R)-2-((R)-1-hydroxy-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl) 
cyclopropyl) hexadecyl)hexacosanoate-α-D-arabinofuranoside (78f): 
 
Tetrabutylammonium fluoride (0.56 mL, 1.9 mmol, 1.0 M) and α-D-arabinofuranoside (77f)   
(98 mg, 0.028 mmol); to give (78f) as a colourless thick oil (45 mg, 38%) [NSI–Found (M+Na)+: 
3267.9; C216H378NaO17, requires: 3267.9]; []
22
D +7.1 (c 0.34, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.39 – 7.22 (25H, m), 5.01 (1H, br.d, J 4.3 Hz), 4.97 (1H, br.s), 4.71 (2H, d, J 11.5 Hz), 4.67 
(2H, m), 4.62 (1H, d, J 11.5 Hz), 4.56 – 4.50 (3H, m), 4.51 (1H, d, J 11.6 Hz), 4.45 (1H, d, J 11.6 
Hz), 4.32 (1H, br.d, J 1.7 Hz), 4.30 – 4.21 (5H, m), 4.17 – 4.08 (2H, including a broad pentet J 6.0 Hz 
at 4.12), 4.02 (1H, br.dd, J 4.4, 6.3 Hz), 3.99 – 3.93 (1H, m), 3.84 (1H, dd, J 5.3, 10.3 Hz), 3.81 – 3.76 
(1H, br.p, J 5.3 Hz), 3.59 (5H, including a broad double doublet  J 4.5, 10.8 Hz at 3.59), 2.56 – 2.46 
(4H, including a sextet J 6.8 Hz at 2.51), 2.42 (4H, dt, J 1.1, 7.6 Hz),  1.65 – 1.11 (290H, m), 1.06 (6H, 
d, J 6.9 Hz), 0.89 (12H, t, J 6.8 Hz), 0.71 – 0.61 (4H, m), 0.60 – 0.53 (2H, dt, J 4.0, 8.5 Hz), -0.32 (2H, 
br.q, J 5.1 Hz); δC (101 MHz, CDCl3): 215.2, 175.0, 138.5, 138.3, 137.7, 137.3, 128.6, 128.5, 128.4, 
128.3, 128.2, 128.1, 128.0, 127.8, 127.75, 127.7, 127.6, 127.5, 105.9, 100.4, 85.5, 84.4, 83.7, 82.8, 
80.3, 78.9, 77.2, 73.4, 72.7, 72.6, 72.5, 72.4, 72.2, 72.1, 70.2, 67.2, 66.1, 63.7, 51.9, 51.6, 46.3, 41.1, 
35.4, 35.3, 33.0, 31.9, 30.3, 30.2, 29.8, 29.75, 29.7, 29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 
29.2, 28.7, 27.5, 27.4, 27.3, 25.7, 23.7, 22.7, 16.4, 15.8, 14.1, 10.9; νmax: 3501, 3063, 2920, 2852, 
1736, 1714, 1465, 1116, 757, 698 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(R)-2-((R)-1-hydroxy-12-((1S,2R)-
2-(14-((1S,2R)-2-icosylcyclopropyl)tetradecyl)cyclopropyl)dodecyl)hexacosanoate-β-
D-arabinofuranosyl-(1→2)-3-O-benzyl-5-O-(R)-2-((R)-1-hydroxy-12-((1S,2R)-2-(14-((1S,2R)-2-
icosylcyclopropyl)tetradecyl)cyclopropyl)dodecyl)hexacosanoate-α-D-arabinofuranoside 
(78g): 
 
Tetrabutylammonium fluoride (0.40 mL, 1.4 mmol, 1.0 M) and  α-D-arabinofuranoside (77g) 
(112 mg, 0.0340 mmol); to give (78g) as a colourless thick oil (66 mg, 64%) [NSI–Found 
(M+Na)+: 3067.7; C204H354NaO15, requires: 3067.7]; []
24
D -18.3 (c 0.24, CHCl3), which showed 
δH (400 MHz, CDCl3): 7.42 – 7.21 (25H, m), 5.02 (1H, br.d, J 4.3 Hz), 4.97 (1H, br.s), 4.71 (2H, 
d, J 11.4 Hz), 4.67 (2H, m), 4.62 (1H, d, J 11.4 Hz), 4.56 – 4.50 (4H, m), 4.45 (1H, d, J 11.6 Hz), 
4.32 (1H, br.d, J 1.6 Hz), 4.31 – 4.21 (5H, m), 4.16 – 4.09 (2H, including a broad pentet J 5.9 Hz 
at 4.13), 4.02 (1H, br.dd, J 4.6, 6.2 Hz), 3.97 (1H, br.d, J 2.8 Hz), 3.85 (1H, dd, J 5.3, 10.3 Hz), 
3.79 (1H, br.p, J 5.0 Hz), 3.66 – 3.54 (5H, including a broad double doublet J 4.5, 10.7 Hz at 3.6), 
2.46 – 2.35 (2H, m), 1.68 – 1.03 (270H, m), 0.89 (12H, t, J 6.7 Hz), 0.71 – 0.61 (8H, m), 0.57 (4H, 
dt, J 4.0, 8.4 Hz), -0.32 (4H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3): 175.1, 175.0, 138.5, 138.3, 
137.8, 137.3, 128.5, 128.4, 128.35, 128.3, 128.25, 128.2, 128.1, 127.8, 127.75, 127.7, 127.65, 
127.60, 127.5, 105.9, 100.4, 85.5, 84.4, 83.7, 82.8, 80.3, 78.9, 77.1, 73.4, 72.6, 72.5, 72.4, 72.3, 
72.2, 72.1, 70.2, 67.2, 66.1, 63.7, 51.9, 51.6, 41.3, 36.1, 35.4, 35.3, 33.7, 31.9, 30.3, 30.2, 29.8, 
29.75, 29.7, 29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 29.1, 28.9, 28.7, 27.7, 27.5, 27.4, 
25.7, 25.6, 22.7, 22.6, 22.3, 20.4, 19.4, 18.8, 15.8, 14.3, 14.1, 11.4, 11.0, 10.9; νmax: 3516, 3061, 
2920, 2851, 1734, 1728, 1465, 1116, 737, 696 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-hydroxy-17-((1S,2R)-
2-((22S)-22-methyl-21-oxotetracontan-2-yl)cyclopropyl)heptadecyl) hexacosano-ate-β-
D-arabinofuranosyl-(1→2)-3-O-benzyl-5-O-(2R)-2-((1R)-1-hydroxy-17-((1S,2R)-2-((22S)-22-
methyl-21-oxotetracontan-2-yl)cyclopropyl)heptadecyl)hexacosanoate-α-D-arabinofuranoside 
(78h): 
 
Tetrabutylammonium fluoride (0.35 mL, 1.2 mmol, 1.0 M) and α-D-arabinofuranoside (77h) 
(105 mg, 0.0295 mmol); to give (78h) as a colourless thick oil (30 mg, 31%) [NSI–Found 
(M+Na)+: 3352.0; C222H390NaO17, requires: 3352.0]; []
24
D +5.0 (c 0.32, CHCl3), which showed δH 
(400 MHz, CDCl3): 7.39 – 7.22 (25H, m), 5.01 (1H, br.d, J 4.2 Hz), 4.97 (1H, br.s), 4.71 (2H, d, J 
11.7 Hz), 4.68 – 4.65 (2H, m), 4.62 (1H, d, J 11.7 Hz), 4.56 – 4.49 (4H, m), 4.45 (1H, d, J 11.6 Hz), 
4.32 (1H, br.d, J 1.3 Hz), 4.29 – 4.22 (4H, m), 4.17 – 4.08 (3H, including a broad pentet J 5.5 Hz at 
4.13 m), 4.04 – 3.99 (1H, m), 3.97 (1H, br.d, J 2.3 Hz), 3.85 (1H, dd, J 5.3, 10.2 Hz), 3.79 (1H, 
br.p, J 5.3 Hz), 3.60 (5H, including a broad double doublet J 4.4, 10.6 Hz at 3.6), 2.57 – 2.47 (4H, 
m), 2.42 (4H, dt, J 1.0, 7.5 Hz), 1.66 – 1.09 (294H, m), 1.06 (6H, d, J 6.9 Hz), 0.88 – 0.85 (18H, 
including a triplet J 6.8 Hz at 0.87), 0.77 – 0.61 (2H, m), 0.52 – 0.40 (2H, m), 0.26 – 0.07 (6H, m); 
δC (101 MHz, CDCl3): 215.2, 175.1, 175.0, 138.5, 138.3, 137.8, 137.3, 128.5, 128.45, 128.4, 
128.35, 128.3, 128.2, 128.1, 127.9, 127.8, 127.75, 127.7, 127.6, 127.5, 105.9, 100.4, 85.5, 84.4, 
83.7, 82.8, 80.3, 78.9, 77.1, 73.4, 72.6, 72.5, 72.4, 72.3, 72.2, 72.1, 70.2, 67.2, 66.1, 63.8, 60.4, 51.9, 
51.6, 46.3, 41.3, 41.1, 38.1, 37.4, 36.1, 35.4, 35.3, 34.5, 33.7, 33.0, 31.9, 30.1, 29.9, 29.8, 29.75, 
29.7, 29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 29.1, 28.9, 27.7, 27.5, 27.4, 27.35, 27.3, 
26.1, 25.7, 25.6, 23.8, 22.7, 22.6, 22.3, 21.0, 20.4, 19.7, 19.4, 18.7, 18.6, 16.4, 14.3, 14.1, 11.4, 10.5; 
νmax: 3472, 3063, 2920, 2851, 1735, 1714, 1465, 1116, 757, 698 cm-1. 
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L-Glycerol-(1'→1)-5-O-mycolate-β-D-arabinofuranosyl-(1→2)-5-O-mycolate-α-D-arabinofuranoside 
(79f-h): 
 
General procedure: 
Palladium hydroxide on activated charcoal was added to a stirred solution of α-D-
arabinofuranoside (78f-h) in CH2Cl2:MeOH (1:1, 1 mL) at room temperature under hydrogen. 
The mixture was stirred for 36 h then TLC showed no starting material was left. The mixture 
was filtered off through celite and the solvent was evaporated under reduced pressure to give 
a residue which was purified by column chromatography on silica eluting with 
chloroform/methanol (10:1) affording the title compounds (79f-h). 
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L-Glycerol-(1'→1)-5-O--(R)-2-((R)-1-hydroxy-16-((1S,2R)-2-((S)-20-methyl-19-oxoocta-
triacontyl)cyclopropyl)hexadecyl)hexacosanoate-β-D-arabinofuranosyl -(1→2)-5-O-(R)-2-
((R)-1-hydroxy-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl)hexadecyl) 
hexacosanoate-α-D-arabinofuranoside (79f): 
 
(Pd(OH)2-C/20%, 26 mg, 0.75 fold by weight) and α-D-rabinofuranoside (78f) (35 mg, 0.010 
mmol); to give (79f) as a colourless thick oil (22 mg, 71%) [NSI–Found (M+Na)+: 2817.6; 
C181H348NaO17, requires: 2817.6]; []
22
D +7.4 (c 0.38, CHCl3), which showed δH (400 MHz, 
CDCl3+few drops CD3OD): 4.97 (1H, br.d, J 4.4 Hz), 4.96 (1H, br.s), 4.38 (1H, dd, J 4.7, 
11.6 Hz), 4.33 (1H, br.dd, J 6.9, 11.4 Hz), 4.20 (1H, dd, J 6.0, 11.5 Hz), 4.18 (1H, dd, J 5.4, 
11.5 Hz), 4.11 (1H, br.q, J 5.5 Hz), 4.08 – 3.92 (5H, m), 3.82 – 3.75 (1H, br.m), 3.69 (1H, 
br.dd, J 6.3, 10.5 Hz), 3.66 – 3.62 (3H, m), 3.57 (1H, br.dd, J 4.5, 11.4 Hz), 3.52 (1H, dd, J 
3.4, 10.4 Hz), 2.60 – 2.40 (4H, including sextet J 6.8 Hz at 2.48), 2.38 (4H, br.t, 7.3 Hz), 1.67 
– 1.05 (295H, m), 1.01 (6H, d, J 6.9 Hz), 0.84 (12H, t, J 6.8 Hz), 0.65 – 0.56 (4H, m), 0.52 
(2H, dt, J 4.1, 8.5 Hz), -0.37 (2H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3+few drops CD3OD): 
215.9, 175.1, 175.0, 105.8, 101.5, 87.6, 80.7, 79.5, 77.2, 76.4, 76.1, 72.7, 72.5, 70.3, 69.4, 
65.4, 63.2, 53.3, 52.6, 46.3, 41.1, 34.8, 34.7, 32.9, 31.8, 30.2, 30.1, 29.7, 29.6, 29.55, 29.5, 
29.45, 29.4, 29.35, 29.3, 29.25, 29.2, 29.1, 29.0, 28.6, 27.4, 27.3, 27.2, 25.3, 25.2, 23.6, 22.6, 
16.2, 15.7, 14.0, 10.8; νmax: 3420,  2919, 2851, 1733, 1714, 1467, 1120, 1046, 721 cm-1. 
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L-Glycerol-(1'→1)-5-O-(R)-2-((R)-1-hydroxy-12-((1S,2R)-2-(14-((1S,2R)-2-icosylcyclopropyl) 
tetradecyl)cyclopropyl)dodecyl)hexacosanoate-β-D-arabinofuranosyl-(1→2)-5-O-(R)-2-
((R)-1-hydroxy-12-((1S,2R)-2-(14-((1S,2R)-2-icosylcyclopropyl)tetradecyl)cyclopropyl) 
dodecyl)hexacosanoate-α-D-arabinofuranoside (79g): 
 
(Pd(OH)2-C/20%, 46 mg, 0.75 fold by weight) and α-D-arabinofuranoside (78g) (62 mg, 
0.020 mmol); to give (79g) as a colourless thick oil (36 mg, 70%) [NSI–Found (M+Na)+: 
2617.5; C169H324NaO15, requires: 2617.5]; []
24
D +2.7 (c 1.9, CHCl3), which showed δH (400 
MHz, CDCl3+few drops CD3OD): 4.99 (1H, br.d, J 6.2 Hz), 4.98 (1H, br.s), 4.42 (1H, dd, J 
4.5, 11.6 Hz), 4.37 (1H, br.dd, J 6.5, 11.1 Hz), 4.23 (1H, dd, J 5.2, 11.2 Hz), 4.20 (1H, br.dd, 
J 4.8, 10.3 Hz), 4.14 (1H, br.q, J 5.3 Hz), 4.10 – 3.97 (5H, m), 3.85 – 3.79 (1H, m), 3.72 (1H, 
br.dd, J 7.0, 11.2 Hz), 3.69 – 3.63 (2H, br.m), 3.62 (1H, br.d, J 3.6 Hz), 3.58 (1H, dd, J 4.2, 
9.7 Hz), 3.55 (1H, dd, J 3.2,  10.4 Hz), 2.47 – 2.39 (2H, m), 1.61 – 1.05 (275H, m), 0.86 
(12H, t, J 6.8 Hz), 0.69 – 0.58 (8H, m), 0.54 (4H, dt, J 4.1, 8.5 Hz), -0.35 (4H, br.q, J 5.0 
Hz); δC (101 MHz, CDCl3+few drops CD3OD): 175.1, 175.0, 105.8, 101.5, 87.6, 80.8, 79.5, 
77.5, 77.2, 76.5, 76.2, 72.8, 72.6, 70.3, 69.6, 65.4, 63.3, 63.2, 53.3, 52.6, 34.8, 34.7, 31.9, 
30.3, 30.2, 29.8, 29.7, 29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 29.2, 29.1, 28.7, 27.5, 27.4, 
25.4, 25.3, 22.6, 15.8, 15.7, 14.0, 10.9, 10.8; νmax: 3417,  2920, 2851, 1729, 1723, 1466, 
1215, 1116, 1045, 761, 669 cm-1. 
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L-Glycerol-(1'→1)-5-O-(2R)-2-((1R)-1-hydroxy-17-((1S,2R)-2-((22S)-22-methyl-21 
-oxotetracontan-2-yl)cyclopropyl)heptadecyl)hexacosanoate-β-D-arabinofuranosyl-(1→2)-5-
O-(2R)-2-((1R)-1-hydroxy-17-((1S,2R)-2-((22S)-22-methyl-21-oxotetracontan-2-yl)cyclopropyl) 
heptadecyl)hexacosanoate-α-D-arabinofuranoside (79h): 
 
(Pd(OH)2-C/20%, 25 mg, 0.75 fold by weight) and α-D-arabinofuranoside (78h) (25 mg, 
0.0075 mmol); to give (79h) as a colourless thick oil (16 mg, 72%) [NSI–Found (M+Na)+: 
2901.7; C187H360NaO17, requires: 2901.7]; []
22
D -7.1 (c 0.34, CHCl3), which showed δH (400 
MHz, CDCl3): 5.04 (1H, br.d, J 7.7 Hz), 5.03 (1H, br.s), 4.49 (1H, dd, J 5.6, 12.7 Hz), 4.46 
(1H, br.dd, J 3.8, 11.6 Hz), 4.29 (1H, dd, J 5.1, 11.6 Hz), 4.24 – 4.20 (1H, m), 4.18 (1H, br.q, 
J 6.1 Hz), 4.13 (1H, d, J 7.2 Hz), 4.11– 4.03 (4H, including a broad doublet J 6.8 Hz at 4.09), 
3.90 – 3.81 (1H, m), 3.79 – 3.60 (6H, m), 2.51 (4H, including a sextet J 6.9 Hz at 2.51), 2.42 
(2H, t, J 7.6 Hz), 2.41 (2H, t, J 7.1 Hz), 1.65 – 1.10 (299H, m), 1.05 (6H, d, J 6.9 Hz), 0.93 – 
0.84 (18H, including a broad triplet J 7.4 Hz at 0.89), 0.72 – 0.62 (2H, m), 0.50 – 0.40 (2H, 
m), 0.25 – -0.06 (6H, m); δC (101 MHz, CDCl3+few drops CD3OD): 215.3, 175.0, 174.8, 
105.8, 101.6, 88.2, 80.5, 79.6, 77.7, 77.2, 76.7, 76.6, 73.1, 72.7, 70.4, 70.0, 69.9, 65.2, 63.7, 
63.2, 60.4, 53.4, 52.5, 46.3, 41.1, 38.1, 37.4, 35.0, 34.8, 34.5, 33.0, 31.9, 30.1, 29.8, 29.7, 
29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 27.4, 27.3, 27.25, 26.1, 25.5, 25.4, 23.7, 22.7, 19.7, 
18.6, 16.4, 14.1, 10.5; νmax: 3421, 2920, 2852, 1735, 1715, 1466, 1119, 1045, 733 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-behenate-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-5-p-methoxybenzyl-α-D-arabinofuranoside (80a): 
 
A solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI)       
(13.6 mg, 0.070 mmol) in dry CH2Cl2 (1 mL) was added dropwise to a stirred solution of α-
D-arabinofuranoside (66) (13.2 mg, 0.0142 mmol), DMAP (8.6 mg, 0.070 mmol) and behenic 
acid (69c) (7.1 mg, 0.020 mmol) in dry CH2Cl2 (1 mL) at 0 ºC under nitrogen. The mixture 
was stirred for 48 h. When TLC showed no starting material was left. The precipitate was 
filtered off and washed with CH2Cl2 (10 mL), the solvent was evaporated and the residue was 
purified by column chromatography on silica eluting with hexane/ethyl acetate (5:1) to afford 
the title compound (80a) as a colourless thick oil (15 mg, 85%) [NSI–Found (M+NH4)+: 
1266.7800; C78H108O13N, requires: 1266.7815]; []
22
D -2.2 (c 0.92, CHCl3), which showed δH 
(400 MHz, CDCl3): 7.30 – 7.17 (25H, m), 7.15 (2H, d, J 8.6 Hz), 6.77 (2H, d, J 8.6 Hz), 5.00 
(1H, br.d, J 4.1 Hz), 4.95 (1H, br.s), 4.61 (1H, d, J 12.1 Hz), 4.60 (2H, br.s), 4.58 (1H, d, J 
12.1 Hz), 4.51 (1H, d, J 11.6 Hz), 4.46 – 4.41 (3H, m), 4.37 (3H, br.d, J 11.7 Hz), 4.36 (1H, 
d, J 11.7 Hz), 4.25 (1H, br.d, J 1.9 Hz), 4.17 – 4.10 (2H, m), 4.07 – 3.98 (3H, m), 3.95 (1H, 
br.q, J 6.6 Hz), 3.89 (1H, br.dd, J 2.4, 6.0 Hz), 3.80 (1H, dd, J 5.1, 10.4 Hz), 3.74 – 3.68 (4H, 
including a singlet at 3.72 for OCH3), 3.57 – 3.50 (3H, including a broad double doublet J 
5.0, 8.5 Hz at 3.53), 3.49 – 3.42 (2H, including a broad double doublet J 4.2, 11.1 Hz at 
3.47), 2.13 (2H, dt, J 3.6, 7.7 Hz), 1.53 – 1.02 (38H, m), 0.81 (3H, t, J 6.7 Hz); δC (101 MHz, 
CDCl3): 173.4, 159.2, 138.7, 138.3, 138.0, 137.8, 137.5, 130.2, 129.4, 128.5, 128.4, 128.3, 
128.2, 128.0, 127.9, 127.8, 127.7, 127.65, 127.6, 127.55, 127.5, 127.4, 113.7, 106.0, 100.5, 
85.9, 84.4, 83.8, 82.6, 81.5, 78.9, 77.0, 73.4, 72.9, 72.5, 72.4, 72.3, 72.2, 70.3, 69.6, 67.2, 
66.0, 55.2, 34.0, 31.9, 29.8, 29.7, 29.65, 29.6, 29.5, 29.4, 29.3, 29.1, 24.8, 22.7, 14.1; νmax: 
3062, 3031, 2924, 2859, 1741, 1612, 1513, 1454, 1248, 1110,738, 699 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-(1-((tert-butyldimethylsilyl) 
oxy)-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl) cyclopropyl) hexadecyl) 
hexacosanoate)-β-D-arabinofuranosyl-(1→2)-3-O-benzyl-5-p-methoxybenzyl-α-D-
arabinofuranoside (80b): 
 
A solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI)       
(17.7 mg, 0.0923 mmol) in dry CH2Cl2 (1 mL) was added dropwise to a stirred solution of α-D-
arabinofuranoside (66) (17.2 mg, 0.0185 mmol), DMAP (11.3 mg, 0.0924 mmol) and (2R)-2-(1-
((tert-butyldimethylsilyl)oxy)-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl) cyclopropyl) 
hexadecyl) hexacosanoic acid (76f) (37.5 mg, 0.0277 mmol) in dry CH2Cl2 (1 mL) at 0 ºC 
under nitrogen atmosphere. The reaction mixture was stirred for 48 h. When TLC showed no 
starting material was left. The reaction mixture was worked up and purified as above 
affording the title compound (80b) (36 mg, 86%) [NSI–Found (M+Na)+: 2282.8; 
C146H238NaO15Si, requires: 2282.8]; []
22
D +12 (c 0.22, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.34 – 7.24 (25H, m), 7.22 (2H, d, J 8.6 Hz), 6.84 (2H, d, J 8.6 Hz), 5.06 (1H, br.d, J 
4.2 Hz), 5.02 (1H, br.s), 4.69 (2H, d, J 11.7 Hz), 4.68 (2H, d, J 11.7 Hz), 4.61 (1H, d, J 11.6 
Hz), 4.54 – 4.49 (3H, m), 4.48 – 4.41 (4H, m), 4.32 (1H, br.d, J 2.0 Hz), 4.21 (3H, br.dd, J 
3.8, 8.4 Hz), 4.13 (1H, dd, J 6.1 Hz), 4.07 – 4.03 (1H, m), 4.01 (1H, dd, J 4.3, 6.6 Hz), 3.95 
(1H, dd, J 2.5, 6.0 Hz), 3.87 (2H, br.dd, J 5.3, 10.4 Hz), 3.82 – 3.75 (4H, including a singlet 
at 3.8 for OCH3), 3.61 (3H, br.dd, J 4.8, 9.4 Hz), 3.53 (2H, dd, J 6.8, 12.1 Hz), 2.52 (2H, 
including a sextet J 6.2 Hz at 2.52) 2.42 (2H, dt, J 1.0, 7.0 Hz), 1.45 – 1.11 (144H, m), 1.05 
(3H, d, J 6.9 Hz), 0.89 (6H, t, J 6.7 Hz), 0.84 (9H, br.s), 0.69 – 0.65 (2H, m), 0.57 (1H, dt, J 
4.0, 7.7 Hz), 0.02 (3H, s), -0.01 (3H, s), -0.33 (1H, q, J 5.2 Hz); δC (101 MHz, CDCl3): 215.2, 
174.1, 159.1, 138.7, 138.3, 138.0, 137.9, 137.6, 130.2, 129.4, 128.5, 128.4, 128.3, 128.25, 
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128.2, 127.9, 127.8, 127.75, 127.7, 127.6, 127.55, 127.5, 127.4, 113.7, 106.0, 100.4, 85.6, 
84.4, 83.7, 83.4, 81.6, 79.2, 77.1, 73.3, 73.1, 72.9, 72.5, 72.4, 72.3, 72.2, 70.4, 69.7, 67.2, 
66.3, 60.4, 55.2, 51.5, 46.3, 41.1, 33.7, 33.0, 31.9, 30.2, 29.8, 29.75, 29.70, 29.6, 29.55, 29.5, 
29.4, 29.35, 29.3, 28.7, 27.8, 27.3, 25.8, 24.0, 23.7, 22.7, 22.6, 22.3, 21.0, 18.0, 16.4, 15.8, 
14.2, 14.1, 14.0, 10.9, -4.4, -4.7; νmax: 3088, 3065, 2923, 2856, 1739, 1614, 1456, 1247, 1115, 
739, 698 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-behenate-β-D-arabinofuranosyl-(1→2)-
3-O-benzyl-α-D-arabinofuranoside (81a): 
 
Cerium ammonium nitrate (13 mg, 0.023 mmol) was added to a stirred solution of compound (80a) 
(15 mg, 0.012 mmol) in CH3CN:H2O:THF (9:1:0.2, 1 mL)at 0 ºC. The mixture was allowed to 
reach room temperature and stirred at ambient temperature for 16 h then TLC showed no starting 
material was left. The reaction mixture was diluted with chloroform (20 mL), washed with aq. 
NaHCO3 (10 mL), dried (MgSO4) and the solvent was evaporated under reduced pressure. The 
residue was purified by column chromatography on silica eluting with petrol/ethyl acetate (4:1) to 
give the title compound (81a) as a colourless thick oil (8.4 mg, 62%) [NSI–Found (M+Na)+: 
1151.7; C70H96NaO12, requires: 1151.7]; []
22
D -11 (c 0.27, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.39 – 7.25 (25H, m), 5.04 (1H, br.d, J 4.1 Hz), 4.98 (1H, br.s), 4.71 (1H, d, J 11.5 Hz), 
4.69 (3H, br.s), 4.62 (1H, d, J 11.5 Hz), 4.54 – 4.49 (5H, m), 4.33 (1H, br.d, J 1.3 Hz), 4.21 (2H, 
including a broad doublet J 6.0 Hz at 4.21), 4.18 – 4.12 (2H, including a broad double doublet J 4.3, 
7.2 Hz at 4.15), 4.11 (1H, br.dd, J 3.6, 7.9 Hz), 4.08 (1H, br.d, J 2.5 Hz), 4.05 (1H, dd, J 4.2, 6.6 
Hz), 3.86 (1H, dd, J 5.2, 10.3 Hz), 3.82 – 3.76 (2H, including a broad double doublet J 4.3, 9.7 Hz 
at 3.8), 3.66 – 3.58 (4H, including a broad double doublet J 4.7, 11.8 Hz at 3.6), 2.25 (2H, dt, J 0.9, 
7.3 Hz), 1.36 – 1.18 (39H, m), 0.90 (3H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 173.5, 138.3, 137.9, 
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137.7, 137.4, 136.9, 128.5, 128.4, 128.3, 128.25, 128.1, 128.0, 127.9, 127.75, 127.7, 127.6, 127.55, 
127.5, 106.0, 100.4, 85.1, 83.8, 83.5, 83.4, 82.5, 78.9, 73.3, 72.6, 72.4, 72.2, 70.1, 67.2, 66.0, 62.3, 
34.0, 31.9, 29.7, 29.65, 29.6, 29.5, 29.4, 29.3, 29.1, 24.8, 22.7, 14.1; νmax: 3414, 3062, 3032, 2915, 
2852, 1737, 1467, 735, 697 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(R)-2-((R)-1-hydroxy-16-((1S,2R)-
2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl)hexadecyl)hexacosanoate)-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-α-D-arabinofuranoside (81b): 
 
Cerium ammonium nitrate (31 mg, 0.057 mmol) was added to a stirred solution of compound 
(80b) (32 mg, 0.014 mmol) in CH3CN:H2O:THF (9:1:0.2, 1 mL) at 0 ºC. The mixture was 
allowed to reach room temperature and stirred at ambient temperature for 16 h then TLC 
showed no starting material was left. The mixture was worked up and purified as above giving 
the title compound (81b) as a colourless thick oil (25 mg, 83%) [NSI–Found (M+Na)+: 2048.7; 
C132H216NaO14, requires: 2048.7]; []
23
D -8.5 (c 0.21, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.38 – 7.23 (25H, m), 5.01 (1H, br.d, J 4.3 Hz), 4.97 (1H, br.s), 4.70 (1H, d, J 11.6 Hz) 
4.68 (1H, d, J 11.6 Hz), 4.67 (2H, br.s), 4.61 (1H, d, J 11.6 Hz), 4.56 – 4.46 (5H, m), 4.30 (2H, 
br.dd, J 8.1, 12.0 Hz), 4.22 (1H, dd, J 3.9, 11.4 Hz), 4.15 (1H, br.dd, J 3.3, 6.7 Hz), 4.10 (3H, 
br.dd, J 5.9, 12.1 Hz), 4.02 (1H, dd, J 4.4, 6.5 Hz), 3.85 (1H, dd, J 5.2, 10.3 Hz), 3.79 (1H, 
br.dd, J 5.1, 9.4 Hz), 3.77 (1H, br.dd, J 3.7, 6.1 Hz), 3.66 – 3.55 (5H, including a broad double 
doublet J 4.6, 12.1 Hz at 3.6), 2.51 (1H, sextet, J 6.7 Hz), 2.44 – 2.38 (3H, including a triplet J 
7.2 Hz at 2.42), 2.08 – 1.07 (146H, m), 1.05 (3H, d, J 6.9 Hz), 0.89 (6H, t, J 6.8 Hz), 0.69 – 
0.62 (2H, m), 0.57 (1H, dt J 4.1, 8.6 Hz), -0.33 (1H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3): 
215.3, 175.0, 138.6, 138.1, 138.0, 137.7, 137.4, 128.5, 128.4, 128.35, 128.3, 128.1, 128.0, 
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127.9, 127.8, 127.7, 127.6, 127.5, 106.1, 100.7, 85.7, 83.8, 83.5, 83.4, 82.5, 78.9, 73.4, 72.6, 
72.4, 72.3, 72.2, 70.2, 67.2, 66.0, 62.2, 51.8, 46.3, 41.1, 35.4, 33.0, 31.9, 30.2, 29.7, 29.6, 29.5, 
29.4, 28.7, 27.4, 27.3, 25.7, 23.7, 22.7, 16.4, 15.8, 14.1, 10.9; νmax: 3496, 3062, 2921, 2850, 
1738, 1465, 1116, 758, 699 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-behenate-β-D-arabinofuranosyl-
(1→2)-3-O-benzyl-5-O-behenate-α-D-arabinofuranoside (82a): 
 
A solution of (EDCI) (5.4 mg, 0.028 mmol) in dry CH2Cl2 (1 mL) was added dropwise to a 
stirred solution of α-D-arabinofuranoside (81a) (6.4 mg, 0.0056 mmol), DMAP (3.4 mg, 0.027 
mmol) and behenic acid (2.9 mg, 0.0085 mmol) in dry CH2Cl2 (1 mL) at 0 ºC under nitrogen. 
The mixture was stirred for 72 h. When TLC showed no starting material was left. The 
precipitate was filtered off and washed with CH2Cl2 (10 mL), the solvent was evaporated and 
the residue was purified by column chromatography on silica eluting with hexane/ethyl acetate 
(5:1) to afford the title compound (82a) as a colourless thick oil (4.2 mg, 50%) [NSI–Found 
(M+Na)+: 1474.0; C92H138NaO13, requires: 1474.0]; []
22
D -4.2 (c 1.1, CHCl3), which showed 
δH (400 MHz, CDCl3): 7.30 – 7.15 (25H, m), 4.97 (1H, br.d, J 4.2 Hz), 4.91 (1H, br.s), 4.62 
(1H, d, J 11.5 Hz), 4.61 (1H, d, J 11.5 Hz), 4.59 (2H, br.s), 4.52 (1H, d, J 11.6 Hz), 4.44 (3H, 
br.s), 4.41 (1H, d, J 11.6 Hz), 4.37 (1H, d, J 11.6 Hz), 4.27 (1H, br.d, J 2.0 Hz), 4.20 (1H, J 3.5 
Hz), 4.16 (1H, J 4.6 Hz), 4.13 (1H, br.dd, J 3.6, 5.8 Hz), 4.10 – 4.04 (2H, including a broad 
double doublet J 4.1, 8.2 Hz at 4.06), 4.03 (1H, dd, J 3.7, 9.7 Hz), 3.99 (1H, d, J 5.2 Hz), 3.95 
(1H, dd, J 4.3, 6.7 Hz), 3.86 (1H, dd, J 2.4, 5.9 Hz), 3.78 (1H, dd, J 5.2, 10.4 Hz), 3.70 (1H, 
br.p J 4.8 Hz), 3.57 – 3.48 (3H, including a broad double doublet J 4.7, 8.3 Hz at 3.52), 2.19 
(2H, t, J 7.6 Hz), 2.14 (2H, dt, J 2.7, 7.5 Hz), 1.53 – 1.03 (76H, m), 0.80 (6H, t, J 6.8 Hz); δC 
(101 MHz, CDCl3): 173.5, 173.4, 138.6, 138.3, 137.8, 137.7, 137.4, 128.5, 128.4, 128.35, 
128.3, 128.0, 127.8, 127.75, 127.7, 127.6, 127.55, 127.5, 106.1, 100.4, 85.6, 84.3, 83.8, 82.5, 
Chapter 4                                                                                                              Experimental  
178 
 
80.1, 78.9, 77.2, 73.4, 72.5, 72.4, 72.35, 72.3, 70.2, 67.3, 66.0, 63.7, 34.0, 31.9, 29.7, 29.65, 
29.6, 29.55, 29.5, 29.4, 29.3, 29.25, 29.2, 29.1, 24.9, 24.8, 22.7, 14.1; νmax: 3063, 3031, 2917, 
2850, 1740, 1732, 1467, 1110, 735, 697 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)- 5-O-(R)-2-((R)-1-hydroxy-16-((1S,2R)-2-((S)-20-methyl-
19-oxooctatriacontyl)cyclopropyl)hexadecyl) hexacosanoate)-β-D-arabinofuranosyl-(1→2)-
5-O-(2R)-2-(1-((tert-butyldimethylsilyl)oxy)-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl) 
cyclopropyl)hexadecyl)hexacosanoate)-α-D-arabinofuranoside (82b): 
 
A solution of (EDCI) (6.1 mg, 0.032 mmol) in dry CH2Cl2 (1 mL) was added dropwise to a 
stirred solution of α-D-arabinofuranoside (81b) (13.5 mg, 0.00630 mmol), DMAP (3.8 mg, 
0.032 mmol) and (R)-2-((R)-1-((tert-butyldimethylsilyl)oxy)-16-((1S,2R)-2-((S)-20-methyl-
19-oxooctatriacontyl) cyclopropyl) hexadecyl)hexacosanoic acid (12.8 mg, 0.00945 mmol) in 
dry CH2Cl2 (1 mL) at 0 ºC under nitrogen. The mixture was stirred for 72 h. then worked up 
and purified as above to afford the title compound (82b) (10 mg, 50%) [NSI–Found (M+Na)+: 
3381.9; C222H392NaO17Si, requires: 3381.9]; []
23
D -7 (c 0.1, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.40 – 7.21 (25H, m), 5.02 (1H, br.d, J 4.3 Hz), 4.97 (1H, br.s), 4.70 (2H, d, J 11.8 Hz), 
4.66 (2H, br.s), 4.61 (1H, d, J 11.8 Hz), 4.55 – 4.46 (4H, m), 4.42 (1H, d, J 11.7 Hz), 4.34 (1H, 
br.d, J 1.4 Hz), 4.26 – 4.21 (2H, including a broad double doublet J 5.4, 9.0 Hz at 4.24), 4.20 
(1H, br.d, J 5.6 Hz), 4.17 – 4.09 (4H, including a broad quartet J 7.1 Hz at 4.13), 4.10 – 4.05 
(1H, m), 4.00 (1H, br.dd, J 4.4, 6.8 Hz), 3.96 – 3.88 (2H, m), 3.84 (1H, dd, J 4.8, 10.3 Hz), 3.79 – 
3.75 (1H, m), 3.64 – 3.58 (3H, including a broad double doublet J 4.5, 10.2 Hz at 3.6), 2.55 – 
2.46 (4H, including a sextet J 6.7 Hz at 2.51), 2.41 (4H, dt, J 0.9, 7.1 Hz), 1.73 – 1.10 (289H, m), 
1.05 (6H, d, J 6.9 Hz), 0.89 (12H, t, J 6.8 Hz), 0.85 (9H, s), 0.70 – 0.61 (4H, m), 0.56 (2H, dt, J 
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4.2, 8.3 Hz), 0.04 (3H, s), 0.01 (3H, s), -0.33 (2H, br.q, 5.1 Hz); δC (101 MHz, CDCl3): 215.2, 
175.0, 174.4, 138.6, 138.5, 137.8, 137.75, 137.7, 137.4, 136.1, 128.5, 128.4, 128.35, 128.3, 128.2, 
128.1, 128.0, 127.8, 127.7, 127.65, 127.6, 127.5, 127.4, 125.0, 105.9, 100.2, 85.2, 84.5, 83.7, 
82.9, 80.1, 78.9, 73.4, 73.2, 72.5, 72.45, 72.4, 72.2, 72.1, 70.3, 67.2, 66.2, 64.3, 51.5, 46.3, 41.1, 
35.5, 33.7, 33.0, 32.2, 31.9, 30.2, 28.7, 27.7, 27.4, 27.3, 26.4, 25.8, 23.7, 23.4, 22.7, 16.4, 15.8, 
14.1, 10.9, -4.4, -4.8; νmax: 3415, 3067, 3032, 2957, 2920, 1740, 1731, 1463, 1217, 1171, 1048, 
881, 721 cm-1. 
 
p-Cresyl 2,3-di-O-benzoyl-5-O-tert-butyldiphenylsilyl-1-thio-α-D-arabinofuranoside (84):239 
 
Benzoyl chloride (21.8 g, 18.1 mL, 155 mmol) was added dropwise to a stirred solution of α-D-
arabinofuranoside (83) (22 g, 4.4 mmol) in anhydrous pyridine (50 mL) at 0 ºC under nitrogen. 
The mixture was allowed to reach room temperature and stirred for 6 h, when TLC showed 
no starting material was left. The solvent was evaporated under reduced pressure, to give the 
residue which was diluted with ethyl acetate (250 mL), and washed with water (2×50 mL), 1 
M aq. HCl (2×50 mL), sat. aq. NaHCO3 (1×50 mL) and brine (1×50 mL). The organic layer 
was dried (MgSO4), then the solvent was evaporated under reduced pressure. The residue was 
purified by column chromatography on silica eluting with hexane/ethyl acetate (5:1) to give the 
title compound (84) as a colourless thick oil (22 g, 85%) [MALDI–Found (M+Na)+: 702.1, 
C42H42NaO6SSi, requires: 702.1], [] 20D -16 (c 1.0, CHCl3), which showed δH (400 MHz, CDCl3): 
7.76 – 7.25 (24H, m), 5.74 (2H, br. d, J 5.4 Hz), 5.68 (1H, br. s), 4.64 (1H, br. q, J 4.5 Hz), 
4.06 (2H, br. d, J 4.4 Hz), 2.35 (3H, s), 1.08 (9H, s); δC (101 MHz, CDCl3): 165.4, 165.3, 
135.7, 135.65, 135.6, 135.5, 133.4, 133.1, 133.0, 132.8, 132.7, 132.4, 129.9, 129.8, 129.7, 
129.5, 128.4, 128.3, 128.2, 127.6, 91.3, 83.1, 82.3, 77.6, 63.5, 26.7, 21.1; νmax: 3069, 2929, 
2858, 1725, 1493, 1109, 708 cm-1. All data were identical to the authentic sample.  
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2-O-benzoyl-α-D-arabinofuranoside (85):  
 
Tetrabutylammonium fluoride (17.8 mL, 0.0616 mol, 1.0 M in THF) was added dropwise to a 
stirred solution of α-D-arabinofuranoside (52) (6.7 g, 0.0089 mol) in anhydrous THF (50 mL) 
at 0 ºC under nitrogen. The mixture was allowed to reach room temperature and stirred for 4 h, 
when TLC showed no starting material was left. The mixture was diluted with ethyl acetate 
(100 mL) and water (50 mL). The organic layer was separated and the aqueous layer was re-
extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with sat. 
aq. NH4Cl (50 mL), brine (50 mL), dried (MgSO4) and the solvent was concentrated. The 
residue was purified by column chromatography on silica eluting with petrol/ethyl acetate 
(1:1) to give the title compound (85) as a colourless thick oil (4.3 g, 95%) [MALDI–Found 
(M+Na)+: 531.2; C29H32NaO8, requires: 531.2]; []
23
D +53 (c 4.0, CHCl3), which showed      
δH (400 MHz, CDCl3): 7.98 – 7.93 (2H, m), 7.53 (1H, t, J 7.4 Hz), 7.39 (2H, t, J 7.7 Hz), 7.33 
– 7.17 (10H, m), 5.20 (1H, br.s), 5.04 (1H, br.s), 4.65 (1H, d, J 12.0 Hz), 4.61 (1H, d, J 12.0 
Hz), 4.51 (1H, d, J 12.2 Hz), 4.48 (1H, d, J 12.2 Hz), 4.10 (2H, br.s), 3.85 (1H, dd, J 5.6, 10.3 
Hz), 3.80 (1H, m), 3.76 (1H, br.p, J 5.2  Hz), 3.72 –  3.66 (1H, m), 3.63 (1H, dd, J 4.3, 10.3 
Hz), 3.60 – 3.52 (2H, including a broad doublet J 4.8 Hz at 3.58), 2.59 – 2.31 (2H, including 
2 x OH groups); δC (101 MHz, CDCl3): 166.6, 138.3, 138.0, 133.6, 129.8, 129.0, 128.5, 
128.4, 128.3, 127.8, 127.6, 105.3, 85.9, 84.2, 76.6, 76.4, 73.4, 72.2, 69.7, 67.1, 61.9; νmax: 
3405, 3065, 3031, 2945, 2868,1715, 1465, 1105, 884, 712 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzoyl-5-O-tert-butyldiphenylsilyl-α-
D-arabinofuranosyl-(1→3)-[2,3-di-O-benzoyl-5-O-tert-butyldiphenylsilyl-α-D-arabinofuranosyl-
(1→5)]-2-O-benzoyl-α-D-arabinofuranoside (86): 
 
Molecular sieves 4 Å (1.5 g) was added to a stirred solution of the donor p-cresyl 2,3-di-O-
benzoyl-5-O-tert-butyldiphenylsilyl-1-thio-α-D-arabinofuranoside (84) (16.7 g, 28.9 mmol) and the 
acceptor 2',3'-di-O-benzyl-L-glycerol-(1'→1)-2-O-benzoyl-α-D-arabinofuranoside (85) (4.2 g, 8.2 
mmol) in dry CH2Cl2 (50 mL) at room temperature under nitrogen. The mixture was stirred for 30 
min., then cooled to -36 ºC and N-iodosuccinimide (9.1 g, 0.037 mol) was added followed by the 
addition of silvertriflate (2.1 g, 8.2 mmol). The mixture was stirred at the same temperature until the 
colour turned red/dark brown. When TLC showed no starting material was left, the mixture was 
quenched by the addition of triethylamine (2 mL) until the colour turned yellow, then diluted with 
CH2Cl2 (100 mL) and filtered through celite. The filtrate was evaporated under reduced pressure, 
and the residue was purified by column chromatography on silica eluting with hexane/ethyl acetate 
(5:2) to give the title compound (86) as a colourless thick oil (13 g, 91%) [MALDI–Found 
(M+Na)+: 1682.6679, C99H104NO20Si2, requires: 1682.6685], []
17
D -1.4 (c 2.8, CHCl3); which showed 
δH (400 MHz, CDCl3): 8.01 – 7.92 (10H, m), 7.70 – 7.67 (4H, m), 7.65 – 7.61 (4H, m), 7.58 – 7.53 (2H, 
m), 7.50 – 7.44 (3H, m), 7.41 – 7.21 (32H, m), 5.66 – 5.62 (2H, including a broad doublet J 4.8 Hz at 
5.63), 5.61 (1H, br.s), 5.55 (1H, br.d, J 1.3 Hz), 5.51 (1H, br.d, J 0.9 Hz), 5.43 (1H, br.d, J 0.9 Hz), 5.31 
(1H, br.s), 5.22 (1H, br.s), 4.68 (2H, br.s), 4.53 (1H, d, J 12.0 Hz), 4.49 (1H, d, J 12.0 Hz), 4.47 (1H, 
br.s), 4.40 (1H, dd, J 5.2, 9.7 Hz), 4.38 – 4.32 (2H, including a broad double doublet J 5.8, 10.5 Hz at 
4.36), 4.04 (1H, dd, J 4.9, 11.4 Hz), 3.95 – 3.89 (5H, m), 3.85 (1H, dd, J 2.2, 11.6 Hz), 3.81 (1H, dd, J 
5.1, 10.1 Hz), 3.68 (1H, dd, J 4.7, 10.4 Hz), 3.65 – 3.59 (2H, including a broad triplet J 4.7 Hz at 3.63), 
1.00 (9H, s), 0.96 (9H, s); δC (101 MHz, CDCl3): 165.5, 165.4, 165.2, 165.1, 138.6, 138.3, 135.7, 135.6, 
135.5, 133.3, 133.2, 133.15, 133.1, 133.0, 130.0, 129.9, 129.8, 129.75, 129.7, 129.6, 129.35, 129.3, 
129.25, 129.2, 128.4, 128.35, 128.3, 128.25, 128.2, 127.8, 127.7, 127.6, 127.55, 127.5, 127.4, 126.3, 
106.1, 105.2, 83.7, 83.4, 82.3, 82.2, 82.1, 81.8, 80.5, 77.2, 76.6, 73.3, 72.2, 70.1, 67.2, 66.1, 63.3, 26.7, 
26.6, 19.3, 19.2; νmax: 3069, 3010, 2932, 2857, 1723, 1602, 1452, 1072, 706 cm
-1. 
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 2',3'-Di-O-benzyl-L-glycerol-(1'→1)-5-O-tert-butyldiphenylsilyl-α-D-arabinofuranosyl-
(1→3)-[5-O-tert-butyldiphenylsilyl-α-D-arabinofuranosyl-(1→5)]-α-D-rabinofuranoside (87):  
 
A solution of sodium methoxide (25 mL, 1M, in methanol) was added to a stirred solution of α-
D-arabinofuranoside (86) (9.1 g, 5.4 mmol) in dry CH2Cl2:MeOH (1:1, 50 mL) at room 
temperature until a PH of 11 was obtained. The mixture was stirred at room temperature for 90 
min. When TLC showed no starting material was left, the mixture was neutralized by the addition 
of acetic acid. The solvent was evaporated under reduced pressure to give an oily residue. The 
residue was purified by column chromatography on silica eluting with chloroform/methanol (1:1) 
to give the title compound (87) as a colourless thick oil (5.1 g, 83%) [MALDI–Found (M+Na)+: 
1167.4913, C64H80NaO15Si2, requires: 1167.4928], []
17
D +35 (c 6.7, CHCl3) which showed δH 
(400 MHz, CDCl3): 7.69 – 7.62 (7H, m), 7.51 – 7.18 (23H, m), 5.18 (1H, br.s), 5.12 (1H, br.s), 
4.93 (1H, br.s), 4.67 (1H, d, J 12.1 Hz), 4.63 (1H, d, J 12.1 Hz), 4.55 (1H, d, J 12.1 Hz), 4.51 
(1H, d, J 12.1 Hz), 4.18 (1H, br.d, J 3.4 Hz), 4.16 (1H, br.dd, J 3.7, 6.1 Hz), 4.12 (1H, br.d, J 3.8 
Hz), 4.07 (2H, br.s), 4.03 – 3.98 (2H, br.m), 3.98 – 3.93 (2H, including a broad doublet J 2.0 Hz 
at 3.96), 3.80 (1H, dd, J 3.3, 8.8 Hz), 3.78 – 3.68 (4H, m), 3.67 – 3.64 (1H, m), 3.63 – 3.59 (2H, 
including a broad double doublet J 3.0, 8.1 Hz at 3.60), 3.57 (1H, dd, J 5.2, 9.9 Hz), 3.02 – 2.55 
(5H, br.m), 1.05 (9H, s), 1.03 (9H, s); δC (101 MHz, CDCl3): 138.4, 138.2, 135.6, 135.5, 131.9, 
131.8, 131.7, 131.6, 130.2, 130.1, 130.0, 128.4, 128.35, 128.3, 128.0, 127.9, 127.8, 127.7, 127.6, 
127.55, 127.5, 108.6, 108.4, 108.3, 87.8, 87.4, 83.7, 82.3, 79.5, 78.8, 78.5, 77.8, 77.7, 76.7, 76.6, 
73.3, 71.9, 69.7, 67.0, 66.0, 64.0, 63.8, 26.7, 26.6, 19.0, 18.9; νmax: 3418, 3071, 2933, 2858, 1454, 
1053, 822 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-tert-butyldiphenylsilyl-α-D-
arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-tert-butyldiphenylsilyl-α-D-arabinofuranosyl-
(1→5)]-2-O-benzyl-α-D-arabinofuranoside (88): 
 
A solution of α-D-rabinofuranoside (87) (5.0 g, 4.0 mmol) in dry DMF was added dropwise to a 
stirred suspension of NaH (1.0 g, 43 mmol) (60% w/w, dispersion in mineral oil) at room 
temperature under nitrogen. The mixture was stirred for 10 min then benzyl bromide (5.2 g, 
3.6 mL, 30 mmol) in dry DMF (2 mL) was added. The mixture was stirred at room temperature 
for 6 h. When TLC showed no starting material was left. The reaction mixture was quenched by 
slow addition of methanol (2 mL), and water (10 mL). The organic layer was separated and the 
aqueous layer was re-extracted with ethyl acetate (2×50 mL). The combined organic layers were 
washed with water (25 mL) and brine (25 mL), dried (MgSO4) and the solvent was evaporated under 
reduced pressure. The residue was purified by column chromatography on silica eluting with 
petrol/ethyl acetate (5:1) to give the title compound (88) as a colourless thick oil (4.5 g, 65%) 
[MALDI–Found (M+Na)+: 1617.7, C99H110NaO15Si2, requires: 1617.7], [] 17D  +43 (c 1.9, CHCl3) 
which showed δH (400 MHz, CDCl3): 7.71 – 7.57 (8H, m), 7.48 – 7.13 (47H, m), 5.18 (2H, br.d, 
J 2.2 Hz), 5.07 (1H, br.s), 4.70 (1H, d, J 12.0 Hz), 4.66 (1H, d, J 12.0 Hz), 4.58 – 4.50 (7H, m), 
4.47 (2H, d, J 11.9 Hz), 4.46 (1H, d, J 11.9 Hz), 4.39 (1H, d, J 11.9 Hz), 4.38 (1H, d, J 11.9 Hz), 
4.30 (1H, br.dd, J 2.8, 6.8 Hz), 4.18 (2H, br.m), 4.13 – 4.07 (4H, m), 4.06 – 3.99 (2H, including a 
broad double doublet J 4.2, 10.6 Hz at 4.03), 3.95 (1H, dd, J 4.7, 11.9 Hz), 3.87 (1H, dd, J 5.0, 
10.5 Hz), 3.84 – 3.80 (2H, including a broad double doublet J 4.0, 11.0 Hz at 3.82), 3.79 – 3.74 
(4H, m), 3.68 – 3.58 (3H, m), 1.03 (18H, s); δC (101 MHz, CDCl3): 138.6, 138.3, 138.2, 138.0, 
137.9, 137.6, 137.5, 135.75, 135.67, 135.65, 135.6, 133.55, 133.5, 133.4, 133.3, 129.6, 129.55, 
129.5, 128.4, 128.35, 128.3, 128.25, 128.2, 127.9, 127.85, 127.8, 127.75, 127.7, 127.65, 127.6, 
127.55, 127.5, 127.45, 127.4, 106.6, 106.4, 105.4, 88.6, 88.5, 88.0, 83.0, 82.8, 82.3, 81.8, 81.3, 
80.3, 73.4, 72.2, 72.0, 71.9, 71.8, 71.7, 71.6, 70.4, 67.0, 66.0, 63.4, 63.2, 26.8, 26.7, 19.3, 19.2; 
νmax: 3067, 3031, 2929, 2857, 1495,1455, 1111, 698 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-α-D-arabinofuranosyl-(1→3)-[2,3-di-
O-benzyl-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl-α-D-arabinofuranoside (89): 
 
Tetrabutylammonium fluoride (14.3 mL, 0.0493 mol, in 1.0 M THF) was added dropwise to a 
stirred solution of α-D-arabinofuranoside (88) (3.8 g, 2.3 mmol) in anhydrous THF (25 mL) at 0 
ºC under nitrogen. The mixture was allowed to reach room temperature and stirred for 8 h 
then TLC showed no starting material was left, the mixture was diluted with ethyl acetate 
(100 mL) washed with sat. aq. NH4Cl (50 mL) and brine (50 mL). The organic layer was 
dried (MgSO4) and concentrated to give the residue which was purified by column 
chromatography on silica eluting with hexane/ethyl acetate (1:1) to give to the title compound 
(89) as a colourless thick oil (2.3 g, 87%) [MALDI–Found (M+Na)+: 1141.5, C67H74NaO15, 
requires: 1141.5], [] 17
D
+53 (c 4.7, CHCl3) which showed   δH (400 MHz, CDCl3): 7.34 – 7.16 
(35H, m), 5.10 (1H, br.s), 5.07 (1H, br.s), 5.04 (1H, br.d, J 0.7 Hz), 4.64 (2H, br.s), 4.55 – 
4.39 (11H, m), 4.31 (1H, d, J 11.7 Hz), 4.27 (1H, dd, J 3.8, 7.4 Hz), 4.23 – 4.17 (1H, m), 4.07 
(1H, br.d, J 2.2 Hz), 4.06 (1H, br.dd, J 4.0, 7.6 Hz), 4.02 (1H, br.dd, J 2.2, 5.9 Hz), 3.98 (1H, 
br.dd, J 1.3, 3.8 Hz), 3.96 (1H, br.dd, J 1.2, 3.6 Hz), 3.88 (1H, br.dd, J 4.1, 12.3 Hz), 3.85 
(1H, br.dd, J 3.2, 6.5 Hz), 3.82 (1H, d, J 5.2 Hz), 3.78 (1H, dd, J 3.7, 7.4 Hz), 3.76 – 3.72 
(2H, m), 3.71 – 3.64 (2H, including a broad double doublet J 12.3, 2.4 Hz at 3.68), 3.61 (1H, 
dd, J 4.8, 7.3 Hz), 3.59 – 3.55 (3H, including a broad doublet J 5.1 Hz at 3.58), 3.53 (1H, dd, 
J 5.9, 12.3 Hz); δC (101 MHz, CDCl3): 138.5, 138.2, 137.7, 137.6, 137.5, 137.4, 137.2, 128.5, 
128.45, 128.4, 128.35, 128.3, 128.0, 127.95, 127.9, 127.85, 127.8, 127.75, 127.7, 127.6, 
127.5, 106.1, 106.0, 105.9, 88.7, 88.3, 87.4, 83.0, 82.9, 82.4, 81.9, 80.8, 79.8, 73.4, 72.3, 
72.25, 72.2, 72.0, 71.9, 71.8, 70.2, 67.2, 64.8, 62.7; νmax: 3459, 3064, 3030, 2921, 2860, 
1605, 1496, 1115, 820 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-methanesulfonyl-α-D-arabinofuranosyl-
(1→3)-[2,3-di-O-benzyl-5-O-methanesulfonyl-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl-
α-D-arabinofuranoside (90): 
 
Methanesulfonyl chloride (0.57 g, 0.40 mL, 0.0050 mol) and DMAP (0.05g, 0.43 mmol) 
were added to a stirred solution of α-D-arabinofuranoside (89) (0.56 g, 0.50 mmol) in dry 
pyridine (5 mL) under nitrogen at room temperature. The mixture was stirred for 16 h then 
TLC showed no starting material was left. The mixture was quenched by the addition of water 
(1 mL), the organic layer was separated by decanting and diluted with CH2Cl2 (10 mL). The 
mixture was washed with 1N aq. HCl (2×10 mL), sat. aq. NaHCO3 (2×10 mL), dried (MgSO4), 
filtered and the solvent was evaporated under reduced pressure to give a thick oil residue which 
was purified by column chromatography on silica eluting with petrol/ethyl acetate (3:1) to 
afford the title compound (90) as a colourless thick oil (0.55 g, 87%) [MALDI–Found 
(M+Na)+: 1297.4;  C69H78NaO19S2, requires: 1297.4]; [] 17D +59 (c 0.60, CHCl3), which showed 
δH (400 MHz, CDCl3): 7.40 – 7.15 (35H, m), 5.16 (1H, br.s), 5.13 (1H, br.s), 5.07 (1H, br.s), 
4.68 (2H, br.s), 4.57 – 4.43 (11H, m), 4.40 (1H, d, J 11.3 Hz), 4.38 – 4.34 (1H, m), 4.33 (1H, 
br.dd, J 3.9, 7.3 Hz), 4.30 – 4.26 (2H, including a broad double doublet J 3.4, 7.3 Hz at 4.29), 
4.24 (1H, d, J 5.4 Hz), 4.22 – 4.12 (2H, m), 4.11 – 4.07 (2H, m), 4.02 – 3.97 (2H, m), 3.91 – 
3.84 (4H, m), 3.80 (1H, br.p, J 4.8 Hz), 3.73 (1H, br.dd, J 1.5, 11.5 Hz), 3.67 – 3.59 (3H, 
including a broad double doublet J 4.8, 8.7 Hz at 3.64), 2.94 (3H, s), 2.89 (3H, s); δC (101 
MHz, CDCl3): 138.5, 138.2, 137.4, 137.3, 137.2, 137.0, 128.6, 128.55, 128.5, 128.45, 128.4, 
128.3, 128.1, 128.05, 128.0, 127.95, 127.9, 127.7, 127.65, 127.6, 127.55, 106.5, 106.1, 105.8, 
88.3, 87.7, 87.5, 82.9, 82.8, 80.3, 80.2, 79.3, 79.2, 77.2, 73.4, 72.35, 72.3, 72.2, 72.1, 72.0, 
71.9, 70.2, 68.8, 68.5, 67.2, 65.2, 37.6, 37.5; νmax: 3088, 3065, 3031, 2933, 2871, 1586, 1454, 
1177, 745 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-behenate-α-D-arabinofuranosyl-
(1→3)-[2,3-di-O-benzyl-5-O-behenate-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl-α-D-
arabinofuranoside (91):  
 
Cesium hydrogencarbonate (0.076 g, 0.39 mmol) was added to a stirred solution of α-D-
arabinofuranoside (90) (0.05 g, 0.03 mmol) and behenic acid (0.03 g, 0.09 mmol) in dry DMF:THF 
(1:5, 1 mL) at room temperature under nitrogen. The mixture was stirred at 70 ºC for 3 days, then 
TLC showed no starting material was left. The suspension was diluted with ethyl acetate (25 mL) and 
water (5 mL). The organic layer was separated and the aqueous layer was re-extracted with ethyl 
acetate (2×10 mL). The combined organic layers were washed with water (5 mL) and brine (5 
mL), dried (MgSO4) and filtered. The filtrate was evaporated under reduced pressure to give a thick 
oil residue which was purified by column chromatography on silica eluting with petrol/ethyl acetate 
(3:1) to afford the title compound (91) as a colourless thick oil (55 mg, 80%) [MALDI–Found 
(M+Na)+: 1786.1, C111H158NaO17, requires: 1786.1], [] 22D +36 (c 1.0, CHCl3), which showed δH (400 
MHz, CDCl3): 7.31 – 7.11 (35H, m), 5.09 (1H, br.s), 5.06 (1H, br.s), 4.97 (1H, br.s), 4.59 (2H, br.s), 
4.51 – 4.35 (10H, m), 4.33 (1H, d, J 11.8 Hz), 4.26 (1H, d, J 11.8 Hz), 4.20 (1H, br.dd, J 3.3, 7.3 Hz), 
4.12 (6H, br.m), 4.04 (1H, br.dd, J 2.8, 6.9 Hz), 4.00 (1H, br.d, J 2.5 Hz), 3.95 – 3.89 (2H, m), 3.84 
(1H, dd, J 4.3, 11.8 Hz), 3.81 – 3.76 (2H, including a broad double doublet J 4.1, 8.5 Hz at 3.78), 3.75 
(1H, br.d, J 3.4 Hz), 3.74 – 3.68 (1H, p, J 5.0 Hz), 3.66 (1H, br.dd, J 2.1, 11.7 Hz), 3.58 – 3.49 (3H, 
including a broad quartet J 4.6 Hz at 3.53), 2.17 (4H, t, J 7.6 Hz), 1.56 – 1.00 (76H, m), 0.81 (6H, t, J 
6.8 Hz); δC (101 MHz, CDCl3): 173.6, 173.5, 138.6, 138.3, 137.7, 137.6, 137.5, 137.4, 137.3, 128.5, 
128.4, 128.35, 128.3, 128.0, 127.95, 127.9, 127.85, 127.8, 127.75, 127.7, 127.65, 127.6, 127.5, 106.5, 
106.2, 105.5, 88.3, 88.2, 88.1, 83.4, 83.3, 80.8, 80.3, 79.2, 78.9, 76.9, 73.4, 72.3, 72.2, 72.1, 72.0, 
71.9, 71.7, 70.3, 67.1, 65.6, 63.3, 63.2, 34.1, 34.0, 31.9, 29.7, 29.6, 29.5, 29.4, 29.35, 29.3, 29.2, 24.8, 
22.7, 14.1; ; νmax: 3064,  3031, 2923, 2853, 1740, 1718, 1455, 1066, 698  cm
-1. 
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L-glycerol-(1'→1)-5-O-behenate-α-D-arabinofuranosyl-(1→3)-5-O-behenate-α-D-
arabinofuranosyl-(1→5)-α-D-arabinofuranoside (92): 
 
Palladium hydroxide on activated charcoal (Pd(OH)2-C/20%, 60 mg, 1.1 fold by weight) was 
added to a stirred solution of α-D-arabinofuranoside (91) (55 mg, 31 mmol) in CH2Cl2:MeOH 
(2:1, 2 mL) at room temperature under hydrogen. The mixture was stirred for 36 h. When TLC 
showed no starting material was left, the mixture was filtered off through celite and the solvent 
was evaporated under reduced pressure to give a residue which was purified by column 
chromatography on silica eluting with chloroform/methanol (10:1) to give (92) as a colourless 
thick oil (29 mg, 82%) [MALDI–Found (M+Na)+: 1155.8; C62H1116NaO17, requires: 1155.8]; 
[] 18D -21 (c 1.1, CHCl3), which showed δH (400 MHz, CDCl3+few drops CD3OD): 5.01 (1H, 
br.s), 4.97 (1H, br.s), 4.90 (1H, br.s), 4.28 – 4.20 (2H, including abroad double doublet J 3.2, 
11.7 Hz at 4.24), 4.19 – 4.13 (3H, including abroad double doublet J 5.0, 11.8 Hz at 4.17), 4.12 
(1H, br.d, J 4.3 Hz), 4.11 – 4.08 (1H, m), 4.04 (1H, br.q, J 5.5 Hz), 4.01 – 3.95 (3H, br.m), 3.94 
(1H, dd, J 3.6, 11.5 Hz), 3.83 – 3.76 (3H, m), 3.73 (1H, br.dd, J 4.8, 10.1 Hz), 3.67 – 3.62 (1H, 
m), 3.62 – 3.57 (2H, including a broad doublet J 3.1 Hz at 3.60), 3.56 – 3.51 (1H, m), 2.30 (4H, 
t, J 7.6 Hz), 1.64 – 1.02 (83H, m), 0.83 (6 H, t, J 6.5 Hz); δC (101 MHz, CDCl3): 174.05, 174.0, 
108.0, 107.7, 83.3, 83.0, 82.4, 81.8, 81.3, 80.7, 79.0, 77.6, 75.8, 69.9, 69.1, 66.4, 63.9, 63.7, 
63.5, 34.0, 33.95, 31.8, 29.6, 29.5, 29.45, 29.4, 29.3, 29.25, 29.2, 29.1, 29.0, 24.8, 24.7, 22.6, 
13.9.; νmax: 3374,  2920, 2852, 1730, 1723, 1180, 757 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-(1-((tert-butyldimethyl-
silyl)oxy)-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl) hexadecyl) 
hexacosanoate-α-D-arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-(2R)-2-(1-((tert-butyl -
dimethylsilyl)oxy)-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl) cyclopropyl) 
hexadecyl)hexacosanoate-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl-α-D-arabinofuranoside 
(93): 
 
A solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (60 mg, 
0.31 mmol), in dry CH2Cl2 (1 mL) was added to a stirred solution of α-D-arabinofuranoside (89) 
(35 mg, 0.031 mmol),  molecular sieves 4 Å (50 mg), DMAP (38 mg, 0.31) (2R)-2-(1-((tert-
butyldimethylsilyl)oxy)-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl) hexadecyl) 
hexacosanoic acid (76f) (85 mg, 0.062 mmol) in dry CH2Cl2 (1 mL) at room temperature 
under nitrogen. The mixture was stirred for 4 days. When TLC showed no starting material 
was left. The precipitate was filtered off and washed with CH2Cl2 (10 mL), the solvent was 
evaporated and the residue was purified by column chromatography on silica eluting with 
hexane/ethylacetate (10:1) to afford the title compound (93) as a colourless thick oil (60 mg, 
51%) [MALDI–Found (M+Na)+: 3808.2; C247H426NaO21Si2, requires: 3808.2]; [] 20D +18                
(c 5.0, CHCl3), which showed δH (400 MHz, CDCl3): 7.69 – 6.95 (35H, m), 5.16 (1H, br.s), 
5.13 (1H, br.s), 5.04 (1H, br.s), 4.68 (1H, d, J 12.1 Hz), 4.65 (1H, d, J 12.1 Hz), 4.58 – 4.45 
(9H, m), 4.45 (1H, d, J 11.9 Hz), 4.38 (1H, d, J 11.9 Hz), 4.33 (1H, d, J 11.8 Hz), 4.29 – 4.22 
(5H, including a broad double doublet J 4.0, 9.1 Hz at 4.25), 4.21 – 4.16 (2H, m), 4.13 (1H, 
br.dd, J 5.7, 8.2 Hz), 4.06 (1H, br.d, J 2.7 Hz), 4.01 – 3.96 (2H, m), 3.94 – 3.87 (5H, m), 3.85 
(1H, br.dd, J 4.8, 10.7 Hz), 3.78 (1H, br.p, J 5.1 Hz), 3.76 – 3.71 (1H, m), 3.65 – 3.56 (3H, 
including a broad double doublet J 4.8, 8.2 Hz at 3.60), 2.53 (4H, including sextet, J 5.4 Hz), 
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2.42 (4H, t, J 7.6 Hz), 1.68 – 1.11 (288H, m), 1.06 (6H, d, J 6.9 Hz), 0.89 (12H, t, J 6.8 Hz), 
0.85 (9H, s), 0.84 (9H, s), 0.71 – 0.61 (4H, m), 0.57 (2H, dt, J 4.0, 8.5 Hz), 0.03 (6H, s), 0.01 
(6H, s), -0.32 (2H, br.q, J 5.1 Hz); δC (101 MHz, CDCl3): 215.2, 174.3, 174.2, 138.5, 138.2, 
137.8, 137.7, 137.6, 137.4, 137.3, 128.5, 128.45, 128.4, 128.35, 128.3, 128.2, 127.9, 127.85, 
127.8, 127.75, 127.7, 127.65, 127.6, 127.55, 127.5, 106.6, 106.3, 105.2, 88.3, 88.2, 87.8, 
83.7, 83.6, 81.2, 80.2, 79.4, 78.9, 77.2, 73.4, 73.1, 72.3, 72.2, 72.0, 71.9, 71.6, 70.3, 67.0, 
65.9, 63.0, 62.7, 51.6, 46.3, 41.1, 33.6, 33.5, 33.0, 31.9, 30.3, 30.2, 29.9, 29.8, 29.75, 29.7, 
29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 28.7, 27.9, 27.8, 27.3, 27.2, 27.1, 25.8, 24.0, 23.7, 
22.7, 22.6, 18.0, 16.4, 15.8, 14.1, 10.9, -4.4, -4.5, -4.7, -4.8; νmax: 3063,3031, 2920, 2851, 
1741, 1714, 1467, 1106, 836, 699 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-(1-hydroxy-16-((1S, 2R)-
2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl)hexadecyl)hexacosanoate-α-D-
arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-((2R)-2-(1-hydroxy-16-((1S,2R)-2-((S)-20-
methyl-19-oxooctatriacontyl) cyclopropyl) hexadecyl) hexacosanoate-α-D-arabinofuranosyl-
(1→5)]-2-O-benzyl-α-D-arabinofuranoside (94): 
 
The protected glycolipid α-D-arabinofuranoside (93) (53 mg, 0.014 mmol) was dissolved in 
dry THF (10 mL) in a dry polyethylene vial equipped with an acid proof rubber septum, 
followed by addition of pyridine (0.1 mL) at room temperature under nitrogen. The mixture 
was cooled to 0 oC, and then hydrogen fluoride-pyridine complex as (70% w, 1.5 mL) was 
added dropwise. The mixture was stirred at 43 oC for 24 h. When TLC showed no starting 
material was left, the mixture was neutralized by pouring it slowly into saturated aqueous 
solution of NaHCO3 and stirred until no more CO2 was liberated. The organic layer was 
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separated and the aqueous layer was re-extracted with chloroform (3×10 mL). The combined 
organic layers were dried (MgSO4) and the solvent was evaporated to give the residue which 
was purified by column chromatography on silica eluting with hexane/ethyl acetate (10:1) 
affording compound (94) as a colourless thick oil (38 mg, 76%) [MALDI–Found (M+Na)+: 
3579.9; C235H398NaO21, requires: 3579.9]; []
21
D +19  (c 1.2, CHCl3), which showed δH (400 
MHz, CDCl3): 7.36 – 7.15 (35H, m), 5.16 (1H, br.s), 5.13 (1H, br.s), 5.05 (1H, br.s), 4.67 
(2H, br.s), 4.55 (1H, d, J 11.8 Hz), 4.53 – 4.47 (7H, m), 4.45 (3H, d, J 11.8 Hz), 4.40 (1H, d, 
J 11.8 Hz), 4.36 – 4.22 (7H, m), 4.17 (1H, br.dd, J 3.7, 6.9 Hz), 4.11 (1H, br.dd, J 3.3, 6.3 
Hz), 4.07 (1H, br.d, J 2.1 Hz), 4.00 – 3.96 (2H, m), 3.94 – 3.88 (2H, m), 3.88 – 3.82 (2H, 
including a broad double doublet J 4.5, 9.8Hz at 3.86), 3.81 – 3.75 (2H, m), 3.73 (1H, br.d, J 
11.7 Hz), 3.67 – 3.51 (5H, including a broad doublet J 5.3 Hz at 3.61), 2.51 (2H, sextet, J 6.7 
Hz), 2.42 (6H, including a triplet J 7.2 Hz), 2.05 – 1.10 (288H, m), 1.06 (6H, d, J 6.9 Hz), 
0.89 (12H, t, J 6.7 Hz), 0.69 – 0.61 (4H, m), 0.57 (2H, dt, J 4.1, 8.5 Hz), -0.33 (2H, br.q, J 
5.0 Hz); δC (101 MHz, CDCl3): 215.2, 175.1, 175.0, 138.6, 138.2, 137.6, 137.5, 137.45, 
137.4, 137.2, 128.5, 128.4, 128.35, 128.3, 128.2, 128.1, 128.0, 127.95, 127.9, 127.85, 127.8, 
127.75, 127.7, 127.6, 127.5, 106.3, 106.2, 105.5, 88.2, 88.0, 87.9, 83.6, 80.7, 80.3, 79.3, 79.2, 
77.2, 73.4, 72.4, 72.2, 72.1, 72.0, 71.7, 70.2, 68.0, 67.1, 65.4, 63.0, 62.9, 51.9, 51.7, 46.3, 
41.1, 35.3, 35.2, 33.0, 31.9, 30.3, 30.2, 29.8, 29.7, 29.65, 29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 
29.2, 28.7, 27.5, 27.4, 27.3, 25.7, 25.6, 23.7, 22.7, 16.4, 15.8, 14.1, 10.9; νmax: 3511, 
3063,3030, 2918, 2851, 1737, 1714, 1467, 1105, 754, 698 cm-1. 
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L-glycerol-(1'→1)-5-O-(2R)-2-(1-hydroxy-16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl) 
cyclopropyl)hexadecyl)hexacosanoate-α-D-arabinofuranosyl-(1→3)-[5-O-((2R)-2-(1-hydroxy-
16-((1S,2R)-2-((S)-20-methyl-19-oxooctatriacontyl)cyclopropyl) hexadecyl) hexacosanoate-α-
D-arabinofuranosyl-(1→5)]-α-D-arabinofuranoside (95): 
 
Palladium hydroxide on activated charcoal (Pd(OH)2-C/20%, 40 mg, 1.1 fold by weight) was 
added to a stirred solution of α-D-arabinofuranoside (94) (36 mg, 0.010 mmol) in CH2Cl2:MeOH 
(2:1, 2 mL) at room temperature under hydrogen. The mixture was stirred for 36 h. When TLC 
showed no starting material was left, the mixture was filtered off through celite and the solvent was 
evaporated under reduced pressure to give a residue which was purified by column chromatography 
on silica eluting with chloroform/methanol (10:1) affording compound (95) as a colourless thick oil 
(25 mg, 86%) [MALDI–Found (M+Na)+: 2949.7; C186H356NaO21, requires: 2949.7]; []
18
D +19 (c 
2.2, CHCl3), which showed δH (400 MHz, CDCl3+few drops CD3OD): 5.00 (1H, br.s), 4.96 (1H, 
br.s), 4.90 (1H, br.s), 4.41 (1H, dd, J 4.2, 11.6 Hz), 4.36 (1H, dd, J 5.1, 11.9 Hz), 4.26 (1H, dd, J 
11.9, 5.4 Hz), 4.21 (1H, d, J 4.0 Hz), 4.17 (1H, dd, J 3.8, 10.3 Hz), 4.12 (1H, br.d, J 4.8 Hz), 4.08 
(1H, br.q, J 6.6 Hz), 4.04 (1H, d, J 5.1 Hz), 4.01 – 3.96 (3H, m), 3.92 (1H, dd, J 3.8, 8.0 Hz), 3.90 – 
3.86 (2H, m), 3.77 (1H, dd, J 2.7, 8.4 Hz), 3.72 (1H, d, J 5.1 Hz), 3.62 (5H, br.m), 3.54 (1H, dd, J 
2.6, 10.5 Hz), 2.52 – 2.44 (2H, m), 2.38 (6H, including a triplet, J 7.5 Hz), 1.65 – 1.05 (207 H, m), 
1.01 (6H, d, J 6.9 Hz), 0.84 (12H, t, J 6.8 Hz), 0.66 – 0.57 (4H, m), 0.52 (2H, dt, J 4.2, 8.2 Hz), -
0.37 (2H, br.q, J 4.7 Hz); δC (101 MHz, CDCl3): 216.2, 175.05, 174.9, 109.2, 108.7, 81.95, 81.2, 
79.4, 78.0, 77.6, 77.2, 76.5, 72.5, 71.9, 65.0, 63.5, 63.4, 61.5, 52.6, 35.0, 32.8, 31.8, 30.1, 29.6, 
29.55, 29.5, 29.4, 29.3, 29.25, 29.2, 28.9, 28.6, 27.3, 27.2, 26.1, 25.3, 23.5, 22.6, 16.1, 15.7, 14.0, 
10.8.; νmax: 3511, 3063,3030, 2918, 2851, 1737, 1714, 1467, 1105, 754, 698 cm-1. 
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-((tert-butyl dimethyl 
silyl)oxy)-12-((2R)-2-(14-((2R)-2-icosylcyclopropyl)tetradecyl) cyclopropyl) dodecyl) 
hexacosanoate-α-D-arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-((tert-
butyldimethylsilyl)oxy)-12-((2R)-2-(14-((2R)-2-icosylcyclopropyl)tetradecyl) cyclopropyl) 
dodecyl) hexacosanoate-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl-α-D-arabinofuranoside 
(96): 
 
A solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (48 mg, 0.25 
mmol) in dry CH2Cl2 (1 mL) was added to a stirred solution of α-D-arabinofuranoside (89) (28 
mg, 0.025 mmol), molecular sieves 4 Å (50 mg), DMAP (30 mg, 0.24 mmol) and (2R)-2-
((1R)-1-((tert-butyldimethylsilyl)oxy)-12-((2R)-2-(14-((2R)-2-icosylcyclopropyl) tetradecyl) 
cyclopropyl) dodecyl)hexacosanoic acid (76g) (62 mg,  0.049 mmol) in dry CH2Cl2 (1 mL) at 
room temperature under nitrogen. The mixture was stirred for 4 days. When TLC showed no 
starting material was left. The precipitate was filtered off and washed with CH2Cl2 (10 mL), 
the solvent was evaporated and the residue was purified by column chromatography on silica 
eluting with hexane/ethylacetate (10:1) to afford the title compound (96) as a colourless thick 
oil (75 mg, 84%) [MALDI–Found (M+Na)+: 3607.9; C235H402NaO19Si2, requires: 3607.9]; 
[] 22
D
+20 (c 0.90, CHCl3), which showed δH (400 MHz, CDCl3): 7.94 – 6.85 (35H, m), 5.16 
(1H, br.s), 5.13 (1H, br.s), 5.04 (1H, br.s), 4.68 (1H, d, J 12.1 Hz), 4.65 (1H, d, J 12.1 Hz), 
4.57 – 4.45 (9H, m), 4.45 (1H, d, J 11.8 Hz), 4.38 (1H, d, J 11.8 Hz), 4.32 (1H, d, J 11.8 Hz), 
4.28 – 4.20 (5H, m), 4.18 (1H, br.dd, J 3.6, 7.4 Hz), 4.15 – 4.09 (1H, m), 4.06 (1H, br.d, J 2.9 
Hz), 4.01 – 3.96 (2H, m), 3.90 (3H, br.m), 3.87 – 3.81 (2H, including a broad double doublet 
J 4.8, 10.7 Hz at 3.85), 3.78 (1H, br.p, J 5.1 Hz), 3.76 – 3.71 (1H, m), 3.64 – 3.49 (3H, 
including a broad double doublet J 4.8, 8.3 Hz at 3.60), 2.60 – 2.47 (2H, m), 1.67 – 1.06 
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(270H, m), 0.89 (12H, t, J 6.8 Hz), 0.85 (9H, s), 0.84 (9H, s), 0.74 – 0.62 (8H, m), 0.57 (4H, 
td, J 4.1 Hz), 0.02 (6H, s), 0.00 (6H, s), -0.33 (4H, br.q, J 4.9 Hz); δC (101 MHz, CDCl3): 
174.3, 174.2, 138.5, 138.3, 137.8, 137.7, 137.6, 137.4, 137.3, 128.5, 128.45, 128.4, 128.35, 
128.3, 127.9, 127.85, 127.8, 127.75, 127.7, 127.65, 127.6, 127.55, 127.5, 106.6, 106.3, 105.2, 
88.3, 88.2, 87.8, 83.7, 83.6, 81.2, 80.2, 79.4, 78.9, 77.2, 73.4, 73.1, 72.3, 72.2, 71.9, 71.6, 
70.3, 67.0, 65.9, 63.0, 62.7, 51.6, 33.6, 33.5, 31.9, 30.3, 30.2, 29.9, 29.8, 29.7, 29.6, 29.5, 
29.4, 28.7, 27.9, 27.8, 27.2, 27.1, 25.9, 25.8, 24.0, 22.7, 18.0, 15.8, 14.1, 11.0, 10.9, -4.4, -4.5, 
-4.7, -4.8; νmax: 3063, 2925, 2854, 1737, 1456, 1101, 770 cm-1. 
 
 2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-hydroxy-12-((2 R)-
2-(14-((2R)-2-icosylcyclopropyl)tetradecyl)cyclopropyl)dodecyl)hexacosanoate-α-
D-arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-hydroxy-12-((2R)-2-
(14-((2R)-2-icosylcyclopropyl)tetradecyl) cyclopropyl) dodecyl)hexacosanoate-α-D-
arabinofuranosyl-(1→5)]-2-O-benzyl-α-D-arabinofuranoside (97): 
 
The protected glycolipid α-D-arabinofuranoside (96) (70 mg, 0.019 mmol) was dissolved in dry 
THF (10 mL) in a dry polyethylene vial equipped with an acid proof rubber septum, followed 
by addition of pyridine (0.1 mL) at room temperature under nitrogen. The mixture was cooled 
to 0 oC, and then hydrogen fluoride-pyridine complex as (70% w, 1.5 mL) was added 
dropwise. The mixture was stirred at 43 oC for 24 h. When TLC showed no starting material 
was left, the mixture was neutralized by pouring it slowly into sat. aq. NaHCO3 and stirred 
until no more CO2 was liberated. The organic layer was separated and the aqueous layer was 
re-extracted with chloroform (3×10 mL). The combined organic layers were dried (MgSO4) 
and the solvent was evaporated to give the residue which was purified by column 
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chromatography on silica eluting with hexane/ethyl acetate (10:1) affording compound (97) as 
a colourless thick oil (33 mg, 51%) [MALDI–Found (M+Na)+: 3379.8; C223H374NaO19, 
requires: 3379.8]; [] 21D +22 (c 0.90, CHCl3), which showed δH (400 MHz, CDCl3): 7.37 – 7.17 
(35H, m), 5.16 (1H, br.s), 5.13 (1H, br.s), 5.05 (1H, br.s), 4.67 (2H, br.s), 4.55 (1H, d, J 11.9 
Hz), 4.53 – 4.47 (8H, m), 4.46 (2H, d, J 11.8 Hz), 4.41 (1H, d, J 11.9 Hz), 4.35 – 4.23 (6H, 
m), 4.17 (1H, br.dd, J 3.7, 6.9 Hz), 4.15 – 4.08 (3H, including a broad triplet J 7.0 Hz at 4.12), 
4.07 (1H, br.d, J 2.1 Hz), 4.00 – 3.95 (2H, m), 3.94 – 3.87 (2H, m), 3.95 – 3.87 (2H, including 
a broad double doublet J 4.6, 10.3 Hz at 3.86), 3.79 (1H, p, J 4.8 Hz), 3.75 – 3.69 (1H, m), 
3.67 – 3.55 (5H, including a broad doublet J 5.3 Hz at 3.61), 2.44 – 2.37 (2H, m), 1.67 – 1.03 
(271H, m), 0.89 (12H, t, J 7.1 Hz), 0.69 – 0.61 (8H, m), 0.57 (4H, dt, J 4.2, 8.5 Hz), -0.32 
(4H, br.q, J 4.9 Hz); δC (101 MHz, CDCl3): 175.1, 175.0, 138.5, 138.2, 137.6, 137.5, 137.4, 
137.4, 137.2, 128.5, 128.4, 128.35, 128.3, 128.0, 127.95, 127.9, 127.85, 127.8, 127.75, 127.7, 
127.6, 127.5, 106.3, 106.2, 105.5, 88.2, 88.0, 87.9, 83.6, 80.7, 80.3, 79.3, 79.2, 77.2, 73.4, 
72.4, 72.2, 72.0, 71.9, 71.7, 70.3, 67.1, 65.4, 63.1, 63.0, 62.0, 51.9, 51.8, 35.3, 35.2, 34.2, 
31.9, 30.3, 30.2, 29.8, 29.75, 29.7, 29.65, 29.6, 29.5, 29.4, 28.7, 27.5, 27.4, 25.8, 25.7, 24.9, 
22.7, 22.6, 20.4, 15.8, 14.1, 10.9; νmax: 3511, 3062, 2921, 2854, 1733,1725, 1456, 1115, 754 
cm-1. 
 
L-glycerol-(1'→1)-5-O-(2R)-2-((1R)-1-hydroxy-12-((2R)-2-(14-((2R)-2-icosylcyclopropyl) 
tetradecyl) cyclopropyl)dodecyl)hexacosanoate-α-D-arabinofuranosyl-(1→3)-[5-O-(2R)-2-
((1R)-1-hydroxy-12-((2R)-2-(14-((2R)-2-icosylcyclopropyl)tetradecyl) cyclopropyl) dodecyl) 
hexacosanoate-α-D-arabinofuranosyl-(1→5)]-α-D-arabinofuranoside (98): 
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Palladium hydroxide on activated charcoal (Pd(OH)2-C/20%, 33 mg, 1.1 fold by weight) was 
added to a stirred solution of α-D-arabinofuranoside (97) (30 mg, 0.0089 mmol) in 
CH2Cl2:MeOH (2:1, 2 mL) at room temperature under hydrogen. The mixture was stirred for 
36 h. When TLC showed no starting material was left, the mixture was filtered off through 
celite and the solvent was evaporated under reduced pressure to give a residue which was 
purified by column chromatography on silica eluting with chloroform/methanol (10:1) 
affording compound (98) as a colourless thick oil (22 mg, 88%) [MALDI–Found (M+Na)+: 
2749.5; C174H332NaO19, requires: 2749.5]; []
18
D +18 (c 2.2, CHCl3), which showed δH (400 
MHz, CDCl3+few drops CD3OD): 5.00 (1H, br.s), 4.96 (1H, br.s), 4.90 (1H, br.s), 4.41 (1H, 
dd, J 4.6, 11.7 Hz), 4.37 (1H, br.dd, J 5.1, 11.9 Hz), 4.26 (1H, dd, J 5.0, 11.7 Hz), 4.20 (1H, 
dd, J 4.7, 11.8 Hz), 4.16 (1H, br.q, J 4.8 Hz), 4.12 (1H, br.d, J 6.2 Hz), 4.10 – 4.06 (2H, 
including a broad triplet J 7.4 Hz at 4.08), 4.05 (1H, br.d, J 5.6 Hz), 4.02 – 3.96 (3H, 
including a broad doublet J 8.5 Hz at 3.99), 3.95 – 3.86 (3H, m), 3.77 (1H, dd, J 4.2, 7.4 Hz), 
3.72 (1H, d, J 5.4 Hz), 3.67 – 3.57 (4H, including a broad doublet J 10.5 Hz at 3.63), 3.54 
(1H, dd, J 2.6, 9.7 Hz), 2.42 – 2.35 (2H, m), 1.64 – 1.04 (277H, m), 0.84 (12H, t, J 6.7 Hz), 
0.64 – 0.56 (8H, m), 0.52 (4H, dt, J 4.1, 8.4 Hz), -0.37 (4H, br.q, J 4.9 Hz); δC (101 MHz, 
CDCl3+few drops CD3OD): 175.0, 174.9, 108.7, 108.0, 81.7, 81.3, 79.7, 79.4, 77.9, 77.5, 
77.2, 76.3, 72.4, 71.9, 69.7, 69.15, 68.9, 67.6, 65.1, 63.4, 62.2, 61.4, 57.8, 52.6, 34.9, 31.8, 
30.1, 29.55, 29.5, 29.45, 29.4, 29.3, 29.2, 29.15, 29.1, 28.6, 27.3, 25.3, 22.5, 20.5, 15.6, 13.9, 
10.7.; νmax: 3399, 2920, 2851, 1734, 1467, 1043 cm-1.  
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2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-((tert-butyl dimethyl 
silyl)oxy)-17-((1S,2R)-2-((22S)-22-methyl-21-oxotetracontan-2-yl) cyclopropyl) heptadecyl) 
hexacosanoate-α-D-arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-((tert-
butyldimethylsilyl)oxy)-17-((1S,2R)-2-((22S)-22-methyl-21-oxotetracontan-2-yl) cyclopropyl) 
heptadecyl)hexacosanoate-α-D-arabinofuranosyl-(1→5)]-2-O-benzyl-α-D-arabinofuranoside 
(99): 
 
A solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) (35 mg, 
0.18 mmol)  in dry CH2Cl2 (1 mL) was added to a stirred solution of α-D-arabinofuranoside (89) (22 
mg, 0.019 mmol), molecular sieves 4 Å (25 mg), DMAP (23 mg, 0.18 mmol) and (2R)-2-((1R)-1-
((tert-butyldimethylsilyl)oxy)-17-((1S,2R)-2-((22S)-22-methyl-21-oxotetracontan-2yl) cyclopropyl) 
heptadecyl) hexacosanoic acid (76h) (50 mg, 0.035 mmol) in dry CH2Cl2 (1 mL) at room 
temperature under nitrogen atmosphere. The reaction mixture was stirred for 4 days. When 
TLC showed no starting material was left. The precipitate was filtered off and washed with 
CH2Cl2 (10 mL), the solvent was evaporated and the residue was purified by column 
chromatography on silica eluting with hexane/ethylacetate (10:1) to afford the title compound 
(99) as a colourless thick oil (35 mg, 46%) [MALDI–Found (M+Na)+: 3892.2; 
C253H438NaO21Si2, requires: 3892.2]; [] 20D +14 (c 3.0, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.54 – 7.00 (35H, m), 5.16 (1H, br.s), 5.13 (1H, br.s), 5.04 (1H, br.s), 4.68 (1H, d, J 
12.1 Hz), 4.65 (1H, d, J 12.1 Hz), 4.58 – 4.47 (9H, m), 4.46 (1H, d, J 11.9 Hz), 4.39 (1H, d, J 
11.8 Hz), 4.33 (1H, d, J 11.9 Hz), 4.30 – 4.22 (5H, including a broad double doublet J 3.9, 
10.4 Hz at 4.26), 4.22 – 4.16 (2H, m), 4.13 (1H, br.dd, J 5.6, 8.4 Hz), 4.06 (1H, br.d, J 2.9 
Hz), 4.01 – 3.97 (2H, m), 3.95 – 3.87 (5H, m), 3.85 (1H, br.dd, J 3.8, 9.4 Hz), 3.78 (1H, br.p, 
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J 4.9 Hz), 3.76 – 3.72 (1H, m), 3.65 – 3.55 (3H, including a broad double doublet J 4.8, 8.3 
Hz at 3.60), 2.53 (4H, including sextet, J 5.6 Hz), 2.42 (4H, t, J 7.5 Hz), 1.62 – 1.14 (295 H, 
m), 1.06 (6H, d, J 6.9 Hz), 0.89 (12H, t, J 6.8 Hz), 0.88 (6H, d, J 6.8 Hz), 0.85 (9H, s), 0.84 
(9H, s), 0.75 – 0.62 (2H, m), 0.51 – 0.40 (2H, m), 0.24 – 0.08 (6H, m), 0.03 (6H, s), 0.01 (6H, 
s); δC (101 MHz, CDCl3): 215.1, 174.2, 174.1, 138.6, 138.3, 137.8, 137.7, 137.6, 137.55, 
137.5, 128.45, 128.4, 128.35, 128.3, 128.25, 128.2, 127.9, 127.85, 127.8, 127.75, 127.7, 
127.65, 127.6, 127.55, 127.5, 106.6, 106.3, 105.2, 88.3, 88.2, 87.8, 83.8, 83.7, 81.2, 80.2, 
79.5, 78.9, 77.2, 73.4, 73.2, 72.3, 72.2, 72.0, 71.9, 71.6, 70.3, 67.0, 65.9, 63.0, 62.7, 51.6, 
46.3, 41.1, 38.1, 37.4, 34.5, 33.7, 33.6, 33.0, 31.9, 30.1, 29.9, 29.8, 29.75, 29.7, 29.65, 29.6, 
29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 27.8, 27.4, 27.3, 27.2, 27.1, 26.1, 25.9, 25.8, 24.1, 23.7, 
22.7, 22.6, 19.7, 18.6, 18.0, 16.4, 14.1, 10.5, -4.4, -4.5, -4.7, -4.8; νmax: 3063,3032, 2919, 
2851, 1739, 1714, 1467, 1105, 836, 698 cm-1. 
 
2',3'-Di-O-benzyl-L-glycerol-(1'→1)-2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-hydroxy-17-((1S, 
2R)-2-((22S)-22-methyl-21-oxotetracontan-2-yl)cyclopropyl)heptadecyl) hexacosanoate-α-D-
arabinofuranosyl-(1→3)-[2,3-di-O-benzyl-5-O-(2R)-2-((1R)-1-hydroxy-17-((1S, 2R)-2-
((22S) -22-methyl-21-oxotetracontan-2-yl)cyclopropyl) heptadecyl) hexacosanoate-α-D-
arabinofuranosyl-(1→5)]-2-O-benzyl-α-D-arabinofuranoside (100): 
 
The protected glycolipid α-D-arabinofuranoside (99) (31 mg, 0.0080 mmol) was dissolved in 
dry THF (10 mL) in a dry polyethylene vial equipped with an acid proof rubber septum, 
followed by addition of pyridine (0.1 mL) at room temperature under nitrogen. The mixture 
was cooled to 0 oC, and then hydrogen fluoride-pyridine complex as (70% w, 1.5 mL) was 
added dropwise. The mixture was stirred at 43 oC for 24 h. When TLC showed no starting 
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material was left, the mixture was neutralized by pouring it slowly into sat. aq. NaHCO3 and 
stirred until no more CO2 was liberated. The organic layer was separated and the aqueous 
layer was re-extracted with chloroform (3×10 mL). The combined organic layers were dried 
(MgSO4) and the solvent was evaporated to give the residue which was purified by column 
chromatography on silica eluting with hexane/ethyl acetate (10:1) affording compound (100) 
as a colourless thick oil (19 mg, 66%) [MALDI–Found (M+Na)+: 3664.1; C241H410NaO21, 
requires: 3664.1]; [] 18D +25 (c 1.1, CHCl3), which showed δH (400 MHz, CDCl3): 7.39 – 7.18 
(35H, m), 5.16 (1H, br.s), 5.13 (1H, br.s), 5.04 (1H, br.s), 4.67 (2H, br.s), 4.55 (1H, d, J 11.9 
Hz), 4.53 – 4.47 (8H, m), 4.45 (2H, d, J 11.8 Hz), 4.40 (1H, d, J 11.8 Hz), 4.29 (6H, br.m), 
4.17 (1H, br.dd, J 3.8, 6.9 Hz), 4.11 (1H, br.dd, J 3.4, 6.2 Hz), 4.07 (1H, br.d, J 2.5 Hz), 3.99 
– 3.95 (2H, m), 3.94 – 3.87 (2H, m), 3.87 – 3.82 (2H, including abroad double doublet J 4.6, 
10.3 Hz at 3.85), 3.79 (1H, br.p, J 4.9 Hz), 3.72 (1H, br.dd, J 1.7, 11.6 Hz), 3.64 – 3.57 (5H, 
m), 2.51 (2H, sextet, J 6.8 Hz), 2.42 (6H, including a triplet, J 7.5 Hz), 1.87 – 1.08 (300H, 
m), 1.05 (6H, d, J 6.9 Hz), 0.89 (12H, t, J 7.3 Hz), 0.72 – 0.62 (2H, m), 0.50 – 0.38 (2H, m), 
0.25 – 0.05 (6H, m); δC (101 MHz, CDCl3): 215.2, 175.1, 175.0, 138.6, 138.3, 137.7, 137.5, 
137.45, 137.4, 137.2, 128.5, 128.4, 128.35, 128.3, 128.2, 128.0, 127.95, 127.9, 127.85, 127.8, 
127.75, 127.7, 127.6, 106.3, 106.2, 105.4, 88.2, 88.0, 87.9, 83.6, 80.7, 80.3, 79.3, 79.2, 77.2, 
73.4, 72.4, 72.2, 72.1, 72.0, 71.9, 71.7, 70.3, 67.1, 65.4, 63.0, 62.9, 51.9, 51.7, 46.3, 41.1, 
38.1, 37.4, 35.3, 35.2, 34.5, 33.0, 31.9, 30.1, 29.75, 29.7, 29.65, 29.6, 29.55, 29.5, 29.45, 
29.4, 29.3, 27.5, 27.4, 27.35, 27.3, 26.1, 25.7, 23.7, 22.7, 19.7, 18.6, 16.4, 14.1, 10.5; νmax: 
3457, 3063,3031, 2919, 2852, 1737, 1715, 1464, 1104,734, 698 cm-1. 
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L-glycerol-(1'→1)-5-O-(2R)-2-((1R)-1-hydroxy-17-((1S,2R)-2-((22S)-22-methyl-21-
oxotetracontan-2-yl)cyclopropyl)heptadecyl) hexacosanoate-α-D-arabinofuranosyl-(1→3)   -
[-5-O-(2R)-2-((1R)-1-hydroxy-17-((1S,2R)-2-((22S)-22-methyl-21-oxotetracontan-2-yl) 
cyclopropyl)heptadecyl)hexacosanoate-α-D-arabinofuranosyl-(1→5)]-α-D-arabinofuranoside 
(101): 
 
Palladium hydroxide on activated charcoal (Pd(OH)2-C/20%, 12 mg, 1.1 fold by weight) was 
added to a stirred solution of α-D-arabinofuranoside (100) (11 mg, 0.0030 mmol) in 
CH2Cl2:MeOH (2:1, 2 mL) at room temperature under hydrogen. The mixture was stirred for 
36 h. When TLC showed no starting material was left, the mixture was filtered off through 
celite and the solvent was evaporated under reduced pressure to give a residue which was 
purified by column chromatography on silica eluting with chloroform/methanol (10:1) 
affording compound (101) as a colourless thick oil (9.0 mg, 82%) [MALDI–Found (M+Na)+: 
3033.8; C192H368NaO21, requires: 3033.8]; []
18
D +26 (c 0.90, CHCl3), which showed δH (400 
MHz, CDCl3+few drops CD3OD): 5.01 (1H, br.s), 4.96 (1H, br.s), 4.91 (1H, br.s), 4.42 (1H, 
dd, J 4.9, 12.1 Hz), 4.37 (1H, dd, J 4.6, 11.8 Hz), 4.27 (1H, dd, J 4.7, 11.1Hz), 4.22 (1H, br.d, J 
4.7 Hz), 4.18 (1H, dd, J 4.2, 9.0 Hz), 4.13 (1H, br.q, J 5.4 Hz), 4.09 (1H, t, J 7.0 Hz), 4.06 (1H, 
d, J 5.1 Hz), 4.02 – 3.97 (3H, br.m), 3.93 (1H, br.dd, J 3.3, 7.3 Hz), 3.89 (2H, br.m), 3.80 – 
3.72 (2H, m), 3.67 – 3.58 (5H, m), 3.55 (1H, dd, J 2.4, 9.6 Hz), 2.53 – 2.44 (2H, sextet, J 6.6 
Hz), 2.39 (6H, including a triplet, J 7.4 Hz), 1.57 – 1.06 (210 H, m), 1.01 (6H, d, J 6.9 Hz), 
0.85 (12H, t, J 7.5 Hz), 0.67 – 0.57 (2H, m), 0.47 – 0.34 (2H, m), 0.21 – 0.02 (6H, m); δC 
(101 MHz, CDCl3): 215.8, 175.0, 174.75, 109.3, 108.7, 87.1, 82.95, 82.9, 80.9, 79.4, 78.8, 
78.2, 77.9, 77.2, 72.6, 71.7, 68.8, 65.0, 64.0, 63.3, 61.8, 52.5, 46.3, 41.1, 38.1, 37.4, 35.1, 
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34.4, 33.0, 32.9, 31.9, 30.0, 29.7, 29.6, 29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 27.4, 27.35, 
27.3, 27.25, 27.2, 26.1, 25.45, 25.4, 23.6, 23.55, 22.6, 19.6, 18.6, 16.3, 16.2, 14.1, 10.4.; νmax: 
3434, 2919, 2852, 1736, 1717, 1467, 1104,735, 699 cm-1. 
 
1-O-p-toluene-sulfonyl-(S)-2,3-di-O-benzyl glycerol (102): 
 
 p-Toluenesulfonyl chloride (4.86 g, 0.0255 mol) was added to a stirred solution of (S)-2,3-di-O-
benzyl propanol (51G) 247 (3.2 g, 0.011 mol), pyridine (5.85 g, 6.20 mL, 73.9 mmol) and DMAP 
(0.71 g, 5.8 mmol) in dry CH2Cl2 (25 mL) at 0 ºC under nitrogen. The mixture was allowed to reach 
room temperature and stirred for 24 h, then TLC showed no starting material was left. The mixture 
was diluted with ethyl acetate (100 mL) and water (40 mL), the organic layer was separated and the 
aqueous layer was re-extracted with ethyl acetate (3×50 mL). The combined organic layers were 
washed with water (25 mL), brine (25 mL) and dried (MgSO4). The solvent was evaporated under 
reduced pressure to give an oily residue which was purified by column chromatography on silica 
eluting with hexane/ethyl acetate (5:1) affording the title compound (102) as a colourless thick oil (3.1 
g, 62%) [MALDI–Found (M+Na)+: 449.1; C24H26O5NaS, requires: 449.1]; []
22
D -5.6 (c 0.71, 
CHCl3), which showed δH (400 MHz, CDCl3): 7.77 (2H, d, J 8.3 Hz), 7.52 – 7.12 (12H, m), 4.58 (2H, 
br.s), 4.47 (2H, br.s), 4.22 (1H, dd, J 4.2, 10.4 Hz), 4.12 (1H, dd, J 5.8, 10.4 Hz), 3.85 – 3.76 (1H, m), 
3.55 – 3.51 (2H, m), 2.43 (3H, s); δC (101 MHz, CDCl3): 129.8, 128.4, 128.3, 128.0, 127.8, 127.75, 
127.7, 127.6, 75.5, 73.4, 72.4, 69.5, 68.8, 21.6; νmax: 3032, 2867, 1598, 1362,  1496, 1177, 1097, 921, 
814 cm-1. All data were identical to the authentic sample248. 
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 (S)-2,3-Bis(benzyloxy)propyl alkanoate (104a-f): 
 
Genera procedure: 
Cesium hydrogencarbonate was added to a stirred solution of 1-O-p-toluene-sulfonyl-(S)-2,3-di-
O-benzyl glycerol (102) and fatty acids (103a-f) in dry DMF:THF (1:5, 2 mL) at room 
temperature. The mixture was stirred at 70 ºC for 2 days. The suspension was diluted with ethyl 
acetate (10 mL) and water (10 mL). The organic layer was separated and the aqueous layer was 
re-extracted with ethyl acetate (3×10 mL). The combined organic layers were washed 
successively with water (15 mL) and brine (15 mL), dried (MgSO4), filtered and evaporated to 
give a thick oil residue. The residue was purified by column chromatography. 
(S)-2,3-Bis(benzyloxy)propyl docosanoate (104a): 
 
Cesium hydrogencarbonate (0.284 g, 1.46 mmol), tosylate (102) (0.137 g, 0.323 mmol) and 
behenic acid (103a) (0.10 g, 0.29 mmol); gave a thick colourless oil residue which was 
purified by column chromatography on silica eluting with hexane/ethyl acetate (5:1) to afford 
the title compound (104a) (59 mg, 83%) [MALDI–Found (M+Na)+: 617.4; C39H62NaO4, 
requires: 617.4]; []
22
D +7 (c 0.6, CHCl3), which showed δH (400 MHz, CDCl3): 7.31 – 7.19 
(10H, m), 4.61 (2H, br.s), 4.49 (2H, br.s), 4.25 (1H, dd, J 4.2, 11.7 Hz), 4.12 (1H, dd, J 5.8, 
11.7 Hz), 3.80 – 3.70 (1H, m), 3.55 – 3.51 (2H, m), 2.23 (2H, t, J 7.6 Hz), 1.66 – 0.97 (38H, 
m), 0.83 (3H, t, J 6.8 Hz); δC (101 MHz, CDCl3): 173.6, 138.2, 138.0, 128.4, 128.3, 127.7, 
127.65, 127.6, 75.8, 73.4, 72.1, 69.6, 63.6, 34.2, 31.9, 29.7, 29.65, 29.6, 29.4, 29.35, 29.3, 
29.1, 24.9, 22.7, 14.1; νmax: 2917, 2850, 1740, 1467 cm-1. 
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(S)-2,3-Bis(benzyloxy)propyl(2R)-2-((1R)-1-hydroxy-16-((1R,2S)-2-(20-methyl-19-
oxooctatriacontyl) cyclopropyl)hexadecyl)hexacosanoate (104b): 
 
Cesium hydrogencarbonate (0.0572 g, 0.295 mmol), tosylate (102) (0.0277 g, 0.0649 mmol) 
and (2R)-2-((1R)-1-hydroxy-16-((1R,2S)-2-(20-methyl-19-oxooctatriacontyl)cyclopropyl) 
hexadecyl) hexacosanoic acid (103b) (0.0731 g, 0.0590 mmol); gave a thick colourless oil 
residue which was purified by column chromatography on silica eluting with hexane/ethyl 
acetate (10:1) to afford the title compound (104b) (52 mg, 59%) [MALDI–Found (M+Na)+: 
1514.3829, C101H182NaO6, requires: 1514.3834]; []
23
D +6.5 (c 0.55, CHCl3); δH (400 MHz, CDCl3): 
7.31 – 7.05 (10H, m), 4.60 (1H, d, J 11.8 Hz), 4.57 (1H, d, J 11.8 Hz), 4.47 (2H, br.s), 4.35 
(1H, dd, J 4.0, 11.7 Hz), 4.14 (1H, dd, J 5.5, 11.7 Hz), 3.80 – 3.71 (1H, m), 3.58 – 3.48 (3H, 
including br dd,  J 1.4, 5.4 Hz at 3.52), 2.48 – 2.38 (2H, including OH proton at 2.43), 2.38 – 
2.29 (3H, including dt,  J 5.4, 7.9 Hz at 2.35), 1.75 – 1.01 (144H, m), 0.98 (3H, d, J 6.9 Hz), 
0.81 (6H, t, J 6.7 Hz), 0.62 – 0.53 (2H, m), 0.49 (1H, dt, J 4.0, 8.5 Hz), -0.40 (1H, br.q, J 5.1 
Hz); δC (101 MHz, CDCl3): 215.0, 175.7, 138.0, 128.4, 128.3, 127.7, 127.6, 127.5, 75.7, 
73.4, 72.2, 72.0, 69.5, 63.4, 51.3, 46.2, 41.0, 35.4, 33.0, 31.8, 30.1, 29.6, 29.55, 29.5, 29.4, 
29.35, 29.3, 29.2, 28.6, 27.4, 27.2, 25.7, 23.7, 23.6, 22.6, 16.3, 15.7, 14.0, 10.8; νmax: 2918, 
2850, 1717, 1467 cm-1. 
 
(S)-2,3-Bis(benzyloxy)propyl(R)-2-((R)-1-hydroxy-12-((1S,2R)-2-(14-((1S,2R)-2-icosyl-
cyclopropyl) tetradecyl)cyclopropyl)dodecyl)hexacosanoate (104c): 
 
Cesium hydrogencarbonate (0.0605 g, 0.312 mmol), tosylate (102) (0.0293 g, 0.0687 mmol) and 
(R)-2-((R)-1-hydroxy-12-((1S,2R)-2-(14-((1S,2R)-2-icosylcyclopropyl)tetradecyl) cyclopropyl) 
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dodecyl) hexacosanoic acid (103c) (0.0711 g, 0.0624 mmol); gave a thick colourless oil 
residue which was purified by column chromatography on silica eluting with hexane/ethyl 
acetate (10:1) to afford the title compound (104c) (51 mg, 58%) [MALDI–Found (M+Na)+: 
1414.2940, C95H170NaO5, requires: 1414.2946]; []
23
D +3.6 (c 0.88, CHCl3); δH (400 MHz, CDCl3): 
7.37 – 7.26 (10H, m), 4.68 (1H, d, J 11.8 Hz), 4.65 (1H, d, J 11.9 Hz), 4.55 (2H, br.s), 4.43 
(1H, dd, J 4.0, 11.7 Hz), 4.22 (1H, dd, J 5.5, 11.7 Hz), 3.86 – 3.80 (1H, m), 3.67 – 3.56 (3H, 
including br.dd J 1.6, 5.4 Hz at 3.60), 2.45 (1H, d, J 7.9 Hz), 2.43 (1H, br.dd, J 3.5, 7.4 Hz) 
1.85 – 0.97 (134H, m), 0.89 (6H, t, J 7.2 Hz), 0.70 – 0.61 (4H, m), 0.60 – 0.57 (2H, dt, J 4.0, 
8.5 Hz), -0.32 (2H, br q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.4, 138.0, 137.8, 128.4, 128.3, 
127.7, 127.6, 127.5, 121.9, 75.7, 73.4, 72.3, 72.0, 69.5, 63.4, 51.3, 35.5, 31.9, 30.1, 29.7, 
29.6, 29.5, 29.45, 29.4, 29.3, 28.6, 27.4, 25.7, 22.6, 15.7, 14.0, 10.8; νmax: 3435, 2917, 2850, 
1732, 1468 cm-1. 
 
(S)-2,3-Bis(benzyloxy)propyl(2R)-2-(1-hydroxy-12-((1R,2S)-2-(14-((2S)-2-icosylcyclo-propyl) 
tetradecyl)cyclopropyl)dodecyl)hexacosanoate (104d): 
 
Cesium hydrogencarbonate (0.0616 g, 0.317 mmol), tosylate (102) (0.0298 g, 0.0698 mmol) 
and (2R)-2-(1-hydroxy-12-((1R,2S)-2-(14-((2S)-2-icosylcyclopropyl) tetradecyl) cyclopropyl) 
dodecyl) hexacosanoic acid (103d) (0.0724 g, 0.0636 mmol); gave a thick colourless oil 
residue which was purified by column chromatography on silica eluting with hexane/ethyl 
acetate (10:1) to afford the title compound (104d) (62 mg, 71%) [MALDI–Found (M+Na)+: 
1414.3; C95H170NaO5, requires: 1414.3]; []
22
D +3.8 (c 0.31, CHCl3); δH (400 MHz, CDCl3): 
7.35 – 7.27 (10H, m), 4.68 (1H, d, J 11.8 Hz), 4.65 (1H, d, J 11.8 Hz), 4.55 (2H, br.s), 4.43 
(1H, dd, J 4.1, 11.7 Hz), 4.22 (1H, dd, J 5.5, 11.7 Hz), 3.86 – 3.80 (1H, m), 3.67 – 3.55 (3H, 
including br dd J 1.6, 5.4 Hz at δ 3.6), 2.45 (1H, d, J 8.0 Hz), 2.43 (1H, br.dd, J 3.8, 10.5 Hz), 
1.80 – 1.00 (134H, m), 0.89 (6H, t, J 6.7 Hz), 0.71 – 0.61 (4H, m), 0.57 (2H, dt, J 3.9, 8.4 
Hz), -0.32 (2H, br.q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.4, 138.0, 137.9, 128.4, 128.3, 
127.8, 127.7, 127.6, 75.8, 73.5, 72.3, 72.1, 69.6, 63.5, 51.4, 35.5, 31.9, 30.2, 29.7, 29.6, 29.5, 
29.4, 29.3, 28.7, 27.5, 25.8, 23.0, 15.8, 14.1, 10.9; νmax: 2991, 2917, 2850, 1732, 1599, 1469 cm-1. 
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(S)-2,3-Bis(benzyloxy)propyl(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-
18-methylhexatriacontyl)cyclopropyl)octadecyl)tetracosanoate (104e): 
 
Cesium hydrogencarbonate (0.0436 g, 0.225 mmol), tosylate (102) (0.0211 g, 0.0495 mmol) and 
(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-methylhexatriacontyl) cyclopropyl) 
octadecyl)tetracosanoic acid (103e) (0.0552 g, 0.0450 mmol); gave a thick colourless oil 
residue which was purified by column chromatography on silica eluting with hexane/ethyl 
acetate (10:1) to afford the title compound (104e) (41 mg, 62%) [MALDI–Found (M+Na)+: 
1502.4, C100H182NaO6, requires: 1502.4]; []
22
D +9 (c 0.3, CHCl3), which showed δH (400 MHz, 
CDCl3): 7.32 – 7.19 (10H, m), 4.62 (1H, d, J 11.8 Hz), 4.58 (1H, d, J 11.8 Hz), 4.48 (2H, br s), 
4.36 (1H, dd, J 4.1, 11.7 Hz), 4.15 (1H, dd, J 5.5, 11.7 Hz), 3.81 – 3.72 (1H, m), 3.60 – 3.49 (3H, 
including br dd,  J 1.6, 5.4 Hz, at 3.53), 3.28 (3H, s), 2.90 (1H, br.p, J 4.1 Hz), 2.39 (1H, d, J 7.9 
Hz), 2.36 (1H, br.dd, J 3.5, 7.4 Hz), 1.75 – 0.93 (143H, m), 0.83 (6H, t, J 6.8 Hz), 0.79 (3H, d, J 6.9 
Hz), 0.65 – 0.54 (2H, m), 0.50 (1H, dt, J 4.0, 8.4 Hz), -0.39 (1H, br q, J 5.2 Hz); δC (101MHz, 
CDCl3): 175.3, 137.9, 137.8, 128.3, 128.2, 127.7, 127.6, 127.5, 85.3, 75.7, 73.4, 72.2, 72.0, 
69.5, 63.4, 57.6, 51.3, 38.6, 35.4, 35.2, 32.3, 31.8, 30.4, 30.3, 30.1, 29.9, 29.8, 29.7, 29.6, 29.5, 
29.4, 29.3, 29.2, 28.8, 28.6, 27.5, 27.4, 26.0, 25.7, 23.6, 22.9, 22.6, 15.7, 14.8, 14.0, 13.9, 10.9, 
10.8; νmax: 2923, 2853, 1737, 1465 cm-1. 
 
(S)-2,3-Bis(benzyloxy)propyl(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-
18-methylhexatriacontyl)cyclopropyl)octadecyl)hexacosanoate (104f): 
 
Cesium hydrogencarbonate (0.0351 g, 0.181 mmol), tosylate (102) (0.0170 g, 0.0399 mmol) 
and (R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-methylhexatriacontyl) 
cyclopropyl) octadecyl) hexacosanoic acid (103f) (0.0455 g, 0.0362 mmol); gave a thick 
colourless oil residue which was purified by column chromatography on silica eluting with 
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hexane/ethyl acetate (10:1) to afford the title compound (104f) (40 mg, 72%) [MALDI–Found 
(M+Na)+: 1530.4142, C102H186NaO6, requires: 1530.4147]; []
23
D +6.4 (c 0.50, CHCl3);         
δH (400 MHz, CDCl3): 7.39 – 7.26 (10H, m), 4.70 (1H, d, J 11.8 Hz), 4.66 (1H, d, J 11.8 Hz), 4.57 
(2H, br.s), 4.44 (1H, dd, J 4.1, 11.6 Hz), 4.23 (1H, dd, J 5.5, 11.7 Hz), 3.85 (1H, m), 3.69 – 3.57 
(3H, including br dd,  J 1.6, 5.4 Hz at 3.62), 3.37 (3H, s), 2.98 (1H, br.p, J 3.8 Hz), 2.47 (1H, d, J 
7.9 Hz), 2.44 (1H, br.dd, J 4.5, 8.5 Hz), 1.88 – 1.03 (147H, m), 0.91 (6H, t, J 7.1 Hz), 0.89 (3H, d, J 
6.8 Hz), 0.71 – 0.63 (2H, m), 0.58 (1H, dt, J 4.0, 8.3 Hz), -0.31 (1H, br.q, J 5.2 Hz); δC (101 MHz, 
CDCl3): 175.4, 128.4, 128.3, 127.7, 127.6, 127.5, 85.3, 75.7, 73.4, 72.2, 72.0, 69.5, 68.0, 63.4, 57.6, 
51.3, 38.6, 35.4, 35.2, 32.3, 31.8, 30.4, 30.3, 30.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 28.8, 28.6, 
27.5, 27.4, 26.0, 22.6, 15.7, 14.8, 14.0, 10.8; νmax: 3030, 2923, 2853, 1733, 1496 cm-1. 
 
(S)-2,3-Dihydroxypropyl alkanoate (105a-f): 
 
Genera procedure: 
Palladium hydroxide on activated charcoal (20% Pd, 0.15 fold by weight) was added to a 
stirred solution of compounds (104a-f) in dry CH2Cl2:MeOH (1:1, 2 mL) at room temperature 
under hydrogen atmosphere. The mixture was stirred for 24 h, when TLC showed no starting 
material was left. The mixture was filtered through celite and the precipitate was washed with 
CH2Cl2 (10 mL), the filtrate was evaporated and the residue was purified by column 
chromatography to give compounds (105a-f).  
 
(S)-2,3-Dihydroxypropyl docosanoate (105a): 
  
Palladium hydroxide on activated charcoal (0.0085 g) and compound (104a) (0.0573 g, 
0.0963 mmol); gave a thick colourless oil residue which was purified by column 
chromatography on silica eluting with chloroform/methanol (5:1) to afford the title compound 
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(105a) (28 mg, 70%) [MALDI–Found (M+Na)+: 437.3601, C25H50NaO4, requires: 437.3607]; 
[]
22
D -24 (c 0.25, CHCl3), which showed δH (400 MHz, CDCl3+few drops of CD3OD): 4.07 
(1H, dd, J 3.6, 9.9 Hz), 4.03 (1H, dd, J 4.4, 10.0 Hz), 3.80 (1H, m), 3.57 (1H, dd, J 4.1, 11.5 
Hz), 3.48 (1H, dd, J 6.1, 11.5 Hz), 2.28 (2H, t, J 7.6 Hz), 1.63 – 0.92 (40H, m), 0.81 (3H, t, J 
6.8 Hz); δC (101 MHz, CDCl3+few drops of CD3OD): 174.4, 69.9, 65.0, 63.1, 34.1, 31.8, 
29.6, 29.55, 29.5, 29.4, 29.3, 29.2, 29.0, 24.8, 22.6, 14.0; νmax: 3342, 2955, 2918, 2849, 1733, 
1472 cm-1. 
 
(S)-2,3-Dihydroxypropyl(2R)-2-((1R)-1-hydroxy-16-((1R,2S)-2-(20-methyl-19-oxooctatriacontyl) 
cyclopropyl)hexadecyl)hexacosanoate (105b): 
 
Palladium hydroxide on activated charcoal (0.0075 g) and compound (104b) (0.0505 g, 0.0338 
mmol); gave a thick colourless oil which was purified by column chromatography on silica eluting 
with (chloroform/methanol, 40:1) to afford the title compound (105b) (38 mg, 87%) [MALDI–
Found (M+Na)+: 1334.2890, C87H170NaO6, requires: 1334.2895]; []
23
D +2.8 (c 3.6, CHCl3), which 
showed δH (400 MHz, CDCl3+few drops of CD3OD): 4.22 (1H, dd, J 4.2, 11.4 Hz), 4.11 (1H, dd, J 
6.5, 11.4 Hz), 3.89 – 3.81 (1H, m), 3.68 – 3.57 (2H, including br dd J 4.3, 11.5 Hz at δ 3.61), 3.54 
(1H, dd, J 5.8, 11.6 Hz), 2.53 – 2.44 (1H, m), 2.38 (3H, including br t, J 2.38), 1.68 – 1.05 (147H, 
m), 1.01 (3H, d, J 6.9 Hz), 0.84 (6H, t, J 6.7 Hz), 0.65 – 0.57 (2H, m), 0.52 (1H, dt, J 4.1, 8.4 Hz), -
0.37 (1H, br.q, J 5.2 Hz); δC (126 MHz, CDCl3+few drops of CD3OD): 216.0, 175.5, 72.6, 69.7, 
65.1, 63.0, 52.5, 46.3, 41.1, 35.0, 32.9, 31.8, 30.1, 29.7, 29.6, 29.55, 29.5, 29.45, 29.4, 29.35, 29.3, 
29.25, 29.2, 29.15, 29.1, 28.6, 27.4, 27.2, 25.3, 23.6, 22.6, 16.2, 15.7, 14.0, 10.8; νmax: 3396, 3017, 
2922, 2853, 1713, 1467 cm-1. 
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(S)-2,3-Dihydroxypropyl(R)-2-((R)-1-hydroxy-12-((1S,2R)-2-(14-((1S,2R)-2-icosylcyclopropyl) 
tetradecyl)cyclopropyl)dodecyl)hexacosanoate (105c): 
 
Palladium hydroxide on activated charcoal (0.0063 g) and compound (104c) (0.0425g, 0.0305 
mmol); gave a thick clourless oil residue which was purified by column chromatography on 
silica eluting with (chloroform/methanol, 20:1) to afford the title compound (105c) (27 mg, 
74%) [MALDI–Found (M+Na)+: 1234.2001, C81H158NaO5, requires: 1234.2007]; []
23
D +2.3   
(c 5.2, CHCl3); δH (400 MHz, CDCl3+few drops of CD3OD): 4.22 (1H, dd, J 4.4, 11.5 Hz), 
4.12 (1H, dd, J 6.4, 11.5 Hz), 3.89 – 3.83 (1H, m), 3.67 – 3.58 (2H, including br dd, J 4.0, 11.1 
Hz at 3.61), 3.55 (1H, dd, J 5.8, 11.6 Hz), (1H, ddd, J 4.4, 7.9, 10.0 Hz), 1.79 – 0.96 (137H, m), 
0.85 (6H, t, J 6.8 Hz), 0.66 – 0.57 (4H, m), 0.53 (2H, dt, J 4.4, 8.4 Hz), -0.36 (2H, br.q, J 5.1 
Hz); δC (126 MHz, CDCl3+few drops of CD3OD): 175.4, 72.4, 69.6, 65.0, 62.8, 52.4, 31.7, 
30.0, 29.4, 29.1, 29.0, 28.5, 27.2, 25.1, 22.4, 15.5, 13.8, 10.6; νmax: 3400, 3017, 2917, 2850, 
1733, 1468 cm-1. 
 
(S)-2,3-Dihydroxypropyl(2R)-2-(1-hydroxy-12-((1R,2S)-2-(14-((2S)-2-icosylcyclopropyl) 
tetradecyl) cyclopropyl)dodecyl)hexacosanoate (105d): 
 
Palladium hydroxide on activated charcoal (0.0077 g) and compound (104d) (0.0515 g, 0.0369 
mmol); gave a thick colourless oil residue which was purified by column chromatography on 
silica eluting with (chloroform/methanol, 10:1) to afford the title compound (105d) (40 mg, 92%) 
[MALDI–Found (M+Na)+: 1234.2001, C81H158NaO5, requires: 1234.2007]; []
22
D +1.8 (c 0.34, 
CHCl3); δH (400 MHz, CDCl3+few drops of CD3OD): 4.21 (1H, dd, J 4.3, 11.4 Hz), 4.10 (1H, 
dd, J 6.4, 11.5 Hz), 3.89 – 3.80 (1H, m), 3.60 (2H, br dd, J 4.1, 11.5 Hz), 3.54 (1H, dd, J 5.8, 
11.6 Hz), 2.39 (1H, ddd, J 4.8, 7.6, 10.0 Hz), 1.86 – 0.94 (137H, m), 0.84 (6H, t, J 6.8 Hz), 
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0.65 – 0.56 (4H, m), 0.52 (2H, dt, J 3.9, 8.5 Hz), -0.37 (2H, br.q, J 4.9 Hz); δC (101 MHz, 
CDCl3+few drops of CD3OD): 175.5, 72.6, 69.8, 65.1, 63.0, 52.5, 37.0, 35.0, 31.8, 30.1, 29.6, 
29.55, 29.5, 29.45, 29.4, 29.3, 29.2, 28.6, 27.4, 25.3, 22.6, 15.7, 14.0, 10.8; νmax: 3585, 2917, 
2849, 1734, 1468 cm-1. 
 
(S)-2,3-Dihydroxypropyl(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-
methylhexatriacontyl)cyclopropyl)octadecyl)tetracosanoate (105e): 
 
Palladium hydroxide on activated charcoal (0.0054 g) and compound (104e) (0.0364 g, 
0.0245mmol); gave a thick colourless oil residue which was purified by column chromatography 
on silica eluting with (chloroform/methanol, 20:1) to afford the title compound (105e)        
(27 mg, 85%) [MALDI–Found (M+Na)+: 1322.2890, C86H170NaO6, requires: 1322.2895]; 
[]
23
D +1.6 (c 2.1, CHCl3); δH (400 MHz, CDCl3+few drops of CD3OD): 4.21 (1H, dd, J 4.3, 
11.4 Hz), 4.11 (1H, dd, J 6.4, 11.4 Hz), 3.88 – 3.82 (1H, m), 3.66 – 3.57 (2H, including br dd, J 
4.3, 11.4 Hz at δ 3.6), 3.54 (1H, dd, J 5.8, 11.6 Hz), 3.31 (3H, s), 2.94 (1H, br.p, J 4.4 Hz), 2.40 
(1H, ddd, J 4.8, 7.4, 10.2 Hz), 1.81 – 0.94 (146H, m), 0.84 (6H, t, J 7.0 Hz), 0.81 (3H, d, J 6.9 
Hz), 0.65 – 0.57 (2H, m), 0.52 (1H, dt, J 4.0, 8.5 Hz), -0.37 (1H, br.q, J 5.1 Hz); δC (101 MHz, 
CDCl3+few drops of CD3OD): 175.5, 85.5, 72.6, 69.8, 65.1, 63.0, 57.6, 52.4, 35.3, 35.0, 32.3, 
31.8, 30.4, 30.1, 29.9, 29.8, 29.7, 29.6, 29.55, 29.5, 29.45, 29.4, 29.3, 28.6, 27.5, 27.4, 26.0, 25.3, 
22.6, 15.7, 14.7, 14.0, 10.8; νmax: 3368, 2918, 2850, 1731, 1467 cm-1. 
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(S)-2,3-Dihydroxypropyl(R)-2-((R)-1-hydroxy-18-((1R,2S)-2-((17S,18S)-17-methoxy-18-
methylhexatriacontyl)cyclopropyl)octadecyl)hexacosanoate (105f):  
 
Palladium hydroxide on activated charcoal (0.0032g) and compound (104f) (0.0215g, 0.0142 
mmol); gave a thick colourless oil residue which was purified by column chromatography on 
silica eluting with (chloroform/methanol, 20:1) to afford the title compound (105f)              
(18 mg, 92%) [MALDI–Found (M+Na)+: 1350.3203, C88H174NaO6, requires: 1350.3208]; 
[]
23
D +1.9 (c 0.74, CHCl3); δH (400 MHz, CDCl3+few drops of CD03OD): 4.22 (1H, dd, J 
4.2, 11.5 Hz), 4.12 (1H, dd, J 6.4, 11.5 Hz), 3.89 – 3.83 (1H, m), 3.71 – 3.58 (2H, including 
br dd, J 4.1, 11.5 Hz at δ 3.61), 3.55 (1H, dd, J 5.8, 11.5 Hz), 3.31 (3H, s), 2.94 (1H, br.p, J 
3.7 Hz), 2.40 (1H, ddd, J 4.8, 7.4, 10.4 Hz), 1.68 – 0.94 (150H, m), 0.85 (6H, t, J 6.9 Hz), 
0.82 (3H, d, J 6.9 Hz), 0.65 – 0.58 (2H, m), 0.52 (1H, dt, J 4.0, 8.1 Hz), -0.37 (1H, br.q, J 5.2 
Hz); δC (101 MHz, CDCl3+few drops of CD3OD): 175.5, 85.5, 72.6, 69.7, 65.1, 63.0, 58.0, 
52.5, 35.2, 35.0, 33.0, 31.8, 30.4, 30.1, 29.8, 29.7, 29.6, 29.55, 29.5, 29.4, 29.3, 29.2, 29.1, 
28.6, 27.4, 27.3, 26.0, 25.3, 22.6, 15.7, 14.7, 14.0, 10.8;  νmax: 3389, 3017, 2919, 2850, 1733, 1467 
cm-1.
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ELISA protocol from Mr. Paul Mason 
0.5% casein w/v PBS buffer - KCl (0.4 g), KH2PO4 (0.4 g), anhydrous Na2HPO4 (2.3 g), 
NaCl (16 g) was dissolved in 1800 mL d H2O, stirred and heated to 37 ºC. Casein (10 g) was 
added slowly and the solution was stirred at 37°C and 400 rpm for 2 hours. It was then 
adjusted to pH 7.4 with NaOH (1 M) and made up to 2000 mL.  
Citrate Buffer (0.1 M) - Citric acid monohydrate (2.365 g) and tri-sodium citrate (2.925 g) 
were dissolved in separate beakers with d H2O 112.5 mL. Citric acid monohydrate was added 
to trisodium citrate until pH 4.5 was reached, then was made up to 250 mL with d H2O. OPD 
(5 mg) and H2O2 (4 mg) were weighed out in separate black eppendorfs.  
Dilute antigen (50 μl) was centrally pipetted into each well of the ELISA plate (96 well, flat 
bottomed, polystyrene, sterile, gamma irradiated), to G,H-11,12 only hexane was added. The 
plates were allowed to evaporate before being sealed.  
The plates were unsealed and 0.5% casein PBS (350 μl) was dispensed using a 96 well plate 
washer, then incubated at 25°C for 30 minutes. Blood product (6 μL) were diluted to 1:40 
with 0.5% casein PBS and resuspended by pipette. Casein was aspirated off the plates and 
tapped dry, serum or plasma (50 μl) was added to the wells. Remaining serum or plasma was 
pooled and added (50 μl) to C,D-11,12 and G,H-11,12 for a pooled and negative control 
respectively, 0.5% casein PBS was added to E-F 11-12 for a negative control. The plates 
were then sealed with a self-adhesive plate seal and incubated at 25 ºC for 60 minutes. The 
plates were washed three times using 0.5% casein PBS and tapped dry, before adding 
IgGFcHRP (50 μl, 2.9 μg/mL) using a multichannel pipette and then incubated at 25 ºC for 30 
minutes. The plates were washed three times using 0.5% casein PBS and tapped dry, the OPD 
(5 mg) and H2O2 (4 mg) were dissolved in citrate buffer (25 mL) and added (50 μl) to the 
plates using a multichannel pipette. Plates were incubated at 25 ºC for 30 minutes. H2SO4 (50 
μl, 3.0 M) was added to the plates and the results read on a UV-visible ELISA plate reader at 
450, 492, 620nm. 
 
 
 
 
 
 
